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ABBREVIATIONS
The following abbreviations have been used in the text :
Ab Antibody
Ag Antigen
AIDS Acquired immune deficiency syndrome
AIHA Autoimmune haemolytic anaemia
ALT Alanine aminotransferase
CFT Complement fixation test
CMV Cytomegalovirus
CPT Conventional(ly) purified tetanus (toxoid)
CVI Common variable immunodeficiency
ELISA Enzyme-linked immunosorbent assay
FFP Fresh frozen plasma
HAV Hepatitis A virus
HBsAg Hepatitis B surface antigen
HBV Hepatitis B virus
HBIg Hepatitis B immunoglobulin
HES Hydroxyethyl starch
HIV Human immunodeficiency virus
HLA Histocompatability locus antigen
HNIg Human normal immunoglobulin






IPT Immune purified tetanus
ITP Idiopathic thrombocytopenic purpura
IU International unit
IV Intravenous
MRC Medical Research Council
NANB Non-A, non-B
NLH Nodular lymphoid hyperplasia
PEG Polyethylene glycol
PEGG Human placental eluted gammaglobulin
PKA Prekallikrein activator
RES Reticulo endothelial system
Rh (D) Rhesus (D)
SNBTS Scottish National Blood Transfusion Service
TIG Tetanus immune globulin
t1 / 2 Half-life
VZIg Varicella zoster immunoglobulin
WHO World Health Organisation
XL X-linked
ZIG Zoster immune globulin
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1 SUMMARY
I
The studies carried out in this thesis examined
various aspects of passive immunisation against
infection, from immune plasma procurement to evaluation
of an immunoglobulin preparation. Strategies for
identifying blood donors suitable for donating plasma
for the manufacture of three specific hyperimmune
globulins - hepatitis B (HBV), cytomegalovirus (CMV) and
tetanus antitoxin immunoglobulins - and the use of an
intravenous immunoglobulin (IV IgG) preparation,
Scottish National Blood Transfusion Service (SNBTS) IV
IgG, in patients with primary hypogammaglobulinaemia
were examined.
The screening of 29,265 serum samples identified 19
donors with high HB surface antibody levels. Of
the 10 donors who were plasmapheresed, only two were
still donating plasma regularly one year later.
Similarly, of 845 donors screened, 85 (10%) had suitably
high serum CMV antibody levels ; 48 donors were
plasmapheresed, but only 12 remained suitable donors one
year later. These studies confirm that random
screening is an inefficient means of identifying
hyperimmune plasma donors. The frequency of unselected
blood donors with high tetanus antibody levels is
likewise low (1.5% to 2.8%), so that other methods of
identifying hyperimmune donors need to be examined.
Following a comparative trial of two tetanus toxoids,
hyperimmune donors were plasmapheresed. The results
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show that individuals can be hyperimmunised without an
excess of adverse reactions and that donors most
suitable for hyperimmunisation were young males,
preferably under 25 years of age, with a preimmunisation
tetanus antibody level of around 8 IU/ml.
Hyperimmunisation of suitable donors with vaccines
should, therefore, be considered prior to
plasmapheresis. However, while this may be feasible
for hepatitis B plasma procurement, the concern over the
safety of currently available CMV vaccines means that
repeated random screening remains the only means of
identifying CMV plasma donors.
Studies on the use of SNBTS IV IgG (manufactured from
Cohn fraction II with subsequent ultrafiltration and
mild pepsin proteolysis at pH4) in patients with primary
hypogammaglobulinaemia demonstrated that the product was
well tolerated even when administered in high doses. Ten
of the 25 patients studied experienced adverse reactions
during 34 of the 738 infusions (6.4% of all infusions)
and all but four were mild; 21 (62%) of adverse
reactions were encountered within the first five
infusions in each of the patients. In 13 of 17 patients
studied, treatment with individualised dosage of SNBTS
IV IgG resulted in a trough serum IgG levels of greater
than 4 g/1. Most patients benefitted from an increased
serum IgG level although the frequency of diarrhoea was
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unaffected and one patient with severe bronchiectasis
continued to suffer from respiratory infections. There
was no evidence of viral hepatitis transmission in 16
patients studied who received SNBTS IV IgG over six to
25 months, as measured by serial serum alanine
aminotransferase (ALT) levels. SNBTS IV IgG is
therefore a safe and effective therapy for patients with
primary hypogammaglobulinaemia.
AIMS OF THE THESIS
The treatment of infectious diseases depends
mainly on the use of antimicrobial agents. Where these
agents are either unavailable or ineffective, specific
IgGs may be particularly helpful, either as therapy or
prophylaxis. IgG replacement therapy has been used in
patients with hypogammaglobulinaemia and has improved
their long-term outcome.
This thesis examines the procurement of hyperimmune
plasma for the production of IgG used in the prophylaxis
and treatment of certain infections. It also deals
with the clinical evaluation of a new IgG preparation
designed for safe IV use.
Source plasma for the manufacture of specific
hyperimmune globulins is obtained from hyperimmune or
convalescent donors. The recruitment of such donors has
until recently been limited to random screening of large
donor populations to identify those donors with adequate
antibody level. Alternatively, donors can be
hyperimmunised with specific vaccines to render them
suitable for donating hyperimmune plasma. However, this
is only possible if a safe vaccine is available. The
feasibility of recruiting hyperimmune plasma donors for
the manufacture of tetanus, hepatitis B and CMV
hyperimmune globulins either by random screening or by
specific hyperimmunisation has been examined in this
thesis.
There is no doubt that patients with primary
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hypogammaglobulinaemia benefit from IgG therapy, and
until recently this has been mainly in the form of
intramuscular (IM) IgG injections and of fresh frozen
plasma (FFP) infusions. The IV administration of IgG
has been associated with a high incidence of adverse
reactions, particularly in patients with primary
hypogammaglobulinaemia. However, many clinicians
believe that this route of administration offers more
advantages over conventional therapy with IM
gammaglobulin, due to the higher levels of IgG
administered. As a result, new manufacturing processes
have been developed over the last few decades for the
production of safe IV IgG preparations. One such
process is the mild pepsin proteolysis at pH4 method
that has been adopted by the Protein Fractionation
Centre of the SNBTS.
This product was evaluated in terms of its safety,
tolerance and efficacy in patients with primary
hypogammaglobulinaemia. Safety and tolerance studies
were based on the frequency of adverse reactions and on
the incidence of hepatitis events defined as abnormally
elevated ALT levels in the recipients. Attempts were
made at increasing the serum IgG into the normal range
in patients with primary hypogammaglobulinaemia by
individualising the dose of IV IgG administered and the
clinical response to the higher serum IgG level was
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3.1 HISTORY OF HUMAN SEROTHERAPY
In 1890, nearly a century after Edward Jenner
introduced vaccination, Emil Adolf von Behring and
Shibasaburo Kitasato developed an antitoxin against
diphtheria. In the following year, a little girl
suffering from diphtheria was successfully treated in a
Berlin clinic with diphtheria antitoxin and the era of
passive immunisation was born. Specific antisera
raised in animals were subsequently used in the
treatment of many other serious infections, including
rabies, tetanus and anthrax.
As the use of animal antisera spread,
hypersensitivity reactions to sera were increasingly
described, both in animals (Simon Flexner) and in man.
In 1902, Charles Robert Richet, Professor of Physiology
in Paris, described anaphylaxis after he observed
violent symptoms of poisoning, followed by death within
12 to 24 hours in subjects receiving repeated injections
of foreign animal protein substances. Other allergic
reactions were later described by Nicolas Maurice Arthus
and Charles Peter von Pirquet. With the increasing
awareness of reactions to animal antisera, research was
directed towards the concentration and purification of
serum. It was felt that inactive protein devoid of
protective value caused sensitisation and that removal
of the inactive protein would yield a safer product
(reviewed by Parish, 1965 ; and Janeway, 1970).
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In 1910, Berry Gibson and Edwin Banzaf introduced
salt fractionation to concentrate the antitoxic serum.
Although reduced, the incidence of reactions to the
purified antiserum remained significant and an
alternative source of serum was sought. Interest was
focussed on rabbit antiserum because rabbit antibody
globulin was felt to be less likely to cause adverse
reactions, by virtue of its physical properties.
However, Frank Lappin Horsfall found that the incidence
of adverse reactions associated with the use of rabbit
gammaglobulin was still significant.
Material derived from humans was eventually used in
an attempt to further reduce the incidence of reactions.
In the early 1930s, Charles F McKhann and co-workers
produced a globulin extract using ground human placenta
as a source of human antibody. By 1935 these fractions
were shown to be effective in the prevention or
modification of measles (McKhann et al, 1933 ; 1935).
They were therefore referred to as 'human immune
globulin'.
In the late 1930s, studies by Heidelberger and
Petersen with the ultracentrifuge, and by Tiselius and
Kabat with electrophoresis in liquid media, showed that
antibodies belonged to that globulin fraction of serum
proteins of slow mobility (at that time designated
gammaglobulins).
By the early 1940s, Edwin Joseph Cohn and colleagues
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in Harvard developed the method of large-scale cold
ethanol fractionation. This method, which is still
used today, has three main advantages : firstly, it uses
a cheap, volatile compound (alcohol) as a precipitant
and therefore allows the work to be done below the
freezing point of water, thus minimising the risk of
microbial multiplication or denaturation ; secondly, the
alcohol can be removed rapidly from the relatively small
volume of precipitated protein by lyophilisation ; and
thirdly, it is possible to manipulate five different
variables, allowing maximal opportunity for separating
one protein from another on the basis of solubility
difference.
Cohn was also the first to suggest using convalescent
hyperimmune plasma as a source of material for specific
antimicrobial antibodies. The first two practical
attempts were made during World War II. Convalescent
scarlatina plasma was collected by Thalhimer for use in
man, but became obsolete with the introduction of
penicillin. Stokes collected convalescent mumps
plasma, which was shown by McGuiness and Peters to be
more effective than standard gammaglobulin in the
prevention of mumps orchitis in mumps epidemics among
soldiers. During the Korean war, Cohn saw the
possibility of repeated plasmapheresis of specially
selected donors, and Stokes and Smolens carried out
plasmapheresis using donors hyperimmunised with mumps
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and pertussis vaccine. Since then, plasmapheresis by-
various techniques has been widely used for the
manufacture of human hyperimmune gammaglobulin
preparations.
Early in the clinical use of gammaglobulin, it became
apparent that the IV administration of Cohn II
gammaglobulin fraction to sick children was associated
with severe adverse reactions. Stokes gave a large
dose of gammaglobulin intravenously to a child with
measles encephalitis, who had subsequently developed
marked hyperpyrexia and convulsed. Similarly, Janeway
observed vasomotor collapse, restlessness, chills and
hyperpyrexia in an adolescent with severe measles
following the IV administration of gammaglobulin.
Thus, the IV administration of gammaglobulins was
abandoned.
The recognition of the syndrome of primary
hypogammaglobulinaemia by Bruton in 1952, and of the
need of such patients for large prophylactic IgG
replacement, led to further work on the safety of
gammaglobulin administration. The IM gammaglobulin
preparation was viscous and caused pain following
injection. Large volumes of the immune globulin were
needed to maintain adequate blood levels, and during
periods of infection when IgG losses were higher more
frequent injections were required. Complications were
not uncommon : the large injections caused muscle
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damage, nerve injury and sterile, as well as pyogenic,
abscesses. As a result, patient compliance was poor
and their clinical condition did not improve. Other
routes of administration were explored, including the
subcutaneous infusion of gammaglobulin via a constant
infusion pump (Berger et al, 1980). However, the need
to find a suitable alternative was still present.
Progress in this field depended on understanding the
cause of adverse reactions to the gammaglobulins. In
1962, Barandun and co-workers thought that reactions to
gammaglobulin were linked to the anticomplementary
activity of the gammaglobulin preparations. As a
result, various workers have attempted to modify the
concentrated gammaglobulin so that it would not
aggregate and activate complement, and at the same time
leave both the Fc and Fab parts of the molecule
biologically intact. However, such manoeuvres may
alter the function and half-life of the whole
gammaglobulin molecule, rendering them unacceptable for
clinical use (Janeway et al/ 1968).
Today, after scientists have grappled with the
problem for at least 30 years, numerous IgG preparations
are now available for IV use. However, although the
problems of adverse reactions have been minimised and
gammaglobulins can be safely administered intravenously
in large amounts, other problems have emerged. The
reported outbreaks of non-A, non-B (NANB) hepatitis in
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patients with primary hypogammaglobulinaemia receiving
certain IV IgG preparations (Lever et al, 1984 ; Ochs et
al, 1985) have raised new questions regarding the safety
of IV IgG over the transmission of viral infections.
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3.2 FUTURE TRENDS
Since Kohler and Milstein (1975) published the
first examples of a general method of making monoclonal
antibodies in large quantities, new clinical indications
for IgGs have emerged : cancer and leukaemia
immunotherapy, passive antibody to treat infections and
immune regulation. The potential of monoclonal
antibodies is enormous, and scientists are only now
seeing the beginning of their impact on the study and
treatment of disease ; serotherapy with monoclonal
antibodies has taken on new dimensions.
However, the administration of murine monoclonal
antibodies from murine hybridomas appears to be of
limited value at present, since the species of origin of
the monoclonal antibody severely restricts their
biological usefulness in vivo. The prospect of
obtaining human monoclonals will expand the potential
clinical application of these reagents, not only for the
treatment of infections but also for the possible
modulation of the human immune response. Furthermore,
it may be possible to link monoclonal antibodies with
chemotherapeutic agents for the treatment of cancer (see
Section 3.4.9).
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3.3 ACCEPTED CLINICAL USE OF IMMUNOGLOBULIN
There are well-established and proven uses of IgG
preparations, mainly in the prophylaxis of viral
diseases and in the neutralisation of bacterial toxins.
These have been reviewed by McClelland and Yap (1984).
Basically, there are two main types of IgGs for clinical














3.3.1 Hepatitis A (HAV)
The prophylactic value of human gammaglobulin
against viral hepatitis was first demonstrated in 1944
by Stokes and Neefe, who prevented the spread of an
epidemic of HAV in a children's summer camp (Stokes and
Neefe, 1945). This was later confirmed by two other
studies carried out in adults in the United States armed
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forces (Gellis et al, 1945), and in institutionalised
children (Havens and Paul, 1945). Human normal
immunoglobulin (HNIg) is protective against HAV if
administered any time during the incubation period, and
up to six days before the onset of disease.
Protection is thought to last for six to eight weeks,
although Stokes et al (1951) found that a single dose of
HNIg (0.02 ml/kg bodyweight) provided some protection
for up to nine months for persons living in an
institution where HAV was endemic.
The degree of protection varies from 80% to 95%,
depending on how soon HNIg is administered after
exposure (Grady, 1975). HNIg suppresses the clinical
manifestation of the disease, and the incidence of
anicteric hepatitis may be 12 times that of icteric
hepatitis (Krugman et al, 1960).
Post-exposure prophylaxis is recommended for contacts
in private households (both temporary and permanent
members), and for contacts in large institutions such as
prisons or institutions for the mentally handicapped.
However, transmission of the disease is uncommon in
casual contacts of a single case in schools, offices or
hospitals and HNIg is therefore not recommended for
routine use in this setting, unless in the case of an
obvious epidemic.
Pre-exposure prophylaxis : Handlers of non-human
primates are at risk of HAV, and individuals working
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directly with newly-imported primates should receive
HNIg at four- to six-monthly intervals. In addition,
HNIg has been shown to be of benefit and is routinely
recommended to travellers to tropical areas and
developing countries where sanitation is substandard.
The dose is 750 mg, or 8 mg/kg bodyweight of HNIg at
four- to six-monthly intervals.
3.3.2 Hepatitis B (HBV)
The first trial using hepatitis B immunoglobulin
(HBIg) was carried out by Krugman and his colleagues in
1971, with HBIg prepared from plasma containing high
titre anti-HB Ab obtained from a single donor with
haemophilia. Of 10 children who received the HBIg, six
were completely protected and one of the remaining four
developed an attenuated illness (60-70% protection).
Later studies by the same group of workers confirmed
that HBIg could significantly reduce the incidence,
severity and carrier rate of hepatitis B surface antigen
(HBsAg) after parenteral' exposure to HBV (Krugman
et al, 1971 ; 1 973) .
Other studies examining the use of HBIg for
prophylaxis against HBV infection have been conflicting
for a variety of reasons. There were differences in
study designs, in populations studied, in the methods,
intensity and duration of follow-up evaluation and in
the assays and criteria chosen to diagnose hepatitis.
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Finally, there were large variations in the amount of
anti-HBV antibody contained in the HBIg preparations
used. Nonetheless, it can be inferred that (1) HBIg
given promptly after exposure reduces the incidence of
clinical hepatitis ; (2) HBIg is effective in preventing
mother-to-infant transmission of HBV ; and (3) HBIg
should be administered promptly, probably within three
days of exposure, to be effective.
Post-exposure prophylaxis : Indications for HBIg
post-exposure prophylaxis depend on the risk of
contracting HBV infection, as assessed by the nature of
the exposure and from the HBV status of the infecting
source. Other indications include babies born to
HBsAg-positive mothers, regular sexual contacts of
carriers and cases of HBV and accidental transfusion of
HBsAg-positive blood or blood products (Morbidity and
Mortality Weekly Report, 1981). HBIg has no place in
the treatment of ongoing infection, even if administered
in large doses (Acute Hepatitis Failure Group, 1977).
The recommended dose is 8-11 mg/kg bodyweight.
Whenever immediate protection is required, as for
example for infants born to HBsAg-positive mothers or
following transfer of an individual into a high-risk
setting or after accidental inoculation, active
immunisation with the vaccine should be combined with
simultaneous administration of HBIg at a different site
(Zuckerman, 1986). The presence of passive antibodies
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does not impair the development of an active antibody
response to the vaccine (Szmuness et al, 1981a ;
Deinhardt et al, 1981).
Wong et al (1984) found that vaccine plus HBIg
appeared more effective than vaccine alone in preventing
the perinatal transmission of HB virus, but the results
were not statistically significant. Giving HBIg alone
in these circumstances often merely delayed the
appearance of chronic antigenaemia (Reesink et al,
1979).
3.3.3 Non-A, non-B (NANB) Hepatitis
Kuhns et al (1976) found HNIg to be of no
benefit in the prevention of NANB hepatitis. However,
later studies by Seeff et al (1977) and Knodell et al
(1976) showed that HNIg reduced the incidence of NANB
post-transfusion hepatitis. It is therefore suggested
that HNIg should probably be used for post-exposure
prophylaxis following needle-stick injuries involving
clinical cases of NANB hepatitis.
3.3.4 Measles
Measles may be a severe illness in young
children who are either immunocompromised or severely
malnourished. Early studies have established the
efficacy of convalescent serum or placental extracts in
the prevention or modification of measles (Zingher,
1924 ; Park and Freeman, 1926; McKhann et al, 1935). The
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degree of protection was found to be dose-dependent;
large doses of HNIg given immediately after exposure
could prevent measles and small doses only modified the
illness (Stokes et al, 1944 ; Ordman et al, 1944). There
was also a reduced incidence of encephalitis in measles
modified by HNIg (Greenberg et al 1955). Children who
are immunocompromised as a result of malignancy, or of
immunosuppressive therapy, should receive a large dose
of HNIg (0.5 ml/kg bodyweight, maximum of 15 ml) as soon
as possible after exposure.
Krugman et al (1962) have shown that HNIg could
reduce the incidence of adverse reactions to the
Edmonston strain of attenuated measles vaccine. The
incidence of high fever and rash was reduced from 40% to
14% and 10% to 2 % respectively. HNIg is also used to
prevent adverse reactions to measles vaccine in children
with a past history of convulsions or with a family
history of idiopathic epilepsy, but the dose used is
very much smaller than when used in passive immunisation
of immunocompromised children (less than 200 times
smaller).
3.3.5 Rubella
Congenital rubella is a consequence of
maternal viraemia, and immunoprophylaxis has a very
limited role in its prevention. Schiff (1969) found
that 20 ml of high-titred rubella IgG could prevent
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viraemia. Pollack (1969) and the Public Health
Laboratory Service Working Party (1970) have shown that
HNIg cannot be relied upon to prevent viraemia,
particularly in clinical practice where it is often very
difficult to establish the timing of exposure to the
virus. Other studies using rubella IgG have failed to
demonstrate significant protective effect in congenital
rubella.
Attempted prophylaxis is therefore restricted to
pregnant women who are exposed to rubella and in whom
therapeutic abortion is excluded for any reason ; the
largest acceptable dose (10-20 ml) should then be given.
3.3.6 Varicella zoster
There is no evidence that HNIg can prevent
chickenpox, but many studies have shown that HNIg given
in large doses can modify the severity of the illness
(Trimble, 1957 ; Ross, 1962 ; Iriarte et al, 1965).
Brunell and co-workers have shown that high-titred
IgG prepared from patients convalescing from chickenpox
or herpes zoster can protect children against
chickenpox, but larger doses are required to prevent or
modify the disease in the immunosuppressed (Brunell et
al, 1969 ; 1972). Furthermore, zoster immune globulin
(ZIG) could allow subclinical infection associated with
the acquisition of passive-active immunity (Gershon,
1974). The plasma used to produce this hyperimmune
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globulin has been in short supply and a suitable
alternative is to collect plasma from donors found to
have high antibody titres to varicella zoster virus
during antibody screening programmes. The IgG produced
from the latter source of plasma, called varicella
zoster immunoglobulin (VZIg), has been shown to be
equally, if not more, effective in protecting
immunosuppressed children from severe chickenpox (Zaia
et al, 1983).
VZIg is used for the passive immunisation of
susceptible immunocompromised patients and premature
babies after significant exposure to varicella virus. It
should be given as soon as possible after exposure but
may be effective when given as late as 96 hours after
exposure.
3.3.7 Rabies
Rabies is probably the ideal infection for post¬
exposure prophylaxis by passive immunisation since the
exact time, nature and source of exposure are usually
identifiable and the long incubation period enhances the
effectiveness of passively administered antibody.
Habel (1945) demonstrated that passively
administered antibody in experimental rabies neutralised
the virus in the tissues, and slowed the spread of the
virus within the nervous system, and increased
protection by allowing active immunity by vaccine to
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become better established. Rabies IgG should only be
used with active rabies vaccine to provide protective
antibody during the period before the active immune
response develops (Baltazard, 1955). However, when
given with the vaccine, the antibody response to the
vaccine is reduced (Loofbourow et al, 1971). Smaller
doses are therefore used to achieve passive-active
immunity; doses of 20 IU/kg bodyweight do not inhibit
the immune response to a course of three or more doses
of human diploid cell vaccine and should not be exceeded
(Mertz et al, 1982).
Until 1971, equine antirabies serum was the only
preparation available for use. Human rabies
IgG has now been produced in some centres. It is very
safe and has a circulation half-life twice that of
equine antibody. It should be given IM and by local
infiltration round the wound for bites in which rabies
is considered to be a risk, and for non-bite exposure to
animals known or suspected to be rabid.
3.3.8 Tetanus
Antitoxin in the treatment of tetanus was
introduced in medicine by Behring and Kitasato in 1890.
The aim of passive immunisation is to prevent any
tetanus toxin produced by Clostridium tetani from being
fixed to the central nervous system cells since it is
very difficult to neutralise the toxin which has already
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been fixed to the nervous tissues. Therefore, to be
effective, tetanus antitoxin should be administered
shortly after injury before any toxin can reach the
nervous system. There is still some controversy
regarding the place of antitoxin in the treatment of
established tetanus.
Heterologous tetanus antiserum is a powerful
allergen. Laurent and Parish (1952) estimated an
incidence of one death for every 50,000 to 200,000
injections of the antitoxin administered. The incidence
of serum sickness following the administration of the
heterologous antitoxin has been estimated to range from
5.2% (Moynihan, 1956) to 30% (Scheibel, 1955).
Furthermore, in developing countries, more deaths have
been caused from anaphylactic shock due to heterologous
antitoxin than from tetanus itself (Ericksson and
Ullberg-Olsson, 1967). The use of heterologous antitoxin
will therefore not be discussed further as it should not
be used unless homologous antitoxin is unavailable.
Interest in the use of homologous antitoxin grew
following studies by Suri and Rubbo who showed that the
use of homologous antitoxin was 100 times more effective
than heterologous antitoxin in the prevention of tetanus
(Suri & Rubbo, 1961). They also showed that in man
homologous antitoxin has a longer half-life. Human
tetanus immunoglobulin (TIG) does not cause
sensitisation in man and provides a more effective and
longer-lasting immunity than heterologous antiserum.
Passive-active immunisation is recommended for
individuals who have never received basic immunisation
and who are in need of immediate protection against
tetanus. For prophylaxis TIG in a dose of 250 units is
administered simultaneously with tetanus toxoid given at
a different injection site. In established tetanus,
the dose of homologous antitoxin is 5000 to 10000 units.
Because tetanus toxin has been found in the
cerebrospinal fluid of tetanic patients (Patel and
Mehta, 1966), intrathecal administration of antitoxin
has been attempted. Most studies (Ildrim, 1975; Diop-Mar
et al, 1975 ; Gupta et al, 1980) have shown improved
survival among those receiving parenteral and
intrathecal antitoxin.
3.3.9 Mumps
There have been many trials of convalescent
serum or plasma from mumps patients which have shown a
certain degree of benefit or protection against mumps
(Rambar, 1946). However, Gellis et al (1945) found
that HNIg was ineffective in the prevention or
modification of mumps, but that convalescent mumps IgG
reduced the incidence of orchitis.
3.3.10 Pertussis
Early investigators used convalescent serum or
blood in an attempt to prevent or modify whooping cough.
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In 1923, Debre found that convalescent serum was
protective if given early during the incubation period.
However, the disease was only modified if serum was
given late during the incubation period and was
unaffected if the serum was administered during the
coughing stage (Bradford, 1935).
In 1957, Morris and McDonald found that human
hyperimmune pertussis globulin did not prevent pertussis
in family contacts. Subsequent trials could not
demonstrate any beneficial effect of pertussis IgG in
the treatment of pertussis (Bass et al, 1969 ; Balagtas,
1971 ) .
There is no place for pertussis IgG in the treatment
or post-exposure prophylaxis of pertussis.
3.3.11 Hypoqammaglobulinaemia
Patients with hypogammaglobulinaemia benefit
from IgG replacement therapy. The initial trial by the
Medical Research Council in 1970 used IM IgG in a weekly
dose of 25-50 mg/kg. With the availability of safe IV
IgG preparations, it is now possible to administer a
much higher dose of IgG, resulting in the achievement of
higher serum IgG levels. This is discussed further in
section 5.1.5.
3.3.12 Prevention of rhesus (Rh(D)) alloimmunisation
The most common cause of Rh (D) alloimmunisation
is feto-maternal bleeding, which may occur at any time
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during pregnancy, or following manoeuvres which may
cause fetal blood to enter the mother's circulation.
The formation of Rh(D) antibodies in Rh(D)-negative
mothers may lead to haemolytic disease in any Rh(D)-
positive infants born to them.
Stern, Goodman and Berger (1961) showed that if Rh(D)
positive red cells were pre-coated with antibody, they
did not induce an anti-Rh(D) response when given to
Rh(D) negative recipients. This principle was
successfully used to prevent maternal sensitisation by
fetal red cells (Clarke et al, 1963; Combined study,
1966). It is thought that 20 mg of anti-Rh(D)
IgG is required to suppress the immune response for
every 1 ml of fetal cells that enter the maternal
circulation. The IgG should be administered as soon as
possible, as delays in excess of 72 hours reduce the
effectiveness of the immune suppression.
Although anti-Rh(D) IgG is very effective, a small
number of mothers become sensitised, probably as a
result of clinically silent feto-maternal bleeding.
Some centres therefore treat all Rh(D) negative mothers
with 100 mg of anti-Rh(D) IgG at 28 and 34 weeks of
gestation during their first pregnancy (Tovey and
Taverner, 1981).
Anti-Rh(D) IgG is also indicated following the
accidental transfusion of Rh(D) positive blood to Rh(D)
negative women of child-bearing age. The recommended
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dose is 20-25 rag/ml of transfused blood by IM route.
Recently, Berlin et al (1985) found that high dose
IV HNIg maintained a reduction in anti-Rh(D) antibody
level achieved by plasma exchange during pregnancy.
They postulated that high dose IgG inhibited maternal
antibody synthesis and caused a partial blockade of
antibody transport across the placenta.
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3.4 AREAS OF DEVELOPMENT
The advent of safe IV IgG preparations and of
monoclonal antibodies has added to the growing list of
accepted clinical uses of immunoglobulins discussed in
section 3.3. Specific hyperimmune globulins can now be
administered in high doses for the treatment of specific
infections. HNIg, however, when used in very high
doses, is thought to have immunomodulating properties
and consequently high dose IV IgG is increasingly used
in clinical conditions that are immunologically
mediated. Furthermore, the development of monoclonal
antibodies has also opened up new possibilities in the
management of malignant conditions. These new
developments will be discussed in this section.
3.4.1 Idiopathic thrombocytopenic purpura
During the treatment of children with humoral
immunodeficiency with IV IgG, Imbach noticed an increase
in platelet count in one such child with coincidental
thrombocytopenia. He then treated a mixed group of
children with acute and chronic idiopathic
thrombocytopenia (ITP) who were refractory to
conventional therapy, with IV IgG. Excellent results
were obtained in the group with acute ITP, but in the
group with chronic disease there was no response in four
patients and those who responded initially required
maintenance therapy (Imbach et al, 1981). This was
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later confirmed by Bussel (1983a ; 1983b).
The mechanism by which high dose IgG leads to an
increase in platelet count is unclear. The main
postulated modes of action (reviewed by Imbach and
Jungi, 1983 ; and Bussel and Hilgartner, 1984) are :
1 Reticuloendothelial system Fc receptor blockade
2 Decreased antiplatelet antibody synthesis
3 Protection of platelets from antiplatelet
antibodies
4 Stimulation of platelet production, and
5 Clearance of persistent viral infection by
infusion of specific antibody.
3.4.1.1 Fc Receptor Blockade
Fc receptor blockade seems to be the most
plausible of postulated modes of action. At least two
studies have shown a prolonged clearance of antibody-
coated autologous red cells, suggesting that there is a
slowing of the destruction of antibody-coated platelets.
However, reticulo-endothelial system (RES) blockade is
short-lived as the rate of red cell clearance returns to
the baseline approximately four weeks after IV IgG
infusion (Fehr et al, 1982 ; Bussel et al, 1983a) RES
blockade, therefore, cannot explain the long-term
response to IV IgG.
It also appears that RES blockade is Fc receptor-
specific, and that non-Fc mediated phagocytosis is
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intact; heat damaged red cell clearance was unchanged in
patients after high dose IV IgG (Newland et al, 1983).
Similarly, ingestion of antibody coated red cells by
circulating monocytes was reduced after IV IgG but
ingestion of neuraminidase treated red cells was
unchanged (Silberman et al 1984). Finally, Clarkson et
al, (1986) successfully treated a patient with
refractory immune thrombocytopenic purpura with an anti-
Fc receptor antibody.
Possible factors that contribute to Fc receptor
blockade are:
1 A reduction in the concentration of free
macrophage Fc receptors available to bind the Fc
part of platelet-associated antibodies
2 Modification of affinity of Fc receptors for the
Fc part of IgG, (Kimberly et al, 1984)
3 Low-grade immune haemolysis of red cells caused
by low-titred red cell alloantibodies in the IgG
that compete with antibody-coated platelets for
available Fc receptors (Salama et al 1983)
4 Small amount of IgG aggregates in the IV IgG,
contributing to RES blockade.
3.4.1.2 Platelet-Associated Antibody
There is no evidence that high dose IV IgG
causes a decrease in platelet-associated antibody as
such. A fall normally occurs following improvement
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with other forms of treatment for ITP. This decrease is
therefore non-specific.
3.4.1.3 Stimulation of Platelet Production
There is also no evidence that IV IgG stimulates
platelet production.
3.4.1.4 Protection of Platelets and/or
Megakaryocytes from Platelet Antibody
IV IgG does not protect the platelets from the
patient's specific platelet antibody. Bussel and
Hilgartner (1984) found no increase in immunoglobulin
staining on the surface of platelets following IV IgG
treatment by direct immunofluorescent staining of fixed
platelets using anti-IgG reagents. Furthermore,
Blanchette et al (1983) found no difference in the
survival of transfused platelets with and without any
previous in vitro incubation with IV IgG.
3.4.1.5 Clearance of Persistent Viral
Infection by Infusion of Specific Antibody
There is no evidence to substantiate this hypothesis.
3.4.2 Use of IV IgG in other immune cytopenias
Wenske et al (1983), and Newland et al (1984)
have successfully used high dose IV IgG without any
serious adverse reactions in the treatment of ITP in
pregnancy. In addition, there are reports of
successful treatment of other kinds of cytopenias such
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as post-transfusion purpura (Hamblin et al, 1985 ;
Becker et al, 1985), thrombocytopenia secondary to
systemic lupus erythematosus, human immunodeficiency
virus (Delfraissy et al, 1985). Four patients with post¬
transfusion purpura benefitted from 0.4 g/kg bodyweight
IgG administered intravenously (Becker et al, 1985).
Bierling et al (1984) found that high dose IV IgG could
prolong the lifespan of incompatible transfused
platelets, and thought that they could facilitate the
management of leukaemic histocompatability locus antigen
(HLA) immunised patients.
High dose IV IgG has been tried in the treatment of
other immune cytopenias. While the use of IV IgG in the
treatment of autoimmune neutropenia is well established
(Pollack et al, 1982 ; Bussel et al, 1983c) there is
some debate regarding its use in the treatment of
autoimmune haemolytic anaemia (AIHA). Mueller-Eckhardt
et al (1985) have found that IV IgG in a dose of 0.2
g/kg bodyweight daily for five days was ineffective in
AIHA, while Bussel et al (1986) found a sustained
response in two of three patients treated with very high
dose IV IgG (1 g/kg/day) for five to seven consecutive
days and maintained on 1 g/kg once every two weeks.
3.4.3 Kawasaki disease
High dose IV IgG administered early in the
course of Kawasaki disease seems to reduce the
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prevalence of coronary artery abnormalities (Furusho et
al, 1984 ; Newburger et al, 1986). Furthermore, in a
single case report, IV IgG reduced the duration of fever
and arthralgia in a young man with Kawasaki disease
(Chavanet et al, 1985).
3.4.4 Myasthenia gravis
Gajdos et al (1984) and Fateh-Moghadam et al
(1984), have reported several cases of myasthenia gravis
improving after the administration of high dose IV IgG.
The improvement was associated with a fall in the
acetylcholine receptor antibody level, presumably as a
result of reduced antibody synthesis, or of an increased
breakdown of total IgG. However, the mode of action
remains speculative.
3.4.5 Epilepsy
Laffont et al (1979), and Pechadre et al (1979)
have described the effect of empirical therapy for
epileptic encephalopathy with gammaglobulin. Ariizumi
et al (1984) have reported partial success in the
treatment of intractable epilepsy with high dose IV IgG,
and Sandstedt et al (1984) have found that high dose IV
IgG has benefitted children with therapy-resistant post¬
encephalitic seizures. The mechanism of action is
unclear, but as autoimmune mechanisms can produce
epilepsy in animal models, and as children with
intractable epilepsy can benefit from immunosuppression,
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it is conceivable that high dose IgG can modulate the
immune response or may neutralise viruses that may be
the cause of encephalopathy.
3.4.6 Malignancy
Wright and Bernstein (1980) have reviewed the
use of passively-administered antibody in the treatment
against neoplasms. There is evidence that neoplasms in
animals as well as in man are at least potentially
responsive to treatment with passively-administered
antibody, but the response is short-lived. There have
been occasional reports of patients with metastatic
melanoma who have completely regressed after receiving
blood from other patients who have previously undergone
complete remission from their melanoma (Sumner et al,
1960). However, subsequent studies have failed to
confirm this.
Antibodies raised against malignant cells have been
shown to reach their target in bone marrow (Ritz et al,
1981), and in lymph nodes, but the damage to their
target cells is usually incomplete and short-lived
(Meeker et al, 1985). Certain tumours secrete free
antigen (Hellstrom and Hellstrom, 1974) and immune lysis
of tumour cells may release large amounts of antigen
which may further block the action of antibody. But the
main problem with serotherapy of human tumours has been
the difficulty in chosing an antigen that is truly
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specific, and in obtaining large quantities of antisera
of sufficient specificity.
The development of monoclonal antibodies of defined
specificity and unlimited quantity has rekindled
interest in the use of passsively-administered antibody
in the treatment of cancer. This is further discussed in
section 3.4.9.
Unfortunately, the use of murine monoclonal
antibodies may lead to the production of antimouse
immunoglobulin antibodies, preventing the usefulness of
further administration of murine monoclonal antibodies.
Indeed, once an immune response to the foreign antigen
has been mounted, further infusions of heterologous
antibody do not reach the tumour cells and are
associated with toxic reactions (Meeker et al, 1985).
But if used in patients with lymphoid malignancies, the
immune response is likely to be minimal and clinically
insignificant as the patients are immunocompromised.
Schroff et al (1985) have found no clinical toxicity
related to the immunoglobulin antibody in their
patients, and there has been no report of such patients
suffering from clinically obvious immune-complex
disease. Nonetheless, the use of human monoclonal




It is thought that the placental membrane may-
play an immunomodulating role in patients suffering from
active rheumatoid arthritis who undergo remission during
pregnancy. Human placental eluted gammaglobulins (PEGG)
composed of purified IgG eluted from trophoblastic cells
are different from commonly used immunoglobulins or
immunoglobulin fractionated from peripheral blood and
may have different immunological properties. In a small
study, seven of 11 patients with active arthritis
improved clinically after PEGG treatment. This was
associated with a significant increase in active E-
rosette forming cells and in mitogen responsiveness.
Such immunomodulating properties were ascribed by the
authors to the PEGG treatment (Sany et al, 1982).
3.4.8 Cytomegalovirus (CMV) infection
Infection with CMV is a serious problem
following organ transplantation (Rubin et al, 1977 ;
Fiala et al, 1975 ; Neiman et al, 1977 ; Rand et al,
1978). These infections can cause a variety of clinical
syndromes, some of which may be severe or fatal (Rubin
et al, 1977; Fiala et al, 1975; Neiman et al, 1977). CMV
infection may also increase the likelihood of graft
rejection and the risk of bacterial and fungal
superinfection.
Present treatment of severe life-threatening CMV
infection following renal transplantation is
unsatisfactory. Antiviral agents such as adenosine
arabinoside have not been successful (Rytel and
Kauffman, 1976) and although interferon may be of value
(Cheeseman et al, 1979), it is unlikely to be generally
available. Attempts to prevent CMV by active
immunisation have also been unhelpful (Glazer et al,
1 979) .
Another method for the prophylaxis and treatment of
CMV infection is that of passive immunisation. Mouse
studies have confirmed the importance of antibody in
combating CMV infection by mechanisms which include
neutralisation requiring complement and antibody
dependent cell mediated cytotoxicity (Araullo et al,
1978; Manischewitz and Quinnan, 1980, and Shanley et al,
1981). Passive immunisation in patients before and after
bone marrow transplantation using high-titre specific
anti-CMV immunoglobulin or high-titre anti-CMV plasma
can prevent or modify CMV infection in these patients
(Meyers et al, 1982; Winston et al, 1982).
Passive immunisation for the treatment of CMV
infection after renal transplantation has also been
attempted. Dijksman et al (1979) reported the
successful use of CMV plasma in a single case of CMV
disease after renal transplantation. In an uncontrolled
study (Condie et al, 1979) of the efficacy of large
doses of HNIg (containing anti-CMV antibodies) given to
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patients with life-threatening infections following
renal transplantation, it was felt that the treatment
benefitted 71% of patients. In those who benefitted,
there was a significant increase in antibodies against
CMV following IgG administration.
Zaia et al (1979) collected 200 units of plasma with
a titre of at least 1:64 against CMV after screening
3080 units. This was fractionated by Cohn's cold
ethanol method. The resultant fraction, called CMV
IgG, represented a 20-fold increase in CMV titre.
Meyers et al (1980b) gave this material to 14
seronegative marrow recipients before and after
transplantation, maintaining a complement fixation titre
(CFT) of 1:16 in these patients. The treated group and
the controls had about the same number of CMV infections
(50% and 42% respectively). The authors postulated
that the antibody was not effective because the virus
was cell-associated at the time of first exposure.
Preliminary data from an uncontrolled study with
high-titre specific anti-CMV IgG in patients with life-
threatening CMV infection following renal
transplantation have shown that anti-CMV IgG may be of
value in these patients (Nicholls et al, 1983).




The production of monoclonal antibodies by in
vitro techniques (Kohler and Milstein, 1975) has opened
up many new avenues for the use of antibodies in
clinical medicine (Dick, 1985). Basically, they can be
used in imaging lesions, treatment of malignancy and as
diagnostic reagents.
3.4.9.1 Imaging
Imaging with radiolabelled antibody has been
successful in studies on animals for both malignant and
non-malignant lesions. Attempts have been made to
delineate myocardial infarcts using antibodies against
cardiac myosin, actin or enzymes released from damaged
muscles (Haber et al, 1982). But specificity has been
difficult to achieve, and there have been problems in
producing a clear picture of the extent of the lesion.
Several groups have used labelled mouse monoclonal
antibodies for tumour localisation in patients with
breast cancer (Rainsbury et'al, 1983), colorectal cancer
(Farrands et al, 1982), and ovarian cancer (Epenetos et
al, 1982). The results of the initial clinical studies
were not spectacular. As a diagnostic technique, it is
no match for the rapidly advancing computerised
radiological techniques such as CT scanning and digital
radiology (Sikora et al, 1984). However, it is the
prospect of using antibodies as carriers of drugs and
A- I
toxins for the efficient localisation of cytotoxic
treatment that makes these studies important.
3.4.9.2 Drug Targetting
The use of monoclonal antibodies to target
cytotoxic agents aims to increase the amount of drug
localising in tumours, particularly metastatic
deposits, and also reduce normal tissue toxicity
(Baldwin and Byers, 1985). This approach requires that
the antibody localises effectively in a tumour and that
the drug must be cleaved from the antibody after
conjugate binding to a tumour cell, and this usually
occurs intracellularly after internalisation of the
conjugate (Baldwin, 1986). Drugs selected for antibody
conjugation should either be highly cytotoxic, such as
ricin (Casellas et al, 1984), or must be amplified to
allow sufficient amounts of less intrinsically cytotoxic
drugs such as methotrexate to be delivered to the tumour
(Baldwin, 1985).
Amplification methods enable more drug to bind to
antibody without destroying its reactivity. The drug is
linked to a carrier such as human serum albumin and the
drug albumin complex is linked to the antibody; at least
ten times more drug can be linked to the antibody by
this technique (Garnett & Baldwin, 1983).
Ribosomal inhibiting proteins such as ricin are under
investigation for use as immunotoxins. Ricin is
composed of two polypeptide chains : B-chain (RTB) binds
to galactose residues present on most mammalian cells
and facilitates entry into the cell of the A- chain
(RTA), which is a potent inhibitor of ribosomal protein
synthesis. When RTA is separated from RTB and coupled
to antibody, the conjugate is specifically cytotoxic for
cells that bind the antibody. RTA conjugates have been
produced with several monoclonal antibodies which are
highly cytotoxic for human tumour cells (Thorpe, 1984).
3.4.9.3 Unmodified Antibodies for Therapy
In most clinical trials of passive treatment
with monoclonal antibodies, the patients were mostly
suffering from haematological malignancies including
lymphoid solid tumours, which were advanced and had
failed to respond to conventional therapy. Nonetheless,
remarkable, if short-lived, responses have been
achieved, particularly in cutaneous malignancies (Miller
and Levy, 1981 ) and in a few B-cell lymphomas with anti¬
idiotype antibody that is a'monoclonal antibody directed
against the immunoglobulin unique to the malignant clone
of B-cells forming the tumour (Stevenson et al, 1984;
Meeker et al, 1985).
The Ortho Multicentre Transplant Study Group (1985)
found that murine monoclonal antibody 0KT3 was
significantly better than conventional steroid treatment
in reversing acute renal-allograft rejection. The high
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incidence of adverse reactions was thought to be due to
a physiologic response to mediators released from T-
cells after the initial 0KT3 treatment.
3.4.9.4 Radiotherapy with Monoclonal Anti¬
bodies
The Hammersmith Oncology Group reported
treatment of 15 patients with ovarian cancer by
intraperitoneal injectionof 131 I-labelled monoclonal
antibodies; symptoms improved in most patients and
complete remissions were achieved in those with stage-
Ill and minimal-residue disease (Epentos, 1985).
3.4.9.5 Bone Marrow Transplantation
Anti-T-lymphocyte monoclonal antibodies are used
in man to eliminate mature T-lymphyocytes in the graft
before transplantation and in vivo to treat graft versus
host disease after transplantation. In vitro depletion
trials have mainly used two or more complement fixing
monoclonal antibodies (Waldman et al, 1984; Prentice et
al, 1984), or antibodies conjugated to whole ricin or
RTA (Filipovich et al, 1985). Graft versus host disease
in HLA-matched sibling transplants can be greatly
reduced both in incidence and in severity. However, most
studies have reported an increase in graft failure with
such T-depleted grafts by comparison with conventional
grafts, and it is clear that this will remain important
even with HLA-matched grafts (Martin et al, 1985).
^4-
Pan-T-lymphocyte monoclonal antibodies have also been
used in vivo to treat graft versus hose disease with a
cocktail of eight complement fixing monoclonal
antibodies (Remlinger et al, 1984). There is some
indication that therapy produced skin clearing but it
was discouragingly ineffective against visceral
manifestations.
3.4.10 New areas of development
Another area which requires careful scientific
investigation is the definition of the conditions under
which synergistic effects between IV IgG and antibiotics
may be expected. Dalhoff (1984) observed that, owing to
its content in anti-betalactamase antibodies, IV IgG
protects B-lactam antibiotics from being hydrolysed,
thus resulting in a synergy between acylureido-
penicillins and IV IgG.
3.5 AREAS OF CONTROVERSY
There is little doubt that passive immunisation
will have an increasingly large role to play in clinical
medicine, particularly in the prophylaxis and treatment
of certain infections and as an immunomodulating agent.
In most countries, plasma for fractionation into
immunoglobulin preparation is obtained either by
separation from conventional blood donations or by
plasmapheresis.
HNIg is prepared from plasma pooled from a large
number of normal donors and must have a minimum level of
antibody against stated viral and bacterial antigens to
meet pharmacopoeial standards. However, batches of
HNIg prepared from different national or racial groups
may vary greatly in their content of specific
antibodies. In contrast, specific or high-titre human
immunoglobulins are prepared from the plasma of donors
who have been screened for high levels of antibody or
who have been intentionally immunised to produce high
levels of specific antibody prior to plasmapheresis.
However, there is some debate as to what constitutes the
most suitable source of plasma for the manufacture of
hyperimmune globulin.
Intramuscular IgG cannot be given rapidly in large
amounts without any discomfort and this limits it as a
useful therapeutic agent. As a result, most effort has
4-6
been put into developing parenterally administered
immunoglobulin preparations. Conventional IM IgG
preparations can produce severe acute reactions if given
intravenously, due to the presence of complement binding
aggregates (Barandun et al, 1962), or vasoactive enzymes
(Alving et al, 1980). Manufacturers have modified the
plasma fractionation process and also developed several
ways of treating the fractionated IgG to avoid
reactions, while retaining the biological activity of
the molecule. To date, while many such preparations
can be safely given by the IV route, there have been
doubts regarding the risk of transmitting hepatitis or
other viral diseases by IV IgG.
IM IgG manufactured by Cohn's cold ethanol
fractionation has an excellent safety record with, to
date, no recorded cases of AIDS transmission (WHO Expert
Committee : reported by Zuckerman at Symposium on AIDS
in Blood Transfusion, 3rd April 1985) and very few
reported cases of hepatitis transmission (Petrilli et
al, 1977 ; John et al, 1979 ; Tabor and Gerety, 1979).
This impressive safety record of IM IgG led to the
belief that IgG manufactured by cold ethanol
fractionation is inherently safe. However, this has
required modification in the light of recent reports of
NANB hepatitis transmission by IV IgG products prepared
by three different manufacturers (Lever et al, 1984 ;
Ochs et al, 1985 ; Weiland et al, 1986). There is,
however, no evidence that the administration of
immunoglobulin products by the IV route is inherently
infective.
In order to meet the increasing demands for
hyperimmune globulins, it is important to identify the
most cost-effective means of recruiting plasma donors.
This thesis will therefore examine the suitability of
random screening for the procurement of CMV, and
HB hyperimmune plasma. The effectiveness of random
screening will be compared with that of boosting donors
with tetanus toxoid for the collection of hyperimmune
tetanus plasma.
A new IV IgG preparation is clinically evaluated in
the thesis. Its safety and efficacy will be studied with
respect to the transmission of hepatitis and the
tolerance of high doses of administered IV IgG in order
to achieve near normal serum IgG levels in patients with
hypogammaglobulinaemia. Finally, an attempt will be
made to assess the clinical benefit to those patients
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Plasma collected from blood donors is usually-
further processed into its various components by ethanol
fractionation. It can be obtained either from whole
blood donations or by plasma donations (plasmapheresis).
Source plasma has two main product use areas; injectable
products such as albumin, coagulation factors, and IgG ;
and non-injectable products such as laboratory reagents.
The source plasma for the manufacture of IgG depends on
whether HNIg or specific hyperimmune globulin is the
desired end product.
4.1.1 Human normal immunoglobulin
HNIg is prepared from pooled plasma collected
from at least 1000 randomly-selected healthy blood
donors, and the antibody distribution reflects the
pattern of infection and immunity in the donor
population. Where adequate concentrations of a
specific antibody are present in normal IgG (for
example, measles antibody), 'it is unnecessary to prepare
a specific high-titred product.
4.1.2 Hyperimmune globulin
A hyperimmune globulin may be designated as such
if it contains at least five times the antibody
potential of the standard preparation per volume.
Therefore, for the manufacture of specific hyperimmune
globulin, donors possessing suitable levels of specific
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antibody are first identified and recruited for
plasmapheresis, or they may be intentionally immunised
to produce high levels of specific antibody prior to
plasmapheresis.
4.1.3 Plasma collection
In 1914, Abel et al described the technique of
plasmapheresis in animals and demonstrated that very
large amounts of plasma could be withdrawn if the red
cells were retransfused. Using this technique,
individuals have been able to donate more plasma
(Grifole-Lucas, 1952).
Plasma donations can be collected both manually and
by machine plasmapheresis. In a manual procedure, whole
blood is collected from the donor, and a component
separation centrifuge separates off-line the whole blood
into red cells and plasma; the red cells are then re-
infused back into the donor. This technique is
relatively cheap, but is time-consuming and carries the
potential risk of returning, the wrong red cells to the
donor because of the off-line separation. Other
potential risks include air embolism and sepsis.
The machine technique harvests source plasma in a
closed extracorporeal system (Rock et al, 1981). Plasma
separation is achieved by high speed centrifugation with
the return of the concentrated red cells to the donor at
the end of each cycle. This technique allows the donor
to spend a minimum of time at a maximum of convenience
but is expensive, due to the higher cost of the capital
equipment and of the disposable software with the unique
self-contained red cell/plasma separator chambers,
allowing on-line separation of whole blood into red
cells and plasma (Gilcher, 1986).
Plasmapheresis by either method is usually
undertaken at monthly intervals when around 600 mis (a
double donation) of plasma is harvested. Such a loss of
plasma in a young healthy donor is replaced within 24
hours by the influx of albumin from the extravascular
space. Hepatic synthesis of albumin is subsequently
increased so that the deficit is replaced after three to
four days (Lundsgaard-Hansen, 1977). Using these data,
it is believed safe to limit the volume of plasma
collected in one session to 600 mis and to restrict the
total plasma volume collected to 15 litres per year.
This plasmapheresis programme has been adopted by the
International Society of Blood Transfusion. However,
certain centres still allow the removal of 1000-1200 ml
of plasma per week, and of 50 to 60 litres per year for
each donor. But there is continuing debate regarding the
long-term safety for the plasma donor following this
particular plasmapheresis programme.
The medical criteria for accepting a donor for
plasmapheresis are basically those for accepting any
blood donor, with the main objectives being the safety,
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purity, potency and efficacy of the final product as
well as the safety and well being of the donor.
Furthermore, if the donor is being recruited for the
collection of specific hyperimmune plasma, he/she
should possess a high enough level of that specific
antibody for which the plasma is collected. Therefore
the donor should fulfil the following criteria:
1 The possession of a suitable antibody level for the
harvesting of specific hyperimmune plasma
2 Age less than 50 years
3 Bodyweight greater than 50 Kg
4 Good venous access
5 No major illnesses
6 Absence of HBsAg
7 Not belonging to a high-risk group for AIDS and
absence of markers of infection with Human
Immunodeficiency Virus (HIV)
8 Availability
4.1.4 Plasma collection for the manufacture of
hyperimmune globulin
The need for hyperimmune globulin has been
discussed in section 3.3. Basically, the role of
hyperimmune globulin lies in the prophylaxis of specific
infections, and although its role in the treatment of
certain infections has yet to be firmly established,
there is increasing evidence to suggest that specific
hyperimmune globulin can modify the outcome of certain
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infections, particularly in the immunocompromised
patient.
This section discusses the problems of recruiting
suitable blood donors for the collection of hyperimmune
plasma. Regular blood donors who possess suitable levels
of useful antibodies are invited to participate in a
given programme of plasmapheresis if they fulfil the
criteria laid out in section 4.1.3. These donors are
usually identified by random screening of the normal
blood donor population. The success and cost
effectiveness of such screening programmes depend on the
prevalence of those particular antibodies in that given
donor population, which is itself a reflection of the
exposure of the microorganism in the community. Factors
that influence the degree of exposure or infection
include the infectivity of the microorganism,
socioeconomic factors such as level of overcrowding
etc,. However, not all infections produce persistently
high levels of antibody, and although the population may
be immune to the pathogen, only a small number of
individuals may possess high enough antibody levels
suitable for plasmapheresis.
Where the frequency of donors with a suitable level
of an antibody in a given population is low, it may be
desirable to enhance the production of such antibodies
in selected individuals by immunisation. The success of
such an operation depends on the existence of a safe
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vaccine that has been shown to produce protective
antibodies in vaccinees with a minimum of side effects.
If such a vaccine exists, there are theoretical
advantages for a planned programme of hyperimmunisation
of selected donors for the purpose of producing
hyperimmune plasma.
To highlight the relative merits of random screening
and of selective hyperimmunisation of blood donors,
plasma procurement for the manufacture of CMV, HBV and
tetanus hyperimmune globulin has been examined.
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4.2 PLASMA PROCUREMENT FOR HEPATITIS B IMMUNOGLOBULIN
4.2.1 Introduction
There is a clinical need for HB hyperimmune
globulin (section 3.2.2). Plasma with high titres of
antibody against HBV for the manufacture of HBIg is
normally collected from suitable donors who have
previously been exposed to HBV infection.
Present plasma procurement systems rely mainly on
large-scale screening of the blood donor population to
find suitable donors to be recruited for plasmapheresis.
Hopkins et al (1981) have found that the prevalence of
hepatitis B surface antibody (HBsAb) in the Scottish
population is quite low and that screening of the
general blood donor population is a large exercise which
is costly as well as time-consuming and labour-
intensive. Furthermore, the serum level of antibody to
HBsAg is not always maintained, leading to a loss of HB
immune plasma donors, and as a consequence such
screening exercises may have to be repeated at regular
intervals. The results of such a screening programme in
South East Scotland are analysed here and its
effectiveness as a means of identifying high-titre
donors suitable for plasmapheresis examined.
4.2.2 Materials and Methods
4.2.2.1 Study Design
Between June and October 1983, all blood
b 6
donations collected from the normal volunteer blood
donor population by the Edinburgh and South East
Scotland Regional Blood Transfusion Centre were screened
for the presence of HBsAb. HBsAb was subsequently
quantified in the positive samples.
Donors with HBsAb levels of 10 IU/ml or greater were
identified and approached with a view to recruiting for
plasmapheresis. The criteria for suitability for
plasmapheresis were :
1 Serum HBsAb level of 10 IU/ml or greater
2 Age less than 50 years
3 Minimum body weight of 50 Kg
4 Good venous access
5 No major illnesses
6 Absence of HBsAg
7 Availability
The recruited donors were plasmapheresed at intervals
varying between once every four and once every 12 weeks
and the volume of each plasma donation was recorded by
weighing. Before each plasmapheresis, quantitation of
HBsAb level was carried out and liver function tests and
absence of HBsAg were monitored.
4.2.2.2 Biochemical Assessment
Venous blood samples were collected at each
plasmapheresis for liver function tests performed by the
Clinical Chemistry Laboratory, Royal Infirmary of
SI
Edinburgh, by Multiple Analysis with Computer System
(SMAC 2).
4.2.2.3 Screening and Quantitation of HBsAb
level
Screening of the blood donations was carried out
using a solid-phase sandwich immunoassay adjusted to
detect samples with HBs antibody level above 1 IU/ml
(Hopkins et al, 1981). The antibody level in positive
sera was measured using AUSAB (Abbott Laboratories,
Chicago, USA) radioimmunassay. A laboratory standard,
calibrated against a WHO standard obtained from the
Amsterdam Red Cross Central Laboratory, was diluted in
0.1 M Tris/HCl pH 7.5 containing 50% normal human serum
(HBsAg/anti-HBs negative) to values of 0.32, 0.16,
0.08, 0.04, 0.02 and 0.01 IU/ml. Anti-HBs containing
sera were diluted 1 in 1 0, 1 in 100, 1 in 1 000 and 1 in
10,000. Count rates were automatically processed by a NE
1612 gamma counter (Nuclear Enterprises, Edinburgh,
Scotland) programmed to construct a standard curve
against which to compare appropriate test serum
dilutions.
4.2.2.4 Assessment of Hepatitis B Status
Venous blood samples were assayed for HBsAg by




Of the 29,265 serum samples screened between
June and October 1983, 129 samples contained more than 1
IU/ml HBsAb. Subsequent quantitation of these 129
positive serum samples showed the following distribution
(see fig 4.2.1).
A total of 19 donors had HBsAb levels of 10 IU/ml
or greater with a range of 10.0 to 116.0 (mean 15.2
IU/ml). Of these 19 newly identified donors that were
approached, 10 agreed to be recruited for regular
plasmapheresis. One donor had to be withdrawn because
routine liver function tests showed evidence of chronic
liver disease. Twelve months after the screening
programme only two of the newly-recruited nine were
still donating hyperimmune HB plasma. Of those lost,
five moved elsewhere and in two cases the HBsAb level
had fallen and remained consistently below 10 IU/ml.
No donor developed abnormal ALT values during the
study.
4.2.3.1 Quantity of Plasma Collected
A total of 30.5 litres of hyperimmune HB plasma
was collected from the nine newly-recruited donors over
the 12 months following recruitment (0.8 to 6.5 litres
per donor). The mean volume of plasma per donor
collected was 3.4 litres. A total of 424,380 IU of




















13.9 IU/ml of HBsAb.
4.2.4 Discussion
HBIg is used in the prevention of HBV infection
following accidental exposure to the virus and in
infants born to mothers who are chronic carriers of the
virus. The requirement for this immunoglobulin is likely
to continue or increase in view of the increasing
incidence of HBV infection (Communicable Diseases,
Scotland, 1984) despite the availability of a safe HBV
vaccine. As a result, a low cost radioimmunoassay for
the screening of donors has been developed (Hopkins et
al, 1981) and the long term value of random screening of
donors for high titre HBsAb plasma was analysed. Of all
the donors identified following the screening of 29,265
blood donations, only two were still donating regularly
12 months after they had been recruited.
The experience in South East Scotland in recent
years is that every year on average a third of donors
from the HBsAb plasmapheresis panel become unsuitable
because of falling antibody level, or because they have
moved elsewhere. Therefore, to maintain a constant panel
of say 15 donors it would be necessary to repeat the
screening programme at less than three-yearly intervals.
This present system therefore appears to be a very
inefficient way of identifying and recruiting hepatitis
B plasma donors.
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In previous years, five other screening campaigns
have been carried out in Edinburgh ; the very poor
recruitment rate is confirmed (Table 4.2.1).
It is therefore important that other methods for
procuring HBsAb plasma for the manufacture of HBIg be
examined. In particular, now that a safe HBV vaccine is
available, the immunisation of suitable donors should be
considered. However, while it is generally very
difficult for individuals to achieve high enough
antibody levels suitable for plasmapheresis (greater
than 10 IU/ml) following a primary course of
immunisation with HBV vaccine (Szmuness et al, 1981b;
Dienstag et al, 1984), preliminary studies in the North
London Blood Transfusion Service have demonstrated that
high enough antibody levels can be reached in
individuals who have pre-existing naturally-acquired HBS
antibody by boosting. A consistent 10-fold rise and in
certain cases a 60-fold rise in antibody levels
following boosting with the Merck, Sharp & Dohme
HBV vaccine has been demonstrated (Barbara et al, 1983).
It is therefore suggested that boosting individuals with
pre-existing naturally-acquired HBsAb be examined as a
means of recruiting suitable HB immune plasma donors.
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Date of No. of No. (%) of No. (%) No. recruited
screening donations positive suitable for for
screened donations plasmapheresis plasmapheresis






























1 983 29,265 1 29 0.67 26 0 .088 9
Table 4.2.1 Screening campaigns carried out in Edinburgh to
detect HBsAb positive donations
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4.3 PLASMA PROCUREMENT FOR CMV HYPERIMMUNE GLOBULIN
4.3.1 Introduction
CMV infection is an important cause of morbidity
and mortality in organ and bone marrow transplant
recipients (Nieman et al, 1977; Peterson et al, 1980).
In order to reduce the frequency and severity of CMV
infection in such patients, a variety of strategies
including the prophylactic administration of CMV
hyperibmune globulin have been proposed. The efficacy of
CMV hyperimmune globulin in the prophylaxis and
treatment of CMV infection in this setting has been
discussed in section 3.4.10.
The demand for CMV hyperimmune globulin in these
clinical conditions is likely to increase with the
increasing number of transplants performed. Source
plasma for the production of CMV hyperimmune globulin is
collected from donors with high levels of naturally
occuring CMV antibodies. These donors are identified by
random screening of the donor population using a number
of serological tests.
The results of a screening programme for indentifying
such donors are described, and the effectiveness of the
programme discussed.
4.3.2 Study design
During a seven-week period, from 27 October 1982
to 16 December 1982, 845 random donors visiting the
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Blood Donor Centre in Edinburgh were screened for the
presence of high-titre CMV antibody by enzyme-linked
immunosorbent (ELISA) test. The screening was performed
by Dr GR Barclay and his technicians at the Edinburgh
Blood Transfusion Centre.
Donors who fulfilled the following criteria were
later invited for regular plasmapheresis;
1 ELISA value equal to or greater than that found for
a CMV-positive plasma previously reported to have a
titre of 1 in 40 by complement fixation test (CFT)
(PHLS, Colindale Hospital, London) or 1 in 32
(Department of Virology, University of Edinburgh).
2 CFT titre of 1 in 16 or greater (Department of
Virology, University of Edinburgh)
3 Good venous access
4 No major illnesses
5 Absence of HBsAg
6 Age less than 50 years
7 Availability
4.3.3 Results
Of the 845 donors screened, 85 (10%) were
considered suitable by serological criteria using ELISA.
After further testing by the Department of Virology at




(a) 11 donors did not respond to the request letter
(b) 13 donors were considered unsuitable for
plasmapheresis on medical grounds
(c) Two donors were not contacted due to clerical
mishap
(d) 48 donors were considered suitable and agreed to be
regularly plasmapheresed.
4.3.3.2 Follow-up
The number of donors who remained on the
plasmapheresis panel at 6, 9, 12, 24, and 36 months is
shown in Table 4.3.1. Donors were withdrawn from
plasmapheresis for a variety of reasons as shown in
Table 4.3.1. The single most common one was a fall in
serum CMV antibody level; 17 donors were withdrawn from
the panel within the first year for that reason.
Fourteen donors were withdrawn for medical reasons;
abnormal liver function tests (five donors), anaemia
(three donors), and the-development of antibodies to
HB core antigen.
A total of 568 single donations equivalent to 142
litres of high-titred CMV plasma were collected within
the first year.
Only 25% of donors recruited from the screening
programme were still donating at 12 months, and this




6 9 1 2 24 36
No. donors active 36 25 1 2 9 6
No. donors withdrawn
because of
Low titre 4 1 2 1 7 1 8 20
Medical condition 4 6 1 4 1 5 1 6
Lost to follow-up 3 3 3 3 3
Moved away from centre 1 2 2 3 3
Total No. withdrawn 1 2 23 36 39 42
Table 4.3.1 Distribution of donors following recruit¬
ment : the medical reasons included
anaemia, pregnancy and liver disease
4.3.4 Discussion
The frequency of CMV infection in adults varies
between and within countries, probably depending on
socioeconomic and hygienic conditions. The infection,
usually asymptomatic, is followed by an antibody
response. Children of low socioeconomic status acquire
the infection earlier than whites (Li & Hanshaw, 1966;
Monif et al, 1970). In the study by Szmuness et al
(1975), male volunteer blood donors who were mostly
white and middle class displayed a relatively low
prevalence of CMV-CFT antibody. The prevalence of CMV-
CFT antibody is also thought to rise with age (Krech et
al, 1973 ; Kane et al, 1975 ; Monif et al, 1974).
In this study, 10% of randomly selected donors had
CMV antibody levels suitable for recruitment into a
regular plasmapheresis programme. In contrast, Zaia et
al (1979) found that source plasma for the production of
hyperimmune CMV IgG could be obtained from 5% of the
normal blood donor population. The marked decrease (75%)
in the number of donors who remain suitable for
plasmapheresis after one year suggests that this form of
recruitment is relatively inefficient. Of the original
48 donors, 17 (35%) were withdrawn because of falling
antibody levels. Interestingly, Waner et al (1973) found
marked fluctuations in CMV antibody levels in 19 of 20
plasmapheresed donors.
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In view of the relatively low prevalence of donors
with suitable CMV antibody levels in contrast to the
high prevalence of high CMV antibody in the homosexual
population (50%), Ikram et al (1983) have suggested that
an adequate supply of hyperimmune CMV plasma could be
obtained from the homosexual population. However, in the
light of the present AIDS epidemic, this plasma source
is totally unacceptable.
However, data from this study show that 44% of female
donors, compared to 21% of male donors, dropped their
CMV antibody level below that acceptable for
plasmapheresis within 12 months of recruitment. Thus,
male donors would appear more suitable for
plasmapheresis.
While random screening of blood donors is
inefficient and requires to be frequently repeated to
meet the increasing demands for CMV IgG, the situation
will remain unchanged until a reliable safe vaccine
becomes available. To date hyperimmunisation of donors
with a CMV vaccine is not feasible as there is still
concern over the long-term safety of the currently
available CMV vaccines, particularly with respect to
their potential oncogenicity. Several herpes viruses
have been associated with cancer (natural and
experimental) and CMV has been shown to cause
morphologic and neoplastic transformation (Albrecht and
Rapp, 1973). Random screening of blood donors therefore
6q
remains the only means of identifying CMV hyperimmune
plasma donors.
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4.4 HYPERIMMUNE TETANUS PLASMA PROCUREMENT
4.4.1 Introduction
Tetanus immune globulin (TIG) is manufactured
from plasma collected from human donors who have high
levels of tetanus antibody. These donors are usually
selected shortly after a course of tetanus immunisation
or a tetanus boost following trauma. However, this
method is not entirely satisfactory because not all
donors achieve suitably high antibody levels (greater
than 10 IU/ml) after immunisation. Some plasma
collecting organisations therefore boost selected donors
to render them suitable for donating hyperimmune tetanus
plasma (Cook et al, 1976; Rubin et al, 1980).
Local and mild systemic reactions following tetanus
toxoid administration are quite common (Deacon et al,
1982), and the frequency and severity of such reactions
is thought to increase with the number of vaccine doses
administered (White et al, 1973). Boosting of blood
donors with tetanus toxoid would therefore have to take
into account the level of adverse reactions that would
be acceptable to the donor population, as well as the
problem of compensation to the donor in the event of
these reactions being unduly serious.
Adverse reactions are thought to be due to
hypersensitivity to the toxoid or to proteins of
Clostridium tetani which co-purify with toxoid during
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the precipitation process used in the conventional
preparation of toxoid. It was therefore thought
possible that a purer toxoid might be less reactive, and
thus safer for hyperimmunisation of donors.
Such an immune purified toxoid containing fewer
contaminant proteins has been prepared by affinity
chromatography at Wellcome Research Laboratories. A
study was therefore designed (1) to compare the IPT
toxoid with conventional toxoid in terms of tetanus
antibody response and adverse reactions in adult
vaccinees, and (2) to define the characteristics of the
donor most suitable for a programme of hyperimmunisation
with tetanus toxoid; and in particular, to examine the
factors that influence the incidence of adverse
reactions to tetanus boosting, and those that determine
the persistence of antibody levels following boosting.
4.4.2 Volunteers, Materials and Methods
4.4.2.1 Volunteers
Two hundred and five healthy adult volunteers of
both sexes aged 18 - 64 years were recruited from blood
donors attending the SNBTS, Edinburgh.
Exclusions from the study were:
1 Administration of TIG within six weeks prior to
the study
2 Administration of tetanus toxoid within 12 months
prior to the study
11
3 Pregnancy
4 Subjects who experienced a severe reaction to
a previous dose of tetanus vaccine.
4.4.2.2 Vaccines
CPT (Adsorbed tetanus vaccine, Wellcome lot IPPT
31) contained 10 Lf of tetanus toxoid (1770 Lf/mg
protein N) and had an immunising potency of 80.2
IU/dose. IPT (Wellcome lot IPPT 27) contained 10 Lf of
tetanus toxoid (2317 Lf/mg protein N) and had an
equivalent immunising potency (109.4 10/ dose). IPT was
purified by antibody affinity chromatography using
equine tetanus antibody conjugated to Sepharose by the
cyanogen bromide method. Both vaccines contained 0.69 mg
Al +++ / dose.
4.4.2.3 Methods
Vaccination and reaction histories were
determined by interview. Initial venous blood samples
were provided for assessment of tetanus antibody.
Volunteers were matched for age and sex (Table 4.4.1),
and with six exceptions tetanus antibody titres were
randomly assigned to receive CPT (n = 102) or IPT
(n = 103). A single 0.5 ml dose of vaccine was
administered to each volunteer by deep subcutaneous
injection using a needle and syringe. All doses were
selected by reference to a list assigning volunteer
names to treatment numbers, and were therefore
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CPT IPT
No. in group (% males) 102 (50%) 103 (51%)
Mean age (range) in years 34 (18-64) 32 (18-64)
Table 4.4.1 Characteristics of recipients of conven¬
tionally purified tetanus (CPT) and
immune purified tetanus (IPT) toxoid
vaccines
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administered on a double-blind basis.
After the completion of the vaccine trial, donors
were invited to be plasmapheresed if they fulfilled the
following criteria :
1 Serum antibody level of 10 IU/ml or greater
2 Age less than 50 years
3 Body weight greater than 50 kg
4 Good venous access
5 No major illnesses
6 Absence of HBsAg
7 Availability
Thirty-six donors were invited to donate plasma for
the manufacture of TIG. The frequency of
plasmapheresis varied from once every four weeks to once
every 12 weeks, depending on availability. Donors
whose tetanus antibody levels dropped below 10 IU/ml on
two successive occasions were withdrawn from the
plasmapheresis panel.
All volunteers provided informed consent to
participation in the study. The protocol was approved by
the Ethical Committee of the SNBTS.
4.4.2.4 Statistics
Statistical evaluation of significance of
differences in frequencies of events between groups was
determined by Fischer's exact test.
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4.4.2.5 Clinical Reactions
Vaccinees were asked to complete a daily record
for seven days after vaccination so as to record any
reactions at the site of injection (pain, redness,
tenderness and the presence of nodule), as well as
systemic reactions (headache, feverishness and malaise).
Pain, redness and tenderness were graded 1-3 according
to whether they were considered mild, moderate or
severe. Volunteers recorded their morning oral
temperature daily for seven days after immunisation.
4.4.2.6 Measurement of Tetanus Antibody
Blood was collected from 204 volunteers before
and approximately two weeks after immunisation. One
recipient of IPT failed to provide paired serum samples.
The concentration of circulating tetanus antibody was
determined on paired pre- and post-immunisation sera by
ELISA for specific IgG antibodies (Dr GR Barclay,
unpublished). The concentration of tetanus antibody in a
subset of vaccinees was also measured by the scientific
staff at the Wellcome Research Laboratories using the
toxin neutralising test of Glenny and Stevens (1938).
4.4.3 Results of vaccine trial
The groups were balanced for age, sex and
preimmunisation tetanus antibody titres. (Table 4.4.1).
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4.4.3.1 Clinical Reactions
Calendar records were returned by 204
participants in the study ; one recipient of immune
purified vaccine failed to return a reaction card.
Inspection of the calendar records revealed no
significant reaction to either vaccine. Only transient
mild systemic symptoms and signs with mild discomfort at
the site of injection was recorded. No significant
difference in the overall frequency of reactions was
detected between the groups, with 83/102 (81%) of CPT
recipients as compared to 88/102 (86%) of IPT recipients
recording any reactions during the study (p > 0.2).
The frequency of local reactions, defined as redness,
pain, tenderness and the presence of a lump at the
injection site, are shown in Table 4.4.2. The
frequency of local reactions reported in the recipients
of CPT was 76/102 (75%) as compared to 83/102 (81%) in
the group receiving IPT. The difference is not
statistically significant. Further details of the
incidence of local reactions are shown in Table 4.4.2.
In the seven days following vaccination, 29 (28%) CPT
recipients and 29 (28%) IPT recipients experienced
systemic symptoms or signs that might have been
associated with the vaccines (Table 4.4.3). These
included pyrexia (temperature > 37.5 C), headache,
influenza-like symptoms, nausea, dizziness, malaise,
myalgia, or peripheral paraesthesia. Other symptoms
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Vaccine CPT IPT
No. of participants 102 102
Any local reactions
No. (%) reporting 76 (75) 83 (81)
Mean no. of days* (range) 4.14 (1-7) 4.17 (1-7)
Redness
No. (%) reporting 54 (53) 53 (52)
No. (%) severe reactions 5 (5) 5 (5)
Mean no. of days* (range) 3.30 (1-7) 3.57 (1-7)
Pain
No. (%) reporting 30 (29) 29 (28)
No. (%) severe reactions 0 (0) 1 (1)
Mean no. of days* (range) 2.47 (1-5) 2.28 (1-7)
Tenderness
No. (%) reporting 62 (61) 61 (60)
No. (%) severe reactions 5 (5) 1 (1)
Mean no. of days* (range) 2.95 (1-7) 2.85 (1-7)
Lump at injection site
No. (%) reporting 49 (48) 53 (52)
Mean no. of days* (range) 4.41 (1-7) 4.30 (1-7)
Other reports**
No. (%) reporting 23 (23) 18 (18)
* Total no. of person days on which reactions were reported
** Itch; bruise; swelling
Table 4.4.2 Local reactions reported by participants
in a clinical comparison of convention¬
ally purified tetanus (CPT) and immune




No. (%) reporting 29 (28) 29 (28)
Mean no. of days* (range) 2.28 (1-7) 1.93 (1-7)
Pyrexia (>37.5 C)
No. (%) reporting 5 (5) 5 (5)
Mean no. of days* (range) 1.80 (1-4) 1.50 (1-2)
Headache
No. (%) reporting 14 (14) 14 (14)
Mean no. of days* (range) 2.36 (1-6) 1.64 (1-7)
Feverishness
No. (%) reporting 4(4) 6 (6)
Mean no. of days* (range) 2.00 (1-3) 1.83 (1-3)
Miscellaneous reports +
No. (%) reporting 13 (13) 12 (12)
Mean no. of days* (range) 2.1 (1-6) 1.4 (1-3)
Other reactions ♦
No. (%) reporting 5 (5) 7 (7)
Mean no. of days* (range) 2.0 (1-3) 2.1 (1-7)
* Total no. of person days on which reactions were
reported.
t Possible vaccine-associated reactions: nausea,
dizziness,
* malaise, peripheral paraesthesia, diarrhoea, abdominal
pain, urinary frequency, upper respiratory infections.
Table 4.4.3 Systemic reactions reported by
participants in a clinical comparison of
conventionally purified tetanus (CPT) and
immune purified tetanus (IPT) toxoid
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such as diarrhoea, abdominal pain, urinary frequency and
sore throats may have been related to concurrent
infections, and were therefore categorised separately.
One recipient of CPT reported peripheral paraesthesia on
the second and third post- vaccination days. It is
unclear whether this arose in the injected or
contralateral arm. Analysis of the frequency of symptoms
and signs did not demonstrate any statistically
significant difference between the two vaccine groups.
4.4.3.2 Vailidity of ELISA Method
Figure 4.4.1 shows the correlation between the
ELISA and the mouse neutralisation test for the
measurement of tetanus antibody ; r = 0.86.
log (mouse) = 0.13 + 0.93 log (ELISA)
4.4.3.3 Antibody Response
Increases in tetanus antibody in the recipients
of each vaccine, assessed by ELISA, are shown in Tables
4.4.4 and 4.4.5. Forty-four (75%) of 59 recipients of
CPT, and 45 (67%) of 59 recipients of IPT with
previously undetectable antibody levels developed
concentrations indicative of immunity to tetanus, i.e.,
at least 0.01 IU/ml. Altogether, 83 CPT recipients
(81%) and 86 IPT recipients (84%) had an increase in
tetanus antibody following immunisation. There was also
no difference in the frequency and magnitude of antibody
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Figure 4.4.1
Correlation between tetanus antibody measurements
by ELISA and mouse neutralisation test
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CPT IPT
Total no. assessed 1 02 1 02
Pre-immunisation tetanus
antitoxin value = 0 59 59
Post-immunisation tetanus
antitoxin value = 0 1 5 1 4
No. with an increase in
tetanus antitoxin 83 86
GMT* pre-immunisation 1 .48 1 .52
post-immunisation 6.21 6.65
*GMT = Geometric mean tetanus antitoxin titre calculated
on the assumption that antitoxin titres were below the
limits of detection, i.e. 0 taken to equal the lowest
possible titre.
Table 4.4.4 Serological responses to conventionally
purified tetanus (CPT) and immune purified
tetanus (IPT) toxoid as assessed by ELISA
<3 2
CPT IPT
> 2.5 IU/ml 1 2 1 5
2.5-5.0 IU/ml 7 15
5.0-10.0 IU/ml 29 23
10.0-20.0 IU/ml 23 20
20.0-40.0 IU/ml 1 2 11
40.0-80.0 IU/ml 0 2
Total 83 86
Table 4.4.5 Increase in tetanus antitoxin.
Analysis of increase in tetanus antitoxin
measured by ELISA.
CPT = conventionally purified tetanus
toxoid
IPT = immune purified tetanus toxoid
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4.4.4 Data following boosting
The two vaccines were found to be similar with
respect to the frequency of reactions encountered in the
vaccinees and to their immunogenicity. For the purposes
of data presentation and analysis, no distinction was
made between the two vaccines.
4.4.4.1 Effect of Age, Sex and Preimmunis-
ation Tetanus Antibody Level on Antibody Level
at Two Weeks after Immunisation
There was a significant correlation between age
and antibody level assayed two weeks after immunisation
(r = -0.30; p < 0.001), and between age and increase in
antibody level defined as the difference between post-
and preimmunisation antibody levels (r = -0.24 ;
p < 0.001 ) (Table 4.4.6 ) .
There was no significant sex difference in the
magnitude of antibody increase (Table 4.4.7).
The magnitude of antibody increase was independent of
the preimmunisation antibody level (Table 4.4.8).
4.4.4.2 Effect of Preimmunisation Antibody
and Age on Incidence of Reactions to Vaccine
The sum of the number of days on which the
vaccinees experienced any moderate or severe symptoms
was used for the analysis of adverse reactions. There
was no significant correlation between preimmunisation
antibody level and overall reactions; however, the






25-35 25-50 >50 19-65
0 1 (2) 10 (13) 15 (30) 5 (24) 31
<10 28 (49) 32 (42) 1 8 (36) 10 (48) 88
>10 28 (49) 34 (45) 1 7 (34) 6 (29) 85
Total 57 (100) 76 (100) 50 (100) 21 (100) 204
Figures in parentheses indicate percentage.




level, IU/ml Male Female
0 14 (13%) 17 (17%) 31
<10 45 (43%) 43 (43%) 88
>10 46 (44%) 39 (39%) 85
Total 105 (100%) 99 (100%) 204
Table 4.4.7 Relationship between sex and antibody
response
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Preimmunisation antibody level, IU/ml
0 0-2 2-4 4-8 >8
Total Number 118 33 23 21 9
No. with increase
in antibody level
post-immunisation 89(75) 31(94) 22(96) 20(95) 7(78)
Increase in anti¬
body, IU/ml
Mean 8.76 8.44 9.50 8.08 7.75
+ SD 1 0.60 7.21 6.46 8.87 1 0.44
Figures in parentheses indicate percentage.
Table 4.4.8 Relationship between preimmunisation
antibody level and antibody increase
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high incidence of reactions amongst vaccinees with
antibody levels which were detectable but less than 2.0
IU/ml (Table 4.4.9). Males had significantly fewer
reactions than females (p < 0.01) (Table 4.4.10), but
there was no evidence that age had any effect on the
incidence of adverse reactions.
When the individual reactions were analysed, there
was a significantly higher incidence of moderate or
severe tenderness and redness among the females
(p < 0.01; Table 4.4.10). There was also a correlation
between preimmunisation antibody level and pain (r =
0.21; p <0.01) and between preimmunisation antibody
level and frequency of tenderness (r = 0.20 ; p <0 .01).
The incidence of individual reactions was also analysed
in vaccinees grouped according to their preimmunisation
antibody levels. While there was a significantly higher
incidence of moderate and severe pain at the injection
site in subjects with preimmunisation antibody levels
above 8 IU/ml (X = 4.15; p < 0.05), the increased
incidence of moderate and severe tenderness in that
group was not statistically significant (X2"= 3.80 ;
p < 0.05), when compared with the group with no
detectable preimmunisation antibody level.
Interestingly, the group with detectable
preimmunisation antibody levels of less than 2 IU/ml
showed the highest frequency of reactions, which in many
cases were significant as compared to the group without
Preimmunisation antibody level, IU/ml
0 0-2 2-4 4-8 >8
Total number 118 33 23 21 9
Local reactions
Redness (%) 17(14) 9(27) 5(22) 3(14) 2(22)
Pain (%) 3(2) 1 (3) 2(9) 3(14) 2(22)
Tenderness (%) 9(8) 1 1 (33)** 1 (4) 5(24) 3(33)
Lump (%) 55(47) 17(52) 12(52) 13(62) 6(66)
Systemic reactions
Temperature (%) 4(3) 4(12) 1 (4) 1 (5) 0
Headache (%) 13(11) 9(27)* 3(13) 2(10) 2(22)
Feverishness (%) 2(2) 4(12) 1 (4) 2(10) 1(11)
No moderate or
severe reaction 95(81) 14(42) 19(83) 13(62) 5(56)
Some moderate or
severe reaction 23(30) 19(59) 4(17) 8(38) 4(44)
Figures in parentheses indicate percentage
* 0 .05> p > 0.025; ** p < 0.001
Table 4.4.9 Correlation between preimmunisation






Redness (%) 11 (10%) 25 (25%)*
Pain (%) 3 (3%) 8 (8%)
Tenderness (%) 8 (8%) 21 (21%)*
Lump (%) 46 (44) 57 (58%)
Systemic reactions
Temperature (%) 2 (2%) 8 (8%)
Headache (%) 1 5 (14%) 1 4 (14%)
Fever (%) 3 (3%) 7 (7%)
Total reactions (pain,
tenderness, fever, headache) 22 (21%) 36 (36%)
* p < 0.01
Table 4.4.10 Frequency of reactions among sexes
detectable preimmunisation antibody.
4.4.4.3 Volume of Hyperimmune Plasma
Collected
Thirty-six donors (23 men and 13 women) with
high post-immunisation antibody levels were recruited
for plasmapheresis. Three donors were withdrawn from
plasmapheresis: two men were unavailable to attend
regularly because of business commitments, and one woman
developed a medical condition unrelated to immunisation
or plasmapheresis. By six months after immunisation,
plasmapheresis had been stopped in 21 of the 33
remaining donors (62%) because their antibody levels
had fallen below 10 IU/ml. The volume of plasma
collected in the six months following immunisation was
54.5 litres containing a total of 1,201,400 IU of
tetanus antibody with a mean antibody concentration
of 22.0 IU/ml.
4.4.4.4 Characteristics of Donors with
Persistently High Antibody Levels
There was no clear relationship between the
persistence of antibody level above 10 I.U/ml and the
interval since the last tetanus boost but 75% of donors
with preimmunisation antibody levels above 8 IU/ml
appeared to maintain an antibody level above 10 IU/ml
after boosting for at least six months (Fig.4.4.2).
Of the 21 men and 12 women who were regularly


































Distribution of plasma donors with post-immunisation
tetanus antibody levels greater than 10 i.u/ml
who were still donating in the six months
following immunisation
Donors are allocated to groups according to their pre-
immunisation tetanus antibody level.
still possessed antibody levels above 10 IU/ml after six
months of plasmapheresis (Fig 4.4.3).
4.4.5 Discussion
4.4.5.1 Data From Vaccine Trial
There was no difference in clinical reactivity
and immunogenicity between the two vaccines. In this
study the overall incidence of local reactions (83.8%)
was higher than that found in a smaller study (68%) in
which a similar method of recording reactions was used
(Deacon et al, 1982 ). Of the 29 non-immune vaccinees
who failed to develop antibodies to the toxoid, 18 had
no memory of any tetanus vaccination, seven said that
they might have been vaccinated during schooldays but
not in the last 25 years, and four clearly remembered
initial vaccination or 'booster' doses but not within
the last 10 years; 24 of the 29 were at least 30 years
of age. It may be that many of the non-responders may
not have been able to mount a secondary immune response
since they would not necessarily have received routine
tetanus immunisation in infancy.
The lack of difference between the two vaccines in
this study, together with the lower incidence of
reactions with plain formol tetanus toxoid (Collier et
al, 1979; Rubin et al, 1980) suggest that local
reactions may be due to the toxoid itself and/or to























Sex distribution of donors with post-immunisation
tetanus antibody levels greater than 10 i.u/ml
during the first six months following immunisation
Qh-
than to the impurities that are co-purified with the
toxoid in the conventional purification technique and
which are removed by antibody-affinity purification.
This is consistent with previous studies in which the
severity and frequency of reactions were not thought to
be reduced by further purification of the toxoid (White
et al, 1973; Griffith, 1967).
4.4.5.2 Data from Plasmapheresis Donors
The frequency of unselected donors with a
tetanus antibody level above 10 IU/ml is very low,
ranging from 1.5% (Entwistle and Eldridge, 1973) to 2.8%
(Sgouris et al, 1966), so that random screening of
suitable donors is an inefficient method of finding
immune plasma donors. A programme of hyperimmunisation
of plasma donors with tetanus toxoid would overcome the
difficulty in recruiting tetanus antibody plasma donors
(Cook et al, 1976; Rubin et al, 1980). However, before
such a programme is set up, it is important to identify
the donors who are unlikely to suffer from severe
adverse reactions and who can be expected to produce
good antibody levels for a long time after boosting.
The results of this study do not show any
statistical difference between the sexes in terms of
antibody response to tetanus toxoid. However, the
increase in antibody level following boosting with
tetanus toxoid was significantly less in those over the
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age of 40 years. The reduced antibody response with
increasing age has previously been observed (Peel et al,
1 978; Yeni et al, 1 978 ) .
It is generally difficult to compare reaction rates
in different tetanus vaccine studies because of
differences in the vaccines and vaccinees, and in the
methods of assessing adverse reactions (Collier, 1980).
Published reports show that women are more susceptible
to reactions than men (Editorial, Br Med J 1974; White
et al, 1973), and that there is a higher frequency of
reactions in persons with high levels of preimmunisation
tetanus antibody (Faktor et al, 1973 ; Levine and
Edsall, 1981). This present study confirms that women
are more likely to experience adverse reactions than
men. In addition, there was a trend towards a higher
frequency of adverse reactions with increasing pre¬
immunisation antibody levels, but this was only
significant for moderate and severe pain in the group of
vaccinees with a preimmunisation antibody level above
8 IU/ml. This study also suggests unexpectedly that the
highest and most significant incidence of reactions with
preimmunisation tetanus antibodies is in the group with
preimmunisation antibody levels between 0 and 2 IU/ml.
This finding has not been previously reported. Since
this increased frequency was observed equally in
recipients of either immuno-purified or conventionally
purified vaccine, it may not be related to vaccine
preparation. These reactions may be an Arthus-type
phenomenon (Editorial, Br Med J, 1974), where it is
possible that in this antibody range the ratio of
antibody to antigen in some subjects was such that
immune complexes were formed and caused the reactions.
Although among the donors with persistently high
tetanus antibody levels (above 10 IU/ml) six months
after boosting there was a preponderance of men and of
donors with a preimmunisation antibody level above
8 IU/ml, it is difficult to draw any definite conclusion
as the numbers are small. Furthermore, it is not
surprising that following boosting, individuals with
high preimmunisation antibody levels would maintain a
high antibody level longer than those with lower pre¬
immunisation antibody levels.
This study confirms that boosting of volunteer
donors for the production of plasma containing high
levels of tetanus antibody produces only minor reactions
and that individuals with high tetanus antibody levels
can be hyperimmunised without an excess of adverse
reactions. Boosting is therefore appropriate in
situations where it is difficult to recruit adequate
plasma donors for tetanus antibody. Finally, donors most
suited for hyperimmunisation with tetanus toxoid are
likely to be young males preferably under 25 years of




Plasmapheresis offers a practical means of meeting
the growing demand for plasma for the manufacture of
immunoglobulins.
The results from the three studies strongly suggest
that boosting of selected blood donors for the
procurement of hyperimmune plasma is not only feasible
but also a desirable alternative. Indeed, in areas where
it is difficult to recruit plasma donors with suitably
high antibody levels because the prevalence of these
antibody levels in the population is low,
hyperimmunisation of selected donors may be the only way
to ensure that adequate volumes of plasma can be
collected.
At present, donors are withdrawn from the
plasmapheresis panel for medical reasons or because
their antibody levels have significantly decreased. The
latter group of donors could be retained as hyperimmune
donors after boosting with,vaccine, thus reducing the
need for recruiting new donors. Furthermore, because the
antibody levels achieved after boosting are so high,
fewer donors are needed. Consequently, plasmapheresis
programmes are more efficiently run because fewer
plasmapheresis procedures are performed and fewer donors
need close monitoring.
However, the procurement of any hyperimmune plasma
should be individually examined in the light of the
qs
results of the three studies. In certain cases, for
example rabies hyperimmune plasma, it is unlikely that
random screening of the blood donor population would
yield adequate numbers of suitable donors, and
hyperimmunisation is the only means whereby hyperimmune
plasma could be obtained. On the other hand, there may
not be any need for a hyperimmune preparation when the
level of antibody in the general population is already
high, as in the case of measles immunoglobulin. Table
4.5.1 summarises the present position regarding the
suitability of hyperimmunisation of donors for the
procurement of hyperimmune plasma.
Active immunisation has long been an accepted
practice for the acquisition of immunity against
infectious diseases. The dangers of immunisation are
well known but have been accepted because of the
benefits afforded to individuals and society. Adverse
reactions to vaccines are likely to result from
sensitisation to the active component of the vaccine, to
other proteins that co-purify with the vaccine, or to
the adjuvant in the vaccine. They can be so mild as to
be unnoticed by the vaccinee or so severe as to manifest
as anaphylactic shock.
Moreover, little is known about the effects of
hyperimmunisation in man. Immunisation and
hyperimmunisation of donors in order to obtain
immunoglobulin for passive protection of others offer no
sq
HYPERIMMUNE GLOBULIN SCREENING VACCINATION
Tetanus yes yes






Table 4.5.1 Methods of recruiting hyperimmune donors
for hyperimmune plasma procurement
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apparent physiological advantages to the donors and
expose them to potential risks. Furthermore, the
repeated administration of antigen may theoretically
result in vasculitis and amyloidosis (Beebe et al, 1964;
Peeler et al, 1965; Bishop et al, 1966; Curran, 1969;
Penny and Hughes, 1970). However, to date these
complications have not been reported, nor are they
likely to occur in plasma donors who have been
hyperimmunised.
In view of these potential problems, there is a need
for a boosting policy for the procurement of each
specific hyperimmune globulin. First of all, the vaccine
used for boosting need to have a proven safety record in
addition to being immunogenic. Secondly, the policy will
define the total number of times that boosting will be
undertaken and the minimum time interval between
boosting in order to further reduce the likelihood of
adverse reactions. This will be based on the findings
from boosting studies that have been designed to
identify donors most suitable for such programmes.
Nonetheless, it is mandatory that any donor should
undergo a full medical examination before entry into any
plasmapheresis programme to ensure that his/her
health is unlikely to be adversely affected by the
plasmapheresis or by hyperimmunisation. Before each
plasmapheresis, the donor's serum protein, liver
transaminase and haemoglobin levels are measured, and at
IOI
two-monthly intervals the physician in charge reviews
each donor's physical condition and the accumulated
laboratory data to determine whether he/she should
continue in the programme. If adverse effects of
plasmapheresis are noted, the donor is advised to obtain
personal medical care.
In addition to the tests performed on all
plasmapheresis donors, serum electrophoresis and
quantitative immunoglobulin estimations are performed
every four months. Administration of antigen or
plasmapheresis is discontinued if these concentrations
fall below or rise significantly above the normal range
established by the laboratory. Such close monitoring is
crucial to safeguard the health of donors.
Whenever a new procedure, including the use of
vaccines for boosting donors, is introduced by the
SNBTS for the procurement of hyperimmune plasma, the
Association of British Insurers are informed. The
Association investigates the procedure, and if accepted,
will recommend to all its members that there should be
no penalty against the donor's life insurance policy in
the event of serious adverse reactions. Furthermore, in
the unlikely event that a donor suffers serious
reactions, there are well-defined procedures to be
followed if the donor wishes to claim for financial loss
or for injury. Claims are considered by a panel of
assessors. After consideration, a recommendation is
I 02
reached. If an ex gratia payment should be made, the
amount is related to what is currently being awarded for
similar injury in the courts. This recommendation is
made through the Scottish Home and Health Department to
the Treasury.
In conclusion, where a safe and effective vaccine
is available it is more efficient to hyperimmunise
selected donors for the procurement of hyperimmune
plasma, particularly in situations where the prevalence
of high specific antibody levels is low in the donor
population. However, if a safe and effective vaccine
does not exist the procurement of plasma for the
manufacture of each specific hyperimmune globulin will
depend on random screening of large donor populations
however inefficient the latter may be. Finally, the
safety of the donor should remain the primary concern in
all plasmapheresis programmes.
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Patients with primary hypogammaglobulinaemia
suffer from recurrent infections. They have low levels
of serum immunoglobulin at presentation, usually of IgG
and IgA isotypes. Table 5.1.1 lists the various types
of primary hypogammaglobulinaemia. Only the two more
common types will be discussed below in detail ;
X-linked hypogammaglobulinaemia, and late onset primary
hypogammaglobulinaemia.
5.1.1 X-linked hypogammaglobulinaemia
In X-linked hypogammaglobulinaemia, also known
as Bruton agammaglobulinaemia (Bruton, 1953), or Swiss
type agammaglobulinaemia, the presentation is during the
first two years of life and usually after the first
three months. It is a recessive disease of variable
clinical severity, characterised by low serum IgG and
virtually absent IgA and IgM, absent B-cells in the
peripheral blood (Froland and Natvig, 1972; Preud'homme
et al, 1973), absent plasma cells in the lymphoid
tissues (Wedgwood, 1978), and normal cell immunity
(Gotoff, 1968). Patients have low C1q levels because of
a shortened half-life of the C1 q secondary to the low
immunoglobulin levels (Kohler and Muller-Ebernard,
1972).
Boys with X-linked hypogammaglobulinaemia suffer




2 X-linked hypogammaglobulinaemia with growth
hormone deficiency
3 Autosomal recessive agammaglobulinaemia
4 Immunoglobulin deficiency with increased IgM
(and IgG)
5 IgA deficiency
6 Selective deficiency of other immunoglobulin
isotypes
7 K-chain deficiency
8 Antibody deficiency with normal gammaglobulin
levels or hypergammaglobulinaemia
9 Immunodeficiency with thymoma
10 Transient hypogammaglobulinaemia of infancy
11 Common variable immunodeficiency
Humoral deficiency associated with other defects
1 Transcobalamin II deficiency
2 Ataxia Telangiectasia
3 Wiskott-Aldrich Syndrome
Table 5.1.1 List of predominantly primary humoral
immunodeficiency diseases
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more serious infections such as septicaemia, meningitis
and osteomyelitis. They recover normally from childhood
exanthematas, but they are unduly susceptible to
enteroviruses, for example chronic echovirus infection
and vaccine-associated poliomyelitis. They may present
with chronic diarrhoea or sprue-like syndromes and
associated protein-losing enteropathy as a result of
persistent gastrointestinal infections with rota-virus
(Saulsbury et al, 1977) or Giardia lamblia (Ochs et al,
1 972 ) .
5.1.2 Late onset primary hypogammaglobulinaemia
Late-onset primary hypogammaglobulinaemia (also
known as CVI) refers to hypogammaglobulinaemia
affecting the three main classes starting after two
years of age, but it can occur at any age and has an
equal incidence in males and females. It is often
familial but no clear mode of inheritance has been
established. There is a high incidence of lupus,
haemolytic anaemia, and idiopathic thrombocytopenic
purpura among first degree relatives. Patients with this
condition suffer from the same sino-pulmonary infections
as patients with X-linked hypogammaglobulinaemia, but
they also suffer from other complications such as
polyarthritis, autoimmune diseases for example
pernicious anaemia, and more severe gastrointestinal
disturbances including nodular lymphoid hyperplasia and
\oi
malignancy. Patients with this condition also have an
increased incidence of sarcoidosis or of a sarcoid-like
syndrome (Leen et al, 1985b).
B-lymphocytes are present in about 20% of patients
and are below 6% in a further 25% (Preud'homme et al,
1973; Horwitz et al, 1977). Up to a third of these
patients have a T-lymphocyte defect as shown by poor
lymphocyte transformation to mitogen and by negative
delayed hypersensitivity skin tests (Webster and
Ascherson, 1974). However, despite these abnormalities
these patients are not usually more susceptible to
infection than those with normal in vitro T-cell
function.
5.1.3 Frequency of primary hypoqammaglobulinaemia
The MRC estimated that the prevalence of
primary hypogammaglobulinaemia in the United Kingdom was
around 1 per 100,000 (MRC, 1971). The prevalence for
Sweden is thought to be at least 2 per 100,000
(Bjorkander et al, 1984). < Figures for Japan, Denmark,
and Italy are even lower ( Hayakawa et al, 1981; Koch et
al, 1981; Luzi et al, 1983).
5.1.4 Hypogammaglobulinaemia and replacement therapy
All patients with hypogammaglobulinaemia benefit
from prophylactic immunoglobulin replacement therapy
(MRC 1971). In children, the treatment limits
irreversible lung damage (Bjorkander et al, 1984), and
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prevents serious infections such as septic arthritis,
osteomyelitis and meningitis. In adults immunoglobulin
replacement is beneficial although it does not always
prevent exacerbation of chest infections in patients
with chronic lung damage. However, if these patients do
not receive immunoglobulin replacement, they may die
from fulminant pneumonia (Ascherson and Webster, 1980).
The benefit is dose-dependent (MRC, 1971; Nolte et al,
1979; Pirofsky et al, 1980; Cunningham-Rundles et al,
1984). Patients with low levels of IgG subclasses with
or without concommittant IgA deficiency who suffer from
respiratory infections have also benefitted from
immunoglobulin prophylaxis (Schur et al, 1970 ; Oxelius,
1974; Hanson et al, 1980). Finally, Buckley (1983) found
that a group of patients with normal levels of IgG and
IgG subclasses who do not develop specific antibodies on
immunisation may also be helped by immunoglobulin
prophylaxis.
The optimal dose and dosage frequency of IgG
prophylaxis is still unknown. This is probably due to
the variable degree of mucosal and lung damage in these
patients, the variability of the clinical expression of
the disease, and other underlying disorders that may
accompany the syndrome. This is also reflected by the
variable half-life of infused IgG reported in these
patients (Schiff et al, 1984).
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5.1.5 Immunoglobulin replacement
Immunoglobulin may be administered either
intramuscularly, subcutaneously, or intravenously. This
can also be effected in the form of plasma infusions.
5.1.5.1 Intramuscular Route
The MRC have conducted a trial of IM IgG
replacement therapy, comparing the effects of high (50
mg/kg/week), medium (25 mg/kg/week), and low (12.5
mg/kg/week) replacement in a large number of patients
with primary hypogammaglobulinaemia (MRC, 1971). The
trial of the low dose was stopped because it was
ineffective. Patients receiving the high dose had
significantly fewer febrile episodes, respiratory and
skin infections and diarrhoea; their weight was higher
and C-reactive protein levels (a non-specific indicator
of inflammation) was lower. The current British
practice is based on this trial. After a loading dose of
50 mg/kg daily for five days, 25 mg/kg is given
every week by IM injection-. If recurrent infections
continue the dose is increased to 50 mg/kg weekly or
twice weekly. For a 60 kg individual, the volume of
IgG for intramuscular injection is 20 ml, and is often
accompanied by severe pain. Patient compliance was
therefore poor.
5.1.5.2 Subcutaneous Route
In view of the problems associated with
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immunoglobulin replacement via the IM route, other
methods of replacement were attempted. Immunoglobulin
can be slowly infused subcutaneously by means of a
constant infusion pump. This may achieve good serum IgG
levels and can be used in patients with poor venous
access. More importantly, the patients can administer
the treatment themselves just like the diabetics use an
insulin infusion pump (Berger et al, 1980). However, not
all patients are capable of using the infusion pump
satisfactorily, and some batches of immunoglobulin for
IM use are associated with pain and mild inflammation at
the site of administration, possibly due to kinin
release (McClelland, personal communication).
5.1.5.3 Plasma Infusion
Immunoglobulin can be administered in the form
of plasma, but carries the risk of transmitting viral
diseases, such as HBV and NANB hepatitis (Kirkpatrick,
1980 ; Holland et al, 1981), and of sensitisation in the
recipients to proteins in the plasma. Wells and Buckley
(1977) reported an anaphylactic reaction in a young girl
with hypogammaglobulinaemia within minutes of receiving
15 ml of ABO-compatible paternal plasma. Subsequent
analysis of the patient's pre-treatment serum revealed
that it contained an anti-IgA antibody titre of 1 in
640. Some of the risks of viral disease transmission may
be reduced but not eliminated by using a "buddy" system
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where a small panel of up to four healthy carefully
selected blood donors are plasmapheresed at regular
intervals to provide sufficient plasma that is
equivalent to 90 mg/kg of immunoglobulin every three to
four weeks. The advantages of this method include
delivery of substantial amounts of immunoglobulin of all
classes, including IgA and IgM, but fluid overload may
be a limiting factor in patients with cardiovascular and
renal diseases, and limiting the number of donors would
limit the antibody repertoire administered to the
patient.
5.1.5.4 Intravenous Immunoglobulin
This form of replacement therapy has been
advocated as the treatment of choice for three main
reasons; firstly, serum IgG levels are immediately
raised; secondly, very high serum levels of IgG can be
reached as there is no volume limitation ; and finally,
there is minimal discomfort for the patient. The main
drawback until recently has been the availability of
immunoglobulin preparations that are safe for
IV use. Clinical trials seem to confirm the efficacy
of IV preparations over IM ones. Most of this
difference in efficacy is probably due to the higher
dose of immunoglobulin which can be administered, and to
the fact that some of the immunoglobulin, which
administered by the IM route, may be subjected to local
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proteolysis.
Finally, it will be quite possible that in future
patients will be able to self-administer the IV IgG in
the comfort of their own homes, just as haemophiliacs
administer their own Factor VIII.
5.1.6 Characteristics of immunoglobulin
There are five classes of human immunoglobulin:
IgG, IgA, IgM, IgD, and IgE. Immunoglobulins in
clinical use are mostly made up of IgG with traces of
IgA and IgE.
5.1.6.1 Structure and Function of
Immunoglobulin
Immunoglobulin molecules are made up of equal
numbers of heavy and light polypeptide chains held
together by non-covalent forces and usually by covalent
interchain disulphide bridges to form a bilaterally
symmetrical structure (Figure 5.1.1). The class and
subclass of an immunoglobulin molecule is determined by
its heavy chain type.
Each polypeptide is made up of a number of loops or
domains of rather constant size (100-110 amino acid
residues) formed by intrachain disulphide bonds. The N-
terminal of each chain is called the variable region as
there is a wide variation in amino acid sequence in that
region.
Papain cleaves the IgG molecule in the hinge region






Digestion of IgG molecule by pepsin and papain
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Fab fragments which include an entire light chain and
the VH and CH1 domains of a heavy chain; one Fc
fragment, composed of the C terminal halves of the heavy
chains (Porter, 1959)
Pepsin splits the molecule on the C-terminal side of
the inter-heavy chain disulphide bonds into a large
F(ab)2 fragment made up of two Fab fragments (Nisonoff
et al, 1960). The F(ab)2 fragment broadly encompasses
the two Fab regions linked by the hinge region, and the
pFc' fragment corresponds to the 0^3 domain of the
molecule. The Fc fragment is extensively degraded by
pepsin (Figure 5.1.1).
Antigen binding activity is associated with the Fab
part of the molecule and most of the secondary
biological activities of the molecule such as complement
fixation, monocyte binding and placental transmission
are mediated through the Fc part.
Each domain acts as a functional subunit which
subserves a specific function. VH and VL domains
interact to form the antigen binding surfaces of the
antibody molecule. The functions performed by the other
domains are summarised in Figure 5.1.2.
IgG makes up 20% of total plasma protein and 70-75%
of total immunoglobulin pool in man. It is a monomeric
protein with a sedimentation coefficient of 7s and a
molecular weight of 146,000. It is evenly distributed
between the intra- and extravascular pools, and is the
MS
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Functions performed by the various domains
of the IgG molecule
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major antibody of the secondary immune responses. It is
also the only immunoglobulin that can cross the placenta
in humans, and it is responsible for the protection of
the newborn during the first few months of life.
There are four subclasses of IgG with different
structure, properties and biological functions. They
are found in different porportions in normal serum with
the relative concentrations of IgG1, 60-70% ; IgG2,
14-20% ; IgG3, 4-8% ; and IgG4, 2-6% (Steinberg
et al, 1973). The subclasses have different numbers and
arrangements of the interchain disulphide bonds.
IgG can fix serum complement with the different
subclasses differing in their ability to do so. IgG4 is
completely unable to fix complement by the classical
pathway but may be active in the alternative pathway. It
is also able to harness basophils and mast cells. IgG2
is thought to be the predominant subclass in response to
bacteriae with polysaccharide capsules. IgG3, although
present in small amounts, is a powerful activator of
complement.
5.1.7 Manufacture of intravenous immunoglobulin
Although there is controversy over what
constitutes a safe IV immunoglobulin preparation, it is
generally agreed that the design of a new intravenous
immunoglobulin preparation should meet the following
basic requirements:
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1 All the general pharraacopoeial requirements for
human normal IgG
2 Low IgG aggregates
3 Low contamination with components of contact
activation system
4 Preservation of functionally intact IgG molecules
5 Freedom from microbial agents.
5.1.7.1 General Pharmacopoeial Requirements
The requirements for human immunoglobulin were
laid down in 1966 by the WHO expert committee on
Biological Standardisation (WHO Technical Report Series,
1 967) .
Immunoglobulins are prepared from plasma of at least
1000 healthy donors from intact placentae or from
retroplacental blood. The large number of donors is
required to ensure that the antibody profile is
representative of the population. The fractionation
method should yield a product which is free from the
transmission of infection and should concentrate the
antibodies in the starting pool by at least ten times.
The final product should also be free from any
contaminant likely to be present in any plasma
derivative, for example, bacterial toxins (pyrogens),
and/or prekallikrein activator (PKA). Physico-chemical
requirements include at least 90% intact IgG molecule
with normal biological activities, and a well balanced
I l *8
distribution of IgG subclasses.
The requirements mean that new immunoglobulin
preparations are developed from Cohn Fraction II (Cohn
et al, 1946), as this method of immunoglobulin
preparation is the only one which has consistently been
shown to yield a product with a low risk of hepatitis
transmission (Finlayson, 1979)
5.1.7.2 Low Immunoglobulin Aggregates
Standard IgG produced by Cohn fractionation
consists mainly of IgG monomers but variable amounts of
polymers and aggregates are also produced during
fractionation. Severe anaphylactoid reactions observed
after IV infusion of standard IgG preparation, are
thought to be due to large molecular weight IgG
aggregates that spontaneously activate the complement
system resulting in the release of vasoactive compounds
(Barandun et al, 1962). Therefore, low levels of IgG
aggregates are desirable to reduce the likelihood of
anaphylactoid reactions.
5.1.7.3 Low Contamination with Components of
the Contact Activation System
Alving et al (1980) noticed that vasoactive
reactions following IV infusions of standard IgG were
similar to those observed following the infusion of
plasma protein fraction (Alving et al, 1978). These
reactions were therefore attributed to the presence of a
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component of the kallikrein-kinin system, PKA. When
rapidly infused, PKA acts on circulating prekallikrein
which in turn cleaves bradykinin from high molecular
weight kininogen. This reaction is self-generating
because of several feedback mechanisms and results in
large amounts of bradykinin causing reactions in the
recipient, for example pain at injection site, flushing,
and dyspnoea.
However, adverse reactions to IV immunoglobulin
cannot always be attributed to PKA levels or to the
aggregate content of the individual IgG preparation.
Eibl (1985) showed that IV immunoglobulin preparations
containing very high levels of PKA (5 to 10 times the
PKA content of the implicated batches of plasma protein
fraction reported by Alving) were not necessarily
associated with adverse reactions. Nonetheless, in view
of the fact that these enzymes can cause reactions and
because of the availability of tests to detect them, it
is generally agreed that IV IgG preparations should
\
contain low levels of vasoactive enzymes.
5.1.7.4 Functionally Intact Molecules
It is important that during the manufacture of
an IV imunoglobulin preparation the resultant IgG
molecule should be as unmodified as possible so that it
will maintain all the essential functions of the native
IgG molecule. In this respect, the manufacture of
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IV IgG using enzymatic degradation may lead to a
preparation devoid of Fc receptor effector activity, and
other manufacturing processes may yield preparations
deficient in certain IgG subclasses (Liehl et al, 1981;
Romer et al, 1982a).
5.1.7.5 Methods of Producing Intravenous
Immunoglobulin Preparations
Because immunoglobulins prepared by standard
fractionation methods are not well tolerated when
infused intravenously (Barandun et al, 1962),
gammaglobulin fractions obtained by these methods have
to be further processed to achieve a product suitable
for IV use.
Several new immunoglobulin preparations have been
developed for IV use. Four main procedures are
employed to ensure safe IV use :
1 Physical methods
Selective elimination of IgG aggregates can be
achieved by precipitation with polyethylene glycol
(PEG) or PEG with hydroxyethyl starch (HES), by
adsorption on DEAE-Sephadex with subsequent
stabilisation by albumin,
Preparations treated with PEG or PEG/HES tend to have
some residual anticomplementary activity, due to
molecular reaggregation during storage. Furthermore, PKA
and kallikrein levels are not reduced by this process.
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Purification of Cohn Fraction II by ion exchange
chromatography on DEAE-Sephadex removes IgA as well as
aggregates. Reaggregation is prevented by the addition
of human albumin as stabiliser. Although some aggregates
are still detectable, the product is free of
anticomplementary activity. In addition, this product
has the added advantage of being the only one known to
be devoid of IgA. However, IgG4 subclass concentration
is relatively low. It is believed that this subclass,
which focusses in a narrow acidic pH region, is
eliminated by the DEAE-Sephadex treatment in the final
purification (Romer et al, 1982a).
2 Chemical modification of the IgG molecule
IgG molecules can be chemically modified by beta-
propiolactone (Stephan, 1975) or by cleavage of the
interchain disulphide bridges by sulphonation (Masuho et
al, 1977), or by reduction and alkylation (Fernandes and
Lundblad, 1980).
Modification of the IgG molecule by beta-
propiolactone causes alkylation of histidyl and
acylation of lysyl residues. The molecule retains the Fc
region and some of its effector function, but IgG3
subclass, which is more susceptible than other IgG
subclasses to denaturation or degradation by plasmin,
sulphonation, or treatment with beta-propiolactone, is
lost (Skvaril et al, 1980).
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An alternative method of chemical modification is
selective cleavage of the interchain disulphide bonds
with sulphite and tetrathionate ions. The IgG molecules
are believed to retain the molecular structure of the
intact IgG through non-covalent interaction and to have
normal in vivo half-life (Kobayashi et al, 1981).
Cutter Laboratories have developed a method whereby
interchain disulphide bonds are split (Schroeder et al,
1980). Mild reduction cleaves three to five interchain
bonds in the hinge region leaving intrachain disulphide
linkages unaffected; alkylation of the free -SH groups
with iodoacetamide prevents reformation of the
disulphide bonds, and results in a stable product which
has low anticomplementary activity and low PKA.
However, beta-propiolactone is classified as a
carcinogen, and iodoacetamide is toxic. It is therefore
essential to ensure that the final product is entirely
free of such toxic reagents.
3 Enzymatic degradation
The IgG molecule undergoes enzymatic degradation by
plasmin (Sgouris, 1967) or pepsin (Schultze and Schwick,
1962) in order to remove the Fc part of IgG.
IV IgG preparation manufactured by enzymatic
degradation results in a product devoid of anti¬
complementary activity. Although such preparations can
irreversibly bind antigen, the immune complexes they
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form can activate complement and in vitro studies have
shown that these preparations may not necessarily
protect against infection (Painter et al, 1966). In
addition, they have a shortened in vivo half-life,
thereby limiting their clinical usefulness (Barandun,
Skvaril and Morell, 1975).
Plasmin cleaves the IgG molecule into two identical
monovalent Fab fragments and one Fc fragment (Figure
5.1.1). The therapeutic effects depend essentially on
the 30-40% of the IgG molecules which are resistant
because of the differing degree of plasmin resistance in
the IgG subclasses (Merler et al, 1967; Barandun,
Skvaril and Morell, 1975).
Pepsin cleaves the IgG molecule at a site immediately
adjacent to the disulphide linkages joining the two
heavy chains, leaving a product consisting of
approximately 80% divalent F(ab)2 and 20% Fc fragments.
These fragments can form antigen-antibody complexes but
cannot activate complement. They are well tolerated when
infused intravenously but they have a shortened half-
life of 18 hours (Janeway et al, 1968). At neutral pH,
pepsin is inactive and therefore there is no further
cleavage of IgG molecules during storage in solution.
Enzymatically digested IgG preparations are highly
fragmented, with a short half-life. They have a limited
clinical usefulness, but are probably ideal for the
neutralisation of toxins, or for the removal of toxic
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drugs, for example in the treatment of digoxin poisoning
(Smith et al, 1982) .
4 Enzyme treatment at pH 4.0
Incubation at pH 4.0 leads to mild denaturation
which removes anticomplementary activity. The exact mode
of action is not entirely understood, but it is thought
that the acid medium activates inherent plasma proteases
contaminants. IgG preparations manufactured by
incubation at pH 4.0 for 48 hours have been shown to
contain low anticomplementary activity but under certain
conditions may be contaminated with high levels of PKA
and IgG aggregates. However, these aggregates are not
anticomplementary in vitro or in vivo, and in mouse
protection studies no noticeable difference is observed
between pH 4.0 and standard preparations (Barandun et
al, 1975).
This method has been modified by the addition of
trace amounts of porcine pepsin during pH 4.0
incubation. The presence of the enzyme causes
aggregate dissociation but little or no fragmentation
(Painter and Law, 1984). A protein stabiliser
(carbohydrate) is added during titration and subsequent
freeze-drying to prevent reaggregation or denaturation
of the IgG molecules.
5.1.7.6 Manufacture of SNBTS IV IgG
The IV IgG produced by the Protein Fractionation
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Centre of the SNBTS is manufactured by further
processing of Cohn Fraction II.
In brief, 0.9% sodoim chloride is added to Cohn
Fraction II to reduce the protein concentration to 50
g/1. The resultant solution is then sterilised by
filtration through a series of filters.
1 Ultrafiltration
This sterile solution is then subjected to
ultrafiltration to remove residual ethanol. The
ultrafiltration is performed in an Amicon DC 10 hollow
fibre dialyser/concentrator using a H10X50 cartridge
with nominal molecular weight cut-off of 50,000. The
resultant solution contains less than 10 mg of ethanol
per gram of protein, a concentration which is known to
cause little or no denaturation on extended storage. The
IgG concentration at this stage is within the range 90
to 120 g/1.
Maltose is added immediately to the above protein
solution at a concentration of 2 g maltose per gram of
dissolved protein. This step is necessary to stabilise
the protein solution with respect to spontaneous
aggregate generation during further processing and in
particular during the pH 4.0 incubation step.
2 Acid hydrolysis and pepsin treatment
The solution is then titrated to pH 4.0 with 0.5 M
hydrochloric acid. Freshly prepared porcine pepsin
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solution is then added to the solution before the whole
mixture is sterilised by membrane filtration.
The resulting sterile solution is incubated at 35 C
for at least 20 hours, after which it is slowly
retitrated to pH 6.9 with 0.5 M sodium hydroxide. The
solution is then sterilised through a 0.2p membrane
filter before freeze-drying. The final product after
reconstituition is a solution of 5% (5g/l00ml) human
normal immunoglobulin with less than 5% aggregates and
at least 95% monomer and dimer. The mean
anticomplementary activity is 28 mg/CH50.
5.1.8 Overall Study Design
After an initial trial in five healthy
volunteers, and following approval from the Physicians
Ethics Committee, a study was undertaken to evaluate the
safety and clinical efficacy of SNBTS IV IgG in patients
with primary hypogammaglobulinaemia.
In view of the large number of different types of
primary humoral immunodeficiency (Table 5.1.1), some of
which are very rare, this study was limited to patients
belonging to the two more common types of primary
hypogammaglobulinaemia ; X-linked hypogammaglobulinaemia
and CVI.
The initial assessment of the efficacy of this IV IgG
preparation having been previously carried out (Yap et
al, 1985), the main objectives of the study were:
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1 To assess the tolerance and incidence of adverse
reactions to the IV administration of SNBTS IV IgG
2 To detect hepatitis events by monitoring the serum
ALT levels in patients following treatment with
SNBTS IV IgG
3 To increase the serum IgG level into the normal
range in patients with hypogammaglobulinaemia with
SNBTS IV IgG therapy
4 To assess the clinical response to SNBTS IV IgG.
With an estimated incidence of primary
hypogammaglobulinaemia of the order of 1 to 2 patients
per 100,000 population, and probably with many of the
mildly affected patients undiagnosed, there was only a
limited number of patients available for study
throughout Scotland. The study took place between
February 1983 and November 1985. As physicians and other
transfusion centres became aware of the existence and
availability of SNBTS IV IgG, and learned of its
potential benefit, more patients were gradually enrolled
into the study. Therefore, the number of patients in the
study increased from nine in early 1983 to 25 by mid-
1 985.
Following referral to the South East Scotland
Regional Blood Transfusion Centre, patients underwent a
full medical examination and were assessed regarding the
need for IV IgG therapy.
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Twenty-one of the 25 patients were assessed by
myself and I reviewed the case notes and radiographs of
the other four patients. A clinical review of all the
patients was important to confirm the diagnosis in each
case, and to examine any interesting clinical features
that might indicate an effect due to the IV IgG therapy,
for example, frequency of infection.
The first infusion of IV IgG was usually carried out
in the Regional Centre, under close medical supervision.
The second and subsequent infusions were carried out in
the patient's local hospital. Pre- and post-infusion
blood samples and nursing observations performed during
the infusions were sent to the Regional Centre by first
class post or special delivery. Detailed progress
reports were obtained from the patients' physicians and
I was very closely involved in the clinical management
of the severely affected patients, and visited those who
were critically ill.
A profile of the patients entered in the study is
outlined in Appendix A. Patients who participated in
the studies described in sections 5.2, 5.3, 5.4 and 5.5
are shown in Table 5.1.2.
Two patients (Cases 8 and 23) moved away from
Scotland three and nine months respectively after
they were entered in the study. Another patient (Case
25) died in a car accident 23 months after he was
entered in the study.
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Patient No. Sex Diagnosis
Case Number in Section
5.2 5.3 5.4 5.5
1 F CVI* 1
2 M CVI 2 1 1 1
3 M CVI 3
4 F CVI 4 2 2 2
5 F CVI 5 3 3
6 M CVI 6 3 4
7 F CVI 7 4 5
8 M CVI 8 4
9 M CVI 9 5 6
1 0 F CVI 1 0
1 1 M CVI 1 1 6 5 7
1 2 M CVI 1 2
1 3 M CVI 1 3 7 8
1 4 M XL** 1 4 8 9
1 5 M XL 1 5 9 1 0
1 6 M XL 1 6 1 0 1 1
1 7 F CVI 1 7 1 1 1 2
18 M CVI 1 8
1 9 F CVI 1 9 1 2 6 1 3
20 F CVI 20 1 3 7 1 4
21 M CVI 21 1 4
22 M XL 22 1 5 1 5
23 F CVI 23
24 M XL 24 1 6 1 6
25 M CVI 25 1 7 1 7
* CVI- common variable immunodeficiency
** XL - X-linked hypogammaglobulinaemia
Table 5.1.2 List of patients with the corresponding
case numbers in the studies described in
sections 5.2, 5.3 and 5.5. Further
details are given in Appendix A.
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5.2 STUDY ON ACUTE TOXICITY (ADVERSE REACTIONS)
5.2.1 Introduction
Early in the clinical use of immunoglobulins,
clinicians became aware that the IV administration of
immunoglobulin was associated with a high incidence of
adverse reactions (Janeway, 1970). Furthermore, adverse
reactions to immunoglobulin occurred more frequently in
patients with primary hypogammaglobulinaemia than in
subjects with normal serum immunoglobulin levels
(Barandun et al 1962).
5.2.2 Causes of Reactions
The underlying mechanism of adverse reactions to
infused immunoglobulin has been a source of controversy.
Barandun et al (1980) described adverse reactions in
newly diagnosed patients after their initial infusions
of IV immunoglobulin manufactured by mild pepsin
treatment at pH 4.0 (Sandoglobulin). On the basis of
the aetiology, Barandun et al (1980b) have attempted to
differentiate four main types of adverse reaction :
anaphylactoid, hypersensitive, vasoactive and
phlogistic.
5.2.2.1 Complement Activation
Anaphylactoid reactions occur almost exclusively
in patients with hypogammaglobulinaemia and are thought
to be triggered by IgG aggregates that have anti-
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complementary activity. IgG preparations containing
aggregates which spontaneously activate complement in
vitro cause anaphylactoid reactions in hypo-
gammaglobulinaemic patients when administered
intravenously under standardised conditions (Barandun et
al, 1962). These reactions include flushing of the face,
dyspnoea, lower back pain, nausea, vomiting followed by
fever and in some cases circulatory collapse and loss of
consciousness. These symptoms, which are usually
observed immediately after the start of the infusion,
are accompanied by a moderate but discernable decrease
in the total haemolytic complement activity.
5.2.2.2 Hypersensitivity
Hypersensitive reactions are due to antibodies
of the recipient, particularly those directed against
IgA (Buckley, 1980) or other immunogenic substances in
the IgG preparation (e.g. thiomersal). Hypersensitive
reactions to thiomersal are now non-existent as IgG
preparations no longer contain thiomersal.
5.2.2.3 Vasoactive Contamination
Some complications are caused by vasoactive or
microbial contaminants (pyrogens, endotoxins, bacteria,
etc) of immunoglobulin preparations that have undergone
inappropriate production and/or handling procedures.
PKA and kallikrein contaminating IV IgG preparations
have been suggested as causes for vasoactive reactions
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(Alving et al, 1980a). Eibl (1985), however, provided
data suggesting that the administration of IV IgG
contaminated with a very high level of PKA was not
necessarily followed by adverse reactions.
5.2.2.4 Phlogistic Reactions
Finally, certain reactions result from
inflammatory phenomena representing physiological
antigen-antibody reactions in the recipients (so called
phlogistic reactions). Barandun et al (1980a) also
observed a marked exacerbation of both local and
systemic inflammatory symptoms following the IV
administration of immunoglobulin in newly diagnosed
hypogammaglobulinaemic patients suffering from
clinically evident infections. Such patients are
believed to be in a state of relative antigen overload,
and the rapid IV infusion of a large dose of antibodies
capable of reacting with their corresponding antigens in
the blood and tissues may thus intensify the
inflammatory processes as a consequence of the formation
of antigen-antibody complexes. Typical phlogistic
reactions are characterised by fever 1 to 3 hours after
the onset of the infusion, transient increase in pre¬
existing local inflammations (e.g. arthritis, pneumonic
infiltrations, erythema, etc) and rise in white cell
count. Subjective symptoms disappear after a few hours
without therapy and objective signs after one to two
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days.
Various different immunoglobulin preparations have
since been developed for safe IV administration. SNBTS
IV IgG, an intravenous immunoglobulin prepared by mild
pepsin proteolysis at pH 4.0 and freeze-dried in the
presence of maltose as a stabiliser, is one such
preparation (see section 5.1.7.3). The tolerance and
incidence of adverse reactions to SNBTS IV IgG were
assessed in patients with primary hypogammaglobulinaemia.
5.2.3 Patients and Methods
Twenty-five patients (16 male, 9 female; age
range 11-64 years) were assessed in this study from
February 1983 to November 1985, with each patient
receiving SNBTS IV IgG therapy for periods ranging from
five to 34 months (mean 19.8 months). In brief, 20
suffered from late onset primary hypogammaglobulinaemia
(CVI) and five from X-linked hypogammaglobulinaemia
(table 5.1.2). Consent was obtained from the local
hospital Ethics Committee, the patient's own physician,
and from the patient prior to the commencement of the
study.
5.2.3.1 Infusion Dose and Rate
In all but eight patients a total dose of 0.2
g/kg body weight SNBTS IV IgG was administered on each
occasion. Two of the eight patients received up to 0.4
g/kg of IV IgG at later infusions as their serum IgG was
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below 3 g/1 when receiving an infusion dose of 0.4 g/kg.
One further patient received an even higher dose of 0.54
g/kg during subsequent infusions because of his
persistently low serum IgG on a dose of 0.4 g/kg. Four
patients were given 0.1 to 0.15 g/kg IV IgG at their
first infusion because they had not previously received
any immunoglobulin replacement of any kind. They
received 0.2 g/kg body weight at their second and
subsequent infusions. One further patient received 0.05
g/kg IV IgG at his first infusion because he had not
previously received any immunoglobulin replacement, and
in addition had a history of allergic reactions to
insulin and numerous antibiotics. He received 0.1 g/kg
of IV IgG at his second infusion and 0.2 g/kg IV IgG at
subsequent infusions.
Infusions were commenced at a rate of 15 mg/kg/hr
with a doubling of the rate 15, 30 and 60 minutes after
the start of the infusion. During their first infusions,
five patients who had previously never received any form
of immunoglobulin therapy were given IV IgG at an
infusion rate of 7.5 mg/kg/hr, and the rate was doubled
every 15 to 30 minutes to 120 mg/kg/hr. Second and third
infusions were generally commenced at a rate of 30
mg/kg/hr and 60 mg/kg/hr respectively, with the rate
gradually increased to 120 mg/kg/hr, as they could
tolerate this without adverse reactions. In two
patients, the infusion rate was increased to 240
135
mg/kg/hr and 264 mg/kg/hr to assess the incidence of
adverse reactions at the increased rates.
Infusions were initially administered at three-weekly
intervals and subsequently varied according to the
patient's clinical state to maintain a serum trough
(pre-infusion) immunoglobulin level at around 3 g/1. The
frequency of infusion therefore ranged from one week to
five weeks.
5.2.3.2 Patient Assessment
The oral temperature, pulse and blood pressure
were monitored during the initial infusion at 0, 15, 30,
45, and 60 minutes and half-hourly thereafter until the
end of the infusion. Patients were also asked to record
any abnormal sensations felt in association with the IV
Ig infusions.
5.2.3.3 Immunological Assays
Assays of total haemolytic complement (CH50),
C3, and C4 were carried out on most patients immediately
before and after their first infusions, and in those
patients who received the infusions at a higher rate
(greater than 120 mg/kg/hr). C3 and C4 were measured by
laser nephelometry (Whicher et al, 1978) and haemolytic




Of a total of 738 infusions, 704 were free of
any significant reactions. Patients received five to
77 infusions (mean 29.5) each over the study period.
Adverse reactions were associated with 34 of the SNBTS
IV IgG infusions (4.6%), and were mostly mild and
encountered in 10 out of 25 (40%) patients. There were
30 episodes of mild fever associated with the infusions,
and four patients (Cases 2, 5, 6 and 20) felt shivery
after their first infusion (Table 5.2.1). The mild
reactions were usually observed in the initial
IgG infusions for nine of the 10 patients with 21 of the
34 adverse reactions (62%) occurring within the first
five infusions in each of the patients (Table 5.2.1).
Four adverse reactions, experienced by three
patients, were moderately severe. The reactions were not
related to any particular production batch of IV IgG,
and no adverse reactions were reported by other patients
receiving similar batches of IV IgG. One patient (Case
6) had never been treated with any form of
immunoglobulin replacement therapy prior to SNBTS IV IgG
and felt unwell a few hours after his first two
infusions, experiencing influenza-like symptoms, with
shivering, sweating and generalised muscle aches.
However, his third and fourth SNBTS IV IgG infusions
were immediately followed by prophylactic oral aspirin













Table 5.2.1 Adverse reactions after SNBTS IV IgG
infusions
l 3S
the fifth infusion no aspirin prophylaxis was
administered, and there was no adverse reaction.
Another patient (Case 20) who had never previously
had any form of immunoglobulin replacement felt
nauseated, and dizzy during her first SNBTS IV IgG
infusion. She felt better once the infusion rate was
reduced and remained well after the infusion rate was
later increased according to the infusion protocol.
However, she vomited after her infusion. Although she
was pyrexial four hours after the completion of the
infusion, she did not experience any other adverse
reactions and remained asymptomatic. All her subsequent
infusions were uneventful although on one occasion she
felt dizzy when the infusion rate was in excess of the
rate recommended in the protocol, and her symptoms
disappeared when the rate of infusion was reduced to 120
mg/kg/hr.
One further patient (Case 15) developed an
urticarial macular rash one hour after the commencement
of his 39th infusion. The infusion was stopped
immediately and he received 10 mg of chlorpheniramine
maleate and 10 mg of metoclopramide because of the itchy
rash and nausea. His temperature and blood pressure were
normal. A tachycardia of 120 per minute was noted but
became normal 45 minutes after the infusion was stopped.
He did not have a pyrexia, and complement studies before
and after the infusion showed no significant changes.
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Although the rate of infusion was 240 mg/kg/hr (twice
the usual rate), he had received similar infusion rates
on at least six previous occasions without any reactions
and without any changes in serum complement levels. His
40th and 41st infusions, 10 days and 21 days later, were
uneventful although the infusion rate was increased
slowly from 120 mg/kg/hr to a maximum of 240 mg/kg/hr by
increments of 60 mg/kg/hr every 30 mins. All subsequent
infusions at a rate of 240 mg/kg/hr were similarly
without adverse reactions.
Complement studies did not show any changes to
suggest complement activation during any of the
infusions (Figures 5.2.1, 5.2.2 and 5.2.3) including
those where adverse reactions had been recorded (see
Table 5.2.2).
5.2.5 Discussion
Immunoglobulin replacement therapy for patients
with primary hypogammaglobulinaemia has up to now been
mainly by the intramuscular route. However, due to the
limited volume of immunoglobulin that can be
administered by this route, (usually 25 - 50 mg/kg/week)
a proportion of such patients still suffer from
recurrent infections.
In previous studies, a 59% incidence of adverse
reactions observed in recipients of an IV IgG
preparation containing large quantities of polymeric IgG
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(50-1 50) (0.20-0.65 g/1) (0 .76-1 .60 g/1)
Case No. Pre Post Pre Post Pre Post
6* 1300 1300 0.22 0.21 0.84 0.86
15 52 48 0.42 0.37 1.20 1.07
20 67 65 0.52 0.43 1.41 1.11
Values for normal range are shown within parentheses
* Tests performed by Dr G Bird, Newcastle General
Hospital. Normal ranges are:
CH50 - 1260-2880; C4 - 0.14-0.42 g/1; C3 - 0.75-1.5 g/1
Table 5.2.2 Complement levels during infusions
associated with adverse reactions
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(Ochs et al, 1982) was reduced to 19% when the same
manufacturers (Cutter Laboratories) produced a
preparation containing lower amounts of polymers and
fragments (Ochs et al, 1984). Studies by Eibl et al
(1984) and by Amman et al (1982) confirmed that
preparations containing mostly IgG monomers and a
carbohydrate as stabiliser were associated with fewer
adverse reactions. Furthermore, the study by Matsumoto
et al (1981) showed the importance of identifying
patients who are at increased risk of developing side
effects; patients with severe combined immunodeficiency
experienced more adverse reactions than patients with X-
linked or common variable hypogammaglobulinaemia. These
studies suggest that the presence of polymeric IgG, the
use of different stabilisers and the population of
patients studied are important factors that may affect
the incidence of adverse reactions to IV IgG
preparations.
Adverse reactions were associated with 34 infusions
(4.6%) in patients with primary hypogammaglobulinaemia.
Three patients suffered four moderately severe adverse
reactions. The other adverse reactions were mostly mild,
asymptomatic and consisted of a mild pyrexia. The low
incidence of reactions following SNBTS IV IgG infusion
is comparable to other intravenous immunoglobulin
preparations and is consistent with the low polymer
content of preparations manufactured by the method using
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mild pepsin treatment at pH 4.0 and with the use of a
carbohydrate stabiliser (Barandun et al, 1980a;
Cunningham-Rundles et al, 1981). Interestingly as the
incidence of adverse reactions in individual patients
decreases with increasing number of infusions, and as
adverse reactions occur with the initial infusions,
studies with a large number of infusions per patient
result in a reduced overall incidence of adverse
reactions. It would therefore be preferable, when
analysing such results, to examine the adverse reactions
in terms of the first 10 to 20 infusions.
Barandun et al (1980a) described similar reactions
in newly diagnosed patients after their initial
infusions of IV IgG manufactured by mild pepsin
treatment at pH 4.0 (Sandoglobulin), and postulated that
these were due to a reaction of antibody with antigen in
tissues which only occurred in patients with clinically
evident infections. However, the two patients who
experienced the severe adverse reactions at their
initial infusions and the patient who developed the
itchy rash and nausea during his 39th infusion all
appeared free of infection at the time. The probable
abolition of reaction in one of the patients by a small
prophylactic oral dose of aspirin is consistent with the
release of prostaglandin as a mechanism for adverse
reactions as proposed by Passwell, Rosen and Merler
(1980). The occurrence of nausea and of an itchy rash
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in one of the patients in this study during his 39th
infusion cannot be fully explained except on the basis
of a high rate of infusion, although the patient
tolerated the same infusion rate previously and on
subsequent occasions.
Although adverse reactions are more frequent during
the early infusions in patients with primary
hypogammaglobulinaemia, they may still occur at any time
during therapy. Concurrent infection, complement
activation and PKA were not associated with the adverse
reactions in this study.
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5.3 STUDY ON THE RISK OF HEPATITIS TRANSMISSION
5.3.1 Introduction
Immunoglobulin preparations generally have a
good record for safety with respect to the transmission
of viral hepatitis (McClelland, 1984). However, there
have been reports of NANB hepatitis in patients with
primary hypogammaglobulinaemia receiving IV IgG
preparations that have been treated so as to make them
safe for intravenous use (Lever et al, 1984; Ochs et al,
1985), raising the possibility that NANB hepatitis
viruses may not always be inactivated or removed during
the manufacture of these immunoglobulin preparations.
In the absence of an acceptable serologic marker for
NANB hepatitis, the incidence of hepatitis following the
administration of SNBTS IV IgG was examined by regular
clinical review of patients with primary
hypogammaglobulinaemia and by serial measurements of
their serum ALT levels. Furthermore, the patients
underwent regular tests for the presence of HBsAg.
This was carried out in a prospective study in patients
receiving SNBTS IV IgG. In addition, because these
patients had received other forms of immunoglobulin
replacement including FFP, their serum ALT levels were
also evaluated retrospectively.
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5.3.2 Patients, Materials and Methods
5.3.2.1 Patients
All 17 patients (Table 5.1.2) had proven primary
hypogammaglobulinaemia. Details on the patients are
outlined in Appendix A. In brief, 16 of the patients
who were receiving IV IgG were enrolled in the
prospective trial. One patient (Case 14) had received
only FFP as replacement therapy.
5.3.2.2 Fresh Frozen Plasma
Plasma was collected for each patient by
plasmapheresis of two or four dedicated donors to
minimise the risks of transmitting infection including
NANB hepatitis. A dose of 15 ml/kg body weight at two-
to four-weekly intervals was used. Plasma donors met
the standard medical and serological requirements for
blood donors, including normal serum ALT levels. The
duration of FFP replacement therapy in the eight
patients in the retrospective study ranged fom 8 months
(Case 8) to 13 years (Case 14).
5.3.2.3 SNBTS IV IgG
Details of the intravenous immunoglobulin
preparation used (SNBTS IV IgG) are shown in section
5.1.7. Patients received 200 to 400 mg/kg of SNBTS IV
IgG every two to five weeks. The duration of SNBTS IV
IgG treatment ranged from six to 25 months.
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5.3.2.4 Other Immunoglobulin Preparations
Seven of the patients in the study received
other IV IgG preparations (Gamimune, Cutter
Laboratories; Sandoglobulin, Sandoz) in an earlier
evaluation of immunoglobulin therapy (Yap et al, 1985),
and 13 of the patients received standard IM IgG
manufactured by Cohn fractionation at the SNBTS Protein
Fractionation Centre, prior to the study period (Figure
5.3.1 ) .
5.3.2.5 ALT Assays
The majority of the ALT levels were measured
either by an enzymatic (kinetic) method on a Multistat
III centrifugal analyser using a Boehringer ALT (OPT)
kit or by sequential multiple analysis with Computer
System (SMAC 2), Technicon Instrument Association. In a
small number of instances, ALT levels were measured at
the patient's local hospital clinical chemistry
laboratories using standard automated methods. The
normal range of serum ALT levels is 11-50 U/l.
5.3.2.6 Hepatitis B serology
Venous blood samples were tested for HBsAg by
radioimmunoassay prior to the first SNBTS IV IgG
infusion and in certain cases again at six to 12 monthly
intervals. Blood samples were also tested for antibodies
to HBsAg and to core and e antigens.
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Figure 5.3.1
Types of immunoglobulin in replacement therapy
received by Cases 1-17
The numbers about the matched lines indicate the number
of samples in which ALT levels were determined.
c = ALT values obtained for patient case notes
f = ALT values obtained on samples stored at -150 C
p = ALT values obtained in a prospective study
Sandoglobulin = Sandoz IVIgG
Gamimune = Cutter IVIgG
Case 1
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Serum ALT values in the patients who had
received FFP therapy were obtained over periods of six
to 29 consecutive months in eight patients. The case
records were examined first and where no ALT results
were recorded, pre-infusion serum samples, stored
at -150 C in the vapour phase of liquid nitrogen, were
retrieved for ALT assays.
All 16 patients receiving SNBTS IV IgG had serum
samples taken before and after each infusion of
immunoglobulin for estimation of IgG and ALT levels.
The following serum samples were available for analysis;
1 From December 1983, ALT levels in all serum samples
were measured prospectively
2 Before December 1983, ALT levels were otained
retrospectively from patient case records
3 Where there were no records of the serum ALT having
been previously determined, pre-infusion serum
samples (stored frozen at -150 C) were retrieved and
ALT levels measured.
Prospective data on ALT levels were therefore
available in 11 patients for 13 to 15 consecutive months
and in a further five patients for five to 11
consecutive months.
Blood samples from seven patients (Cases 1, 3, 6, 8,
9, 10, 11, and 14) were collected in Edinburgh and the
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sera were separated within 24 hours after collection.
Blood samples from 9 patients (Cases 2, 4, 5, 7, 12, 13,
15, 16 and 17) were collected outside Edinburgh as
these patients received their immunoglobulin infusion at
their local hospital and the blood samples were sent by
post; the sera were separated immediately on arrival
(usually within 24 -72 hours of collection) and kept at
4 C until assayed.
A patient was diagnosed as having hepatitis if the
ALT level was above the normal range (50 U/l) in two or
more sequential blood samples taken within a 3 to 17 day
interval and if one of these levels was at least twice
the upper limit of normal (100 U/l). An episode of
hepatitis was considered to be probably of viral
aetiology if there was no other identifiable cause for
the raised ALT (Stevens et al, 1984).
5.3.4 Validity of stored samples
Thirty-one serum samples were collected from
patients with liver disease of non-infective aetiologies
and sent for ALT assay. Aliquots of the sera were
stored at -20 C and at -150 C for at least six months
before they were assayed for ALT activity.
5.3.5 Results
5.3.5.1 Validity of Stored Sera
Twenty-six samples stored at -20 C and 28




Effect of storage at -20 C for six months
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measurement. ALT values of samples stored for at least
six months at -20 C and at -150 C were compared with
the ALT values measured at the time of sample collection
(Figures 5.3.2 and 5.3.3). It was found that serum ALT
activity decreased after storage at -150 C and at
-20 C for up to six months (p <0.001 by Wilcoxon's rank
sum test). The decline in ALT activity was minimal for
samples stored at -150 C (a constant decrease
of 8 U/l), in contrast to samples stored at -20 C when
significant decreases in serum ALT activity were noted
(at least 60% of the original value).
5.3.5.2 ALT Levels During FFP Therapy
Among the eight patients who had received FFP
therapy in the study, 100 serum ALT levels were
available from the case notes: 25 samples (from three
patients) had levels above 50 U/l ; two from Case 1 (67
and 55 U/l), seven from Case 9 (range 53-113 U/l) and
16 from Case 10 (range 52-203 U/l). From an additional
65 frozen serum samples sent for ALT measurement only
three were abnormal, all from Case 1 (114, 60 and 69
U/l). Therefore, of 165 serum ALT values available
for analysis, 28 (from three patients) were abnormal
(Figures 5.3.4.a, 5.3.4e and 5.3.4f).
5.3.5.3 ALT Levels During SNBTS IV IgG Therapy
A total of 249 serum samples were obtained and
assayed for ALT levels immediately prior to each
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Figure 5.3.4 a ^ 2
ALT values in seven patients receiving
different types of immunoglobulin therapy
x = serum ALT values in samples assayed within 72 hours
of collection
• = serum ALT values in samples assayed after storage
at -150 C
Broken horizontal line indicates the upper limit of
normal range for ALT levels
Hatched horizontal areas indicate the type of
immunoglobulin therapy received by the patient
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infusion. All but seven were in the normal range (10—
50 U/l). The seven samples with abnormal values were
from four patients ; Case 3 (91 and 53 U/l), Case 9
(60 U/l), Case 15 (70 U/l) and Case 17 (96, 84 and
234 U/l).
An additional 60 serum samples were retrieved from
-150 C storage and examined for ALT activity. Only four
were abnormal, two from Case 1 (54 and 69 U/l), and two
from Case 5 (75 and 58 U/l).
A further five normal ALT values were noted on review
of the case notes.
Therefore, of a total of 314 serum ALT values, 11
(from six patients) were above the upper limit of normal
(50 U/l).
5.3.5.4 Hepatitis B Serology
HBsAg was negative in all the specimens tested.
5.3.5.5 Relationship of Raised ALT Values to
Clinical Condition of Patients
5.3.5.5.1 FFP therapy
Three out of eight patients studied developed
raised serum ALT values during FFP therapy that could
be consistent with NANB hepatitis. However, in each case
there were more probable explanations for the abnormal
ALT. One patient (Case 1) was diagnosed as suffering
from sarcoidosis which was active at the time the ALT
was raised (Leen et al, 1985b). Another patient (Case
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10) was clinically unwell with recurrent episodes of
septicaemia and had a cholestatic pattern of liver
function tests (alkaline phosphatase of 3351 U/l). The
last patient (Case 9) had multiple problems associated
with hypogammaglobulinaemia including severe
malabsorption with weight loss and recurrent chest
infections.
5.3.5.5.2 SNBTS IV IgG
From a total of 314 blood samples, 11 abnormally
raised ALT values were observed occurring in six of the
16 patients during therapy with SNBTS IV IgG. No
markers of HBV infection were detected in the patients
at any time.
Figures 5.3.4c, 5.3.4d and 5.3.4g illustrate three
patients with normal serum ALT levels during therapy
with FFP and SNBTS IV IgG (Cases 4, 8 and 16).
Further details of the six patients (Cases 1, 3, 5,
9, 15, and 17) who developed raised ALT levels are shown
below.
Case 1 had raised serum ALT levels during FFP therapy
(see above), secondary to active sarcoidosis and it is
likely that the two raised serum ALT values (54 and 69
U/l) were the result of his sarcoidosis.
Case 3 had received SNBTS IV IgG since April 1983. In
April 1984, before her 18th infusion of SNBTS IV IgG,
she was found to have a high serum ALT of 91 U/l while
1 6 ^
remaining clinically very well. Three weeks later her
serum ALT was 44 U/l. No cause for the raised ALT was
found and in particular there was no history of drug or
alcohol ingestion HBsAg, as well as other virological
markers of hepatitis, were absent.
Case 5 received Sandoglobulin and Gamimune for three
months each prior to the study period. His
hypogammaglobulinaemia is associated with malabsorption
secondary to villous atrophy, frequent respiratory and
gastrointestinal infections requiring treatment with
numerous antibiotics including erythromycin for
intractable Campylobacter enteritis. Two abnormal ALT
values (75 and 58 U/l) were observed when the frozen
samples were analysed. Retrospective analysis of the
case records suggest that he was not unwell at the time
of the abnormal ALT levels and there was no apparent
cause for the abnormal ALT.
Case 9 had documented abnormal serum ALT values during
therapy with FFP. At the time of the single abnormal
ALT level (60 U/l) which followed his 15th SNBTS IV IgG
infusion, he was asymptomatic.
Case 15 was diagnosed in 1966. After years of treatment
with IM gammaglobulin, he received FFP followed by
Sandoglobulin and Gamimune (for three months each)
before treatment was commenced with SNBTS IV IgG in
April 1983. A single raised ALT value (70 U/l) was noted
in February 1984. Four days elapsed between the
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collection of the sample and the separation of the
serum, and all subsequent serial ALT values have been
normal. An additional factor in this case is that the
attending physician reports that this patient has a
large regular alcohol consumption.
Case 17 had been on total parenteral nutrition since
1980 because of intractable diarrhoea with severe
malabsorption. His medical history included chronic
cholecystitis and cholelithiasis treated by
cholecystectomy in 1980, and since 1981 documented
abnormal liver function tests including raised ALT
ranging from 50 to 234 U/l. A liver biopsy in 1980
showed mild chronic portal triaditis with occasional
granulomatous foci. A repeat liver biopsy in 1984 had
similar features, and in particular there were no
features to suggest NANB hepatitis. His abnormal liver
function tests were considered by his gastroenterologist
to be a consequence of his underlying disorder and of an
excess intralipid content in his total parenteral
nutrition regime (Sheldon et al, 1978; Lindor et al,
1 979) .
5.3.6 Discussion
Many serum enzymes may remain stable for some
time when stored at -20 C. Serum ALT has also been shown
to be stable for three to four days at room temperature
and up to seven days if kept refrigerated at 4 C
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(Wilding et al, 1977; Schmidt et al 1976). The data
presented here suggests that while there seems to be a
fall in serum ALT activity after storage at -150 C for
six months, the fall is minimal in contrast to storage
at -20 C (Figure 5.3.2). It also seems unlikely that any
serum sample with significantly raised ALT values (100
U/l or greater when considering hepatitis) would have
been missed because they had been stored at -150 C for
six months.
Three of the patients receiving FFP have been noted
to have raised serum ALT levels. Although the magnitude
of their serum ALT rise is consistent with hepatitis
there has been an obvious cause for their abnormally
raised ALT; one had active sarcoidosis, and the
remaining two were very ill with infection including
recurrent septicaemia in one patient. In addition, there
were no features to suggest NANB hepatitis.
None of the patients during therapy with SNBTS IV IgG
would fulfil the criteria for hepatitis except for the
patient with known liver disease. Only a small
proportion of patients receiving regular IV IgG
infusions had any ALT abnormalities. The pattern and
magnitude of disturbance of liver function tests was not
that of NANB hepatitis. In five of the six patients with
raised ALT levels during treatment with IV IgG there
appears to be an explanation other than NANB hepatitis.
Only one patient had an unexplained elevated ALT levels
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(peak ALT of 91 U/l) which became normal within three
weeks, but by definition (Stevens et al, 1984) she did
not have hepatitis and was clinically well throughout.
Furthermore, neither the clinical picture nor the level
of serum ALT rise in these patients resemble that of
NANB hepatitis or the illness described by Lever et al
(1984) and Ochs et al (1985).
Conventional immunoglobulin preparations virtually
never transmit viral infections (Finlayson, 1979; Lane,
1983; Iwarson et al, 1985). However, several recent
reports (Lever et al, 1984 ; Ochs et al,1985) indicate
that some immunoglobulin products designed for
intravenous administration may not be as safe as the
conventional intramuscular product. It is probable that
production methods influence the safety of intravenous
preparations in terms of transmission of viral
infections. In particular, the presence or absence of
further processing to reduce the level of spontaneous
anti-complementary activity and of vasoactive enzymes
following the removal of ethanol may be important. Not
all of these procedures are thought to be virucidal.
Neither of the two intravenous preparations known to
have transmitted NANB hepatitis (Lever et al, 1984; Ochs
et al, 1985) were subjected to a recognised virucidal
finishing treatment, for example, acid treatment
(pH 4.0) or beta-propiolactone and ultraviolet
irradiation (Prince et al, 1983). It can be concluded
I
that SNBTS IV IgG which is processed for intravenous use
by the pH 4.0/pepsin method (Barandun et al, 1962) and
FFP obtained from two to four properly screened dedicated
donors do not transmit NANB hepatitis.
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5.4 HALF-LIFE OF INFUSED IMMUNOGLOBULIN
5.4.1 Introduction
Serum IgG levels achieved in individual patients
following IgG administration are variable, probably as a
consequence of the variable half-life of infused IgG in
such patients. The half-life of infused IgG depends
primarily upon the intactness of the infused IgG
molecule, more specifically on the Fc portion of the IgG
molecule; preparations in which this site is digested or
altered have a shortened half-life. It is also
influenced by other factors including IgG loss through
intestinal and bronchial mucosa, which is itself
dependent on the degree and chronicity of inflammation
affecting those areas.
Knowledge of the half-life of any IV IgG preparation
will dictate the frequency of immunoglobulin
administration, which up to now has been decided on an
empirical basis. An attempt was therefore made to
determine the half-life of infused SNBTS IV IgG in
patients with primary hypogammaglobulinaemia as part of
the evaluation of SNBTS IV IgG.
5.4.2 Materials and Methods
Blood was collected before and immediately after
each infusion of IV IgG for the measurement of serum IgG
levels. Blood samples for half-life estimations were
collected from seven patients, in most cases after their
I lO
first infusion of IV IgG, and additional sequential
blood samples were collected at different intervals
until the next infusion, usually 15 to 30 days later.
Total serum IgG levels were measured in the
sequential samples from seven patients, and serum CMV
IgG levels in four patients; the log serum values were
plotted against time.
Serum IgG measurements were performed by Mr G Neill
and his technicians at the Edinburgh Blood Transfusion
Centre using laser nephelometry (Whicher et al, 1978).
the normal range for serum IgG concentrations (5.0 to
13.0 g/1) was evaluated by the measurement of IgG levels
in 350 normal blood donors.
Serum CMV IgG levels were measured by Dr B
Cuthbertson, of the Protein Fraction Centre of the
SNBTS, using an ELISA system at a single dilution in
duplicate. A complement fixing CMV antigen (Flow
Laboratories) was coated on the plates and the samples
compared to serial dilutions of a reference plasma
standard (Salonem and Vaheri, 1981).
The half-life of the infused IV IgG was determined by
assuming that the metabolism of IgG follows first order
kinetics, as reported by Waldmann and Strober (1969).
Briefly, there is an early alpha-phase, which represents
redistribution of the IgG, followed by a slower beta-
phase, which represents the metabolism of IgG (Figure




Measurement of half-life of infused IgG
Horizontal axis : time in days
Vertical axis : log IgG concentration
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the beta-phase :
Half-life = log2/k = 0.693/k
where k is the slope of the beta-phase determined by
linear regression analysis.
5.4.3 Results
The results have been plotted in Figures 5.4.2
to 5.4.12. Half-life values of total IgG ranged from
15 to 53 days and half-life values of CMV IgG ranged
from 35 to 61 days.
5.4.4 Discussion
The half-life values are prolonged and
consistent with those obtained in other patients with
primary hypogammaglobulinaemia. Indeed, just as in the
study by Schiff (1985), the serum IgG of the patient at
the time of the study did not influence the half-life of
infused IgG. This observation is, however, not
consistent with the previous study by Waldmann and
Strober (1969), who reported that patients with higher
immunoglobulin levels seemed to have the shortest half-
lives .
Specific antibody levels have been used in this study
to measure the half-life of infused IgG, to avoid any
possible artifact introduced by intrinsic IgG
production. Because the number of patients was small,
no comments can be made regarding the difference in the
half-life values estimated from total serum IgG levels
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Figures 5.4.2 ^ 5.4.8
(Cases 1-7)
Half-life of infused IgG using
total IgG measurement
Horizontal axis : time in days
Vertical axis : log IgG concentration
n




















































Figures 5.4.9 ^ 5.4.12
(Cases 2,3,5 and 6)
Half-life of infused IgG using
CMV IgG assay
Horizontal axis : time in days


























and from serum CMV IgG levels.
No attempt was made to repeat the half-life
measurements after a prolonged period of treatment.
However, there is some evidence that the half-life of
infused IgG following a nine-month course of IV IgG was
longer than at the start of therapy (Lever et al, 1987)
Intravenous immunoglobulin manufactured by the mild
pepsin treatment at pH 4.0 therefore has an acceptable
half-life.
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5.5 SERUM IMMUNOGLOBULIN LEVELS IN PATIENTS WITH
PRIMARY HYPOGAMMAGLOBULINAEMIA DURING SNBTS IV IgG
THERAPY
5.5.1 Introduction
The dose of IgG administered to patients with
hypogammaglobulinaemia (25-50 mg/kg/week) has been based
on the clinical trial run by the MRC (1971). However,
the increments in serum IgG level achieved in patients
treated with this dose of IgG are highly variable and
IgG levels hardly ever rise into the normal range. The
intravenous administration of large quantities of
immunoglobulin has now been shown to be both safe and
well-tolerated in patients with primary
hypogammaglobulinaemia (see section 5.2), confirming the
earlier findings of Barandun and Morell (1981),
Cunningham-Rundles et al (1981) and Wedgwood and Ochs
(1981). As a result, clinicians have attempted to
achieve higher serum IgG concentration in their patients
with a view to reducing the incidence of infections.
Most trials have used larger doses of IgG per infusion
but the intervals between infusions have been kept fixed
at either three or four weeks (Cunningham- Rundles et
al, 1984; Eibl et al, 1984; Schiff et al, 1984). The
optimal dose schedule has therefore not been established.
The objective of this study was to examine whether
normal or near normal 'trough' serum IgG concentrations
could be achieved in patients with primary
I 93
hypogammaglobulinaemia with individualised doses of
infused IgG. The effects of varying either the dose of
IgG infused or the frequency of infusions, or of varying
both the dose and frequency of IgG infusions, are
discussed in this section.
5.5.2 Patients, Materials and Methods
5.5.2.1 Patients
A total of 17 patients (age range 11 to 50
years ; 11 male and six female ; see Table 5.1.2)
received SNBTS IV IgG for at least six months between
February 1983 and May 1985. The duration of treatment
was over 12 months in 13 of the 17 patients, over 18
months in 10 patients and over two years in eight
patients. Twelve suffered from late onset primary
hypogammaglobulinaemia (CVI) and five from X-linked
primary hypogammaglobulinaemia. All patients had a
history of recurrent bacterial infections, with low
serum IgG levels measured on at least two occasions at
the time of diagnosis. All but two were already
established on immunoglobulin replacement therapy before
entry into the study. Further clinical details of
individual patients are shown in Table 5.5.1.
Consent was obtained from the local hospital Ethics
Committee, the patient's own physician and from the
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5.5.3 Study design
5.5.3.1 Infusion Dose and Rate
A total SNBTS IV IgG dose of 200 mg/kg body
weight was administered on most occasions. In two
patients, cases 9 and 10, where the 'trough' serum
level, i.e. immediately prior to IgG infusion, was not
maintained above 3 g/1, the infusion dose was steadily
increased to 540 and 400 mg/kg respectively.
In most patients the infusion was administered at a
rate of 120 mg/kg/hr. In patients who had never
received any immunoglobulin replacement, this rate was
initially reduced in the first infusions. The infusion
rate was increased to 264 and 240 mg/kg/hr for cases 9
and 10 without any adverse reactions.
5.5.3.2 Frequency of Infusion
Infusions were initially administered at three-
weekly intervals, except in three patients (cases 9, 10
and 1 1 ) who received their infusions at two-weekly
intervals. Infusion frequency was modified according
to the patient's clinical state while aiming to maintain
a serum 'trough' IgG level as near to the lower limit of
normal as possible.
The infusion frequency was reduced from three-weekly
to four-weekly (or even less) if the 'trough' serum IgG
was above 4 g/l (normal range 5.0 to 13.0 g/1), and if
the patient remained free from infection. If, however,
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the patient was clinically unwell and the 'trough' serum
IgG was below 3 g/1, the infusion frequency was
increased to two-weekly intervals. If the 'trough'
serum IgG was still below 3 g/1 the infusion dose was
doubled or given at weekly intervals. Finally, if there
was still no response a doubled infusion dose was
administered at weekly intervals. The frequency of
infusion therefore ranged from one week (cases 6 and 9)
to 12 weeks (case 3).
A total of 517 infusions from 24 batches of SNBTS IV
IgG was therefore administered to 17 patients over the
study period.
5.5.3.3 Methods of Assessment
Venous blood samples were collected from the
infusion site at the commencement of the infusion and at
the end of the infusion, either from the opposite arm or
from the infusion site, after it had been flushed with
10 ml of blood. Serum IgG levels were assayed in the
pre- and post-infusion samples.
IgG was measured by laser nephelometry as described
in section 5.4.2 (Whicher et al, 1978).
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5.5.4 Results
5.5.4.1 Serum IgG Concentrations Following
SNBTS IV IgG Therapy
5.5.4.1.1 Sequential serum IgG concentrations
Figures 5.5.1 to 5.5.6 demonstrate sequential
serum IgG levels before and after each infusion in
selected patients. Pre-infusion samples give an
indication of the 1 trough1 level or lowest serum IgG
level following SNBTS IV IgG infusion, while post-
infusion samples collected immediately following the
immunoglobulin infusion are a reflection of the
'highest' level that might be achieved following SNBTS
IV IgG infusion.
In 13 of 17 patients who had received SNBTS IV IgG
for more than six months, the serum 'trough' IgG level
was above 4.0 g/1 within eight months of the
commencement of SNBTS IV IgG replacement therapy. In
three of four patients who had received IM IgG before
entry into the study, the 'trough' serum IgG level was
higher than 4.0 g/1 within three months of their initial
infusion. Of the two patients who had never received any
form of replacement therapy previously, only one
achieved a trough IgG concentration greater than 4 g/1
with the first three months but both achieved that level
within eight months from the first infusion.
Six of the 17 had a serum 'trough' IgG level of
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greater than 5.0 g/1 within six months of treatment. Of
the 10 patients who received treatment for at least 18
months, half of them maintained a 'trough' serum IgG
level of greater than 5.0 g/1 for at least a year while
80% maintained their 'trough' IgG above 4.0 g/1 for at
least 12 months. Seven maintained the 'trough' IgG
above 5.0 g/1 for more than three months and eight for
more than two months.
Seven patients started treatment with SNBTS IV IgG
in early 1983, and their sequential serum IgG levels
show the cumulative effect of IV IgG therapy, as shown
in Case 11 (Figure 5.5.5). Two patients with
bronchiectasis maintained their serum IgG level within
the normal range. Some of the high serum IgG levels
prior to commencing SNBTS IV IgG therapy were due to
preceding therapy with FFP or another intravenous
immunoglobulin preparation (e.g. Case 5, Table 5.5.1).
5.5.4.1.2 Effect of increasing dose
Two patients (Cases 9 and 10) with X-linked
primary hypogammaglobulinaemia who had persistently low
serum IgG levels, and who could not attend
for infusions more often than once every two weeks, had
their infusion dose increased to 540 and 400 mg/kg. An
increment in the serum IgG level was observed in only
one patient (Case 10, Figure 5.5.4). Attempts at further
increasing the serum IgG level in Case 9 consisted of
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Figures 5.5,1 5.5.6
Serial serum IgG levels in six patients
on SNBTS IV IgG replacement
The date of serum IgG measurement is shown on the
horizontal axis and serum IgG concentration on the
vertical axis. The lower limit of the normal range for
serum IgG concentrations (5 g/1) is shown by a
horizontal broken line and the infusion dose and






















increasing the infusion frequency (see below).
5.5.4.1.3 Effect of increasing frequency of
infusions
In three patients, IgG replacement therapy was
carried out once every two weeks because of their low
serum IgG despite previous replacement therapy with
other intravenous immunoglobulin preparations (Cases 9
and 11), and with FFP (Case 10). In one further patient
(Case 6), the frequency of infusion was gradually
increased to once weekly when he suffered from recurrent
gastrointestinal infections.
The serum IgG level in Case 11 increased from 2.2 g/1
to greater than 4.0 g/1 after three months (Figure
5.5.5). The serum IgG level in Case 10 who was
receiving 800 ml of FFP every three weeks decreased from
3.2 g/1 to around 2.0 g/1 (Figure 5.5.5) while on an IV
IgG replacement regime of 200 mg/kg every two weeks,
presumably because of an actual decrease in total IgG
infused via the latter replacement regime. However, his
serum IgG level gradually improved when his infusion
dose was doubled. There was no significant increase in
'trough' serum IgG level noted in Case 9 (Figure 5.5.3).
However, when his clinical state worsened attempts at
further increasing his serum IgG levels were made by
weekly infusions of IgG (see below).
In one patient (Case 6), the serum IgG level
reflected the severity of his gastrointestinal disease
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(Figure 5.5.2). His serum IgG initially fell when he
had diarrhoea. Increasing the frequency of SNBTS IV IgG
from three-weekly to two-weekly and then to weekly
intervals brought his trough serum IgG level in the
normal range. However, with a worsening of his
gastrointestinal symptoms, his serum IgG level fell
again despite the increased frequency of the
immunoglobulin administration. Following resection of
the strictured and ulcerated segment of ileum found at
laparotomy, his serum IgG levels were once again in the
normal range while receiving replacement therapy at
three-weekly intervals. Histological examination of the
resected bowel showed ulceration and lymphoid
hyperplasia without any evidence of lymphoma or of
Crohn's disease.
5.5.4.1.4 Effect of increasing infusion dose
and infusion frequency
One patient (Case 9) with X-linked primary
hypogammaglobulinaemia had his infusion dose as well as
his infusion frequency increased when his clinical
condition deteriorated. He had persistently low levels
despite an increased dose of SNBTS IV IgG (300 mg/kg)
and an increase in frequency of treatment to fortnightly
intervals. He has a combination of structural lung
damage and gastrointestinal disease as a result of
recurrent infections. The infusion dose was increased to
540 mg/kg every two weeks without any significant
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increase in trough serum IgG concentration. However, at
a later date while an in-patient in hospital because of
abdominal pain, he received 540 mg/kg at weekly-
intervals and his 'trough' serum IgG level rose to
4.05 g/1 (Figure 5.5.3).
5.5.4.1.5 Effect of reducing infusion
frequency
In five patients (Cases 1,3,7,12 and 17) the
'trough' serum IgG level was maintained above 4.0 g/l
when the frequency of infusion was increased to once
every four weeks. With an infusion frequency of once
every four weeks Cases 1, 3 and 12 maintained their
'trough' serum IgG level above 5.0 g/l. Figure 5.5.6
illustrates the effect of maintenance of serum IgG level
with reduction in the frequency of infusion.
In four patients (Cases 1, 3, 7 and 12) a 'trough'
serum IgG level of greater than 4.0 g/l was still
achieved when the frequency of infusions was further
reduced to once every five weeks.
One patient (Case 3) maintained a high 'trough' serum
IgG level of 8.49 g/l 16 weeks after her last infusion
of SNBTS IV IgG of 200 mg/kg, the last but one infusion
having been carried out 12 weeks previously (Figure
5.5.1 ) .
5.5.4.2 Clinical Efficacy
The clinical outcome of the 17 patients in this
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study is documented in Table 5.5.1. Of the 13 patients
with serum IgG levels above 4 g/1, all but one (Case 5)
experienced a reduction in the number of respiratory
infections; Case 5 had long-standing severe bilateral
bronchiectasis. Case 16 with bronchiectasis continued
to suffer from respiratory infections when his serum IgG
level fell from 6.0 g/1 while receiving treatment with
FFP to 2.7 g/1 following treatment with IV IgG.
The frequency of diarrhoea in three further patients
(Cases 2, 6 and 13) was unchanged when their serum IgG
increased to above 4 g/1. Cases 9 and 10 suffered from
chronic diarrhoea despite serum IgG levels of 3.05 g/1
and 2.8 g/1 respectively. Finally, Case 17 received
total parenteral nutrition because of his malabsorption
and was therefore free from diarrhoea.
Of three patients who developed salmonella
gastroenteritis, the one patient who was receiving
adequate immunoglobulin replacement did not suffer from
invasive salmonellosis.
, Animal studies have
demonstrated a useful role for humoral immunity in
salmonellosis and it is therefore possible that adequate
replacement therapy with IV IgG in that patient
prevented the development of invasive salmonella
infection (Leen et al, 1986b).
5.5.5 Discussion
Immunoglobulin replacement therapy for patients
\Q1
with primary hypogammaglobulinemia has mainly been in
the form of intramuscular injections. In the current
recommended doses of immunoglobulin used (25-50
mg/kg/week), a proportion of such patients still suffer
from recurrent infections and develop structural damage
over a period of years (Bjorkander et al, 1984). The
objective of this study was to examine whether it was
possible to maintain serum IgG concentrations at a
normal or near-normal level over a long period of time
using an intravenous immunoglobulin preparation.
Patients with primary hypogammaglobulinaemia usually
have serum IgG levels of 2 g/1 or less before treatment.
With IM IgG therapy at 25 mg/kg/week, the response is
variable but serum IgG levels are only raised by 1-2 g/1
with the occasional patient showing no increment in IgG
level at all. The serum IgG levels achieved in
individual patients are variable and argue strongly
against the practice of administering the same dose of
IgG to all immunodeficient patients (Buckley, 1980). The
half-life of infused IgG is very variable among such
patients and clinical observations have suggested that
it is shorter during intercurrent infection (Stiehm et
al, 1966). There is therefore a need to individualise
the dosage of infused IgG in patients with
hypogammaglobulinaemia.
Attempts to individualise treatment dosage should
achieve a high enough 'trough' serum IgG level to
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minimise the incidence of infection, using the minimal
quantity of IgG required due to cost and with a minimum
number of infusions to enable the patient to lead as
normal a life as is possible. However, there are
conflicting data on the optimal serum IgG level that
such patients need to maintain in order to minimise the
risk of infection. Janeway et al (1966) have reported
that serum IgG levels of about 2 g/l markedly reduced
the incidence of serious infections. In contrast, Joller
and his colleagues (1980) have concluded that a minimal
serum IgG concentration of about 3 g/l in patients with
hypogammaglobulinaemia is associated with an acceptably
low risk of acute infections. As no definitive clinical
trials have been set up to determine the optimum IgG
level for protection against infection and other
complications of hypogammaglobulinaemia, most clinicians
aim to achieve a near-normal serum IgG level in their
patients since it is likely that the nearer to normal
the serum IgG level, the lower is the incidence of
infection.
Previous studies have attempted to individualise the
dose of immunoglobulin to achieve a satisfactory serum
IgG concentration, but only one study increased the
frequency of IgG infusions. Morell et al (1982)
demonstrated that the administration of 300 mg/kg/month
to patients with antibody deficiency could increase and
maintain their serum IgG level between 3.0 and 5.0 g/l.
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Higher serum levels can be achieved by
disproportionately larger doses of IgG administered at
short intervals and sustained therapeutic IgG levels can
be obtained with 500 mg/kg of IV IgG (Montanaro and
Pirofsky, 1984). However, while most studies have shown
satisfactory increments in serum IgG levels following
administration of 300mg/kg/month, there are still
patients who have persistently low serum IgG levels
(Cunningham-Rundles et al, 1984). In one study, Schiff
et al (1984 ; 1985) used the half-life of infused IgG to
determine the dose required to maintain 'trough' IgG
levels above 2.0 g/1 in his patients with humoral
immunodeficiency. There was no reduction in the number
of infective episodes when the patients received the
higher dose of IgG but this was probably because the
'trough' serum IgG level achieved was only
around 2.0 g/1.
In this study, the serum IgG levels achieved with
SNBTS IV IgG therapy at a dose of 200 mg/kg two- of
three-weekly were excellent with 'trough' levels in the
normal range (greater than 5 g/1) for over a year in 50%
of the patients. Moreover, by increasing the infusion
dose, or by reducing the interval between two infusions,
or by a combination of the two, substantial increments
in the 'trough' IgG level in the patients were
successfully achieved and maintained.
Sequential serum IgG levels in Case 6 demonstrate
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the increased loss of infused IgG in the
gastrointestinal tract. In such patients adequate levels
can be maintained in the near-normal range with frequent
infusions of IgG with the usual dose of 200 mg/kg.
Similar increases could also be achieved in patients by-
using very high doses - the equivalent of eight times
the usual dose of IV IgG, as in Case 9.
When the intervals between infusions were increased
from three to five weeks in six selected patients the
'trough' serum IgG level was maintained above 4.0 g/1.
One possible explanation for this is that once the total
IgG body pool is saturated, the requirement for IgG
becomes less and normal trough serum IgG levels are
easily maintained. This is consistent with the finding
by Lever et al (1987) that the half-life of infused IV
IgG is prolonged after nine months of replacement
therapy. One patient (Case 3) maintained her serum IgG
level in the normal range for 16 weeks after her last
infusion. Although she had primary
panhypogammaglobulinaemia with a history of recurrent
bacterial infections at the time of diagnosis,
preliminary tests suggest that she is now suffering from
IgG 2-IgA deficiency.
In summary, 76% of the patients achieved a 'trough'
serum IgG level of at least 4.0 g/l within eight months
of the start of SNBTS IV IgG and 80% of patients
maintained their trough serum IgG level above 4.0 g/l
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when they received SNBTS IV IgG in a dose of 200 mg/kg
every four to five weeks. In patients with large
immunoglobulin losses, normal 'trough' serum IgG levels
can be achieved by use of larger doses of SNBTS IV IgG
by increasing the infusion doses or the frequency of
infusions, or by increasing both the frequency and dose
of infusions. While most of the patients who achieved
high 'trough' serum IgG level, including those with mild
to moderate bronchiectasis, improved during the study,
the frequency of diarrhoea in those with
gastrointestinal disease was unaffected, and one patient
with long-standing severe bilateral bronchiectasis




SNBTS IV IgG was well tolerated by patients with
primary hypogammaglobulinaemia; the incidence of adverse
reactions was extremely low in this group of patients
known to be more likely to suffer from adverse reactions
during immunoglobulin replacement therapy. The higher
incidence of adverse reactions encountered during the
first few IV IgG infusions was reduced by slowing the
infusion rate and by the additional use of prophylactic
aspirin or other inhibitor of prostaglandin synthesis.
Subsequent increase in the dose and rate of infusion did
not result in a higher incidence of adverse reactions.
The administration of large amounts of SNBTS IV IgG
was not associated with any episodes of hepatitis,
including NANB hepatitis, in the patients studied.
This suggests that the plasma pool may not have been
significantly contaminated with NANB hepatitis
virus(es). But it is more likely that during the
manufacturing process (mild- pepsin proteolysis at pH 4),
residual NANB hepatitis virus(es) present in Cohn II
fraction were inactivated, suggesting that other viruses
may have been likewise inactivated.
The half-life of SNBTS IV IgG was prolonged in
patients with primary hypogammaglobulinaemia. This is
comparable with other IV IgG preparations containing
intact IgG molecules. Individualising the dose and
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frequency of IV IgG infusions was successful in
correcting low serum IgG levels in most patients.
While most patients benefitted from an increased serum
IgG level, the frequency of diarrhoea was unaffected and
patients with severe structural lung damage may continue
to suffer from repeated respiratory infections. Further
controlled clinical studies are needed to examine the
optimal serum IgG level consistent with freedom from
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6.1 MECHANISM OF HUMORAL IMMUNITY
The antibody response resulting from exposure to
antigenic substances has certain well-defined
characteristics.
Following exposure to antigen, there is a delay of
about two weeks before any antibody can be found in the
blood and when there is intense activity in the lymphoid
tissues (spleen, lymph nodes etc), and in the submucosa
of the respiratory and intestinal tracts. This antibody
produced during the 'primary immune response' does not
reach a high level and does not persist unless a second
dose of antigen is given. When this happens, any
remaining antibody is rapidly mopped up by combination
with the antigen reflected by an initial fall in
circulating antibody. Then, after only a day or two "a
remarkable rise in antibody level begins and within a
few days reaches a peak which can be from 10 to 50 times
higher than the primary response. This 'secondary
response' is maintained at a high level, falling slowly
over a period of months. The response can be further
boosted to even higher levels by additional injections
of antigen (booster or recall dose) until a stage is
reached when no further increase occurs.
Protective antibodies generally combine with
antigenic components on the surface of microorganisms
and prevent them from multiplying, and sometimes kill
them. The antimicrobial actions of antibodies can be
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categorised as follows:
1 Promoting phagocytosis and subsequent digestion of
microorganisms by acting as cytophilic antibodies or
opsonins
2 Preventing attachment of microorganisms to
susceptible cells by combining with the surface of
microorganisms
3 Neutralisation of microbial toxins
4 Activating the complement system following their
attachment to the microbes, leading to the release
of vasoactive substances, and of lysosomal enzymes,
leucocyte chemotaxis, immune adherence
(opsonisation) and membrane lysis.
5 Enhancing phagocytosis following agglutination of
small microorganism, and rendering them nonmotile
6.2 SUCCESSFUL IMMUNOGLOBULIN THERAPY
For immunoglobulin treatment to be effective, the
mechanisms by which antibodies protect against
microorganisms should be taken into consideration when
immunoglobulin is manufactured.
By the time they reach adult life all animals,
including man, have been exposed to a wide variety of
infectious agents and have produced antibodies to most
of them. Serum immunoglobulin levels reflect this
extensive and universal natural process of immunisation.
Therefore, pooled plasma from a large number of blood
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donors would contain a large repertoire of antibodies
against a variety of different microorganisms.
6.3 HYPERIMMUNE PLASMA PROCUREMENT
While this pooled plasma can be used for the
manufacture of immunoglobulin for replacement in
patients with primary humoral immunodeficiency, it would
not usually contain high enough levels of specific
antibodies to make it suitable for the manufacture of
specific hyperimmune globulins. For this purpose,
therefore, donors with high levels of specific
antibodies have first to be identified before they are
enrolled in a plasmapheresis programme.
Such donors usually acquire high levels of a specific
antibody through prior natural exposure to the
infectious agent, leading to a subclinical or clinical
infection, or because they have been immunised against
that agent to prevent the infection.
Ways of recruiting donors for the procurement of
hyperimmune plasma for the manufacture of specific
hyperimmune globulin have been examined in this thesis.
There is undoubtedly a need for such immunoglobulin
preparations in the prophylaxis and treatment of certain
infections (see section 3.3). In order to meet this
clinical need, new methods of identifying suitable
plasma donors for regular plasmapheresis have to be
explored.
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The clinical use of immunoglobulins has been reviewed
in section 3.3. Undoubtedly, when new organisms are
discovered or old organisms assume increasing clinical
importance in immunocompromised patients, specific
immunoglobulin preparations are likely to be useful
until other specific therapeutic agents are discovered,
or until safe and effective vaccines become available.
An example is CMV, which can cause life-threatening
infection in the immunocompromised patient. CMV
hyperimmune globulin can certainly modify, if not
prevent, CMV infection but since the advent of new
antiviral agents its role in the treatment of severe
CMV infection is under review. Nonetheless, even when
safe and effective vaccines become available, as in the
case of rabies, the demand for hyperimmune rabies
immunoglobulin in the post-exposure prophylaxis of
rabies will remain.
How can the clinical demand for these preparations be
met? Adequate numbers of; suitable donors with high
levels of specific antibodies have to be identified.
Identifying these donors has depended on large-scale
screening of the blood donor populations which is
expensive and time- and labour-intensive. Random
screening of the blood donor population is routinely
carried out for the identification and recruitment of
hepatitis B and CMV plasma donors (sections 4.2 and
4.3). The two studies examining the CMV and hepatitis B
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plasma procurement have confirmed the difficulties with
such screening programmes, which have to be repeated at
frequent intervals to maintain a panel of suitable
donors. Many donors are withdrawn from the panel because
their antibody levels fall below the minimum required
for hyperimmune donations, or because of underlying
medical conditions, or because they have moved away from
the area.
The suitability of boosting selected donors as a
means of recruiting plasma donors has been demonstrated
by the tetanus study (section 4.4). With the
availability of a suitable and safe vaccine, selected
donors can be rendered hyperimmune and their plasma
harvested for the manufacture of hyperimmune globulin.
The advantages include planned programmes of
hyperimmunisation and subsequent plasma collection to
meet clinical demands which could be repeated at regular
intervals in a controlled way, ensuring ease of adequate
plasma availability. This is certainly possible with
tetanus toxoid, and could well be feasible for other
hyperimmune plasma collection (Table 4.1).
6.4 EVALUATION OF pH 4/PEPSIN TREATED IV IgG
PREPARATION
SNBTS IV IgG, a new intravenous immunoglobulin
preparation manufactured by the pH4/ mild pepsin method,
was been evaluated in patients with primary
hypogammaglobulinaemia (sections 5.2, 5.3, 5.4 and
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5.5) .
Although these patients are more prone to experience
adverse reactions following the administration of IgG,
the incidence of such reactions to the new preparation
was low and mostly mild, with the majority of reactions
occurring with the initial infusions. Reactions could
still occur many months after the patient had been
established on regular IV IgG. Only four adverse
reactions were moderately severe, and no patient was
intolerant of the product. The incidence of adverse
reactions was further reduced by slowing the infusion
rate of the IV IgG adminstered in reduced amounts to
patients who had never previously received any form of
IgG. The prophylactic use of aspirin was thought to be
of benefit to one patient who experienced fever and
influenza-like symptoms following IV IgG. Finally,
although much is known about the cause of adverse
reactions, the pathogenesis of most adverse reactions
remains unclear in many patients. In this study (section
5.2), for example, there was no evidence of complement
activation and no definite cause for the reactions was
ever found, but the general impression was that the
actual rate of infusion might have been an important
factor. Infusion rates of 264 mg/kg/hr were tolerated
without adverse reactions once the patients were well
established on IV IgG therapy.
The half-life of SNBTS IV IgG in some patients with
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hypogammaglobulinaemia was longer than four weeks (range
15-53 days) (section 5.4). This was comparable with
other IV IgG preparations that are currently available
for clinical use. Schiff (1985) reported that in
patients with primary hypogammaglobulinaemia the half-
life of infused IgG was not dependent on the serum IgG
level. However, Lever et al (1987) have found an
increase in the half-life of IgG at the end of a nine-
month course of SNBTS IV IgG treatment. This may be due
to a general decrease in protein catabolism associated
with an improvement in the patients' clinical status
accompanying an increase in serum IgG level.
The wide variation in the half-life of infused IgG
would explain the difficulty in achieving high normal
serum IgG in such patients when using standard IgG doses
of 200 mg/kg every four weeks. This can be overcome by
tailoring the dose and frequency of infusion of IV IgG
to suit the particular needs of the patient (section
5.5). Indeed, 13 of 17 patients studied achieved a serum
'trough' IgG level of greater than 4 g/1. While most
patients studied benefitted from the intravenous
administration of IgG, two patients with severe
bilateral bronchiectasis whose serum IgG was previously
maintained in the normal range while receiving FFP did
not notice any improvement in their chronic respiratory
symptoms.
Studies examining the efficacy of IgG in patients
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with primary hypogammaglobulinaemia are very difficult
to set up. Most of the published trials have compared
the incidence of infection while the patients were
receiving either intramuscular or intravenous
immunoglobulin, and they have shown the IV IgG to be
more beneficial to the patients. However, few clinical
trials have taken into consideration variations in the
seasonal incidence of infection. Trials, therefore,
should run for a prolonged period of time, preferably
at least two years, and have a cross-over design to
avoid seasonal variations in infection rate. The trials
should also compare the infection rate in patients with
different serum IgG levels. This would then allow
physicians to decide upon the optimal serum IgG level
required to minimise the frequency of infections and to
prevent structural lung damage. Finally, these studies
require the total cooperation of patients for the
recordings of antibiotic usage and episodes of fever and
days off work to be accurate. With the prevalence of
primary hypogammaglobulinaemia being so low, such
studies are, therefore, extremely difficult to set up
and smaller studies are probably unsuitable.
Cohn fraction II has an excellent record in terms of
safety from hepatitis B transmission, and the few
outbreaks of hepatitis associated with the
immunoglobulin are thought to be due to some fault in
the processing of a particular batch rather than to an
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inherent unreliability of the fractionation process.
This was reinforced by a study by Murray and Ratner
(1953), who found that IgG prepared by cold ethanol
fractionation, from a starting plasma that was
icterogenic and highly infectious, was not infectious to
volunteers. The starting plasma was later shown to
contain hepatitis B virus. Later studies of plasma
containing hepatitis B surface antigen with all the
markers of infectivity showed that, after cold ethanol
fractionation, the resultant IgG was free of all these
markers which were found in fraction III (Trepo et al,
1978). Furthermore, although hepatitis B surface antigen
was rarely found in fraction II, studies using
ultracentrifugation revealed small amounts of hepatitis
B surface antigen complexed with hepatitis B surface
antibody in fraction II and these complexes were not
infectious (Hoofnagle and Waggoner, 1980). Finally, as
all blood donations are now screened for hepatitis B
surface antigen, immunoglobulin is unlikely to contain
these non-infectious complexes.
NANB hepatitis has been transmitted by several plasma
fractions (Kernoff et al, 1984 ; Fletcher et al, 1983),
but until 1981 there had been no evidence of
transmission of NANB by any of the immunoglobulin
preparations. An outbreak of NANB hepatitis after the
administration of Rh(D) immunoglobulins was reported by
Renger et al (1981). But it was the three outbreaks of
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NANB hepatitis in patients with primary
hypogammaglobulinaemia receiving IV IgG preparations in
the United Kingdom, United States and Finland that have
challenged the view that cold ethanol fractionation
inactivates NANB hepatitis viruses regardless of the
infectivity titre present in the starting pool. While
SNBTS IV IgG and other pH4/mild pepsin treated IV IgG
(e.g. Sandoglobulin and SNBTS IV IgG) have so far been
free of NANB hepatitis transmission (section 5.3), it
could be argued that this is because the original plasma
pool may well have been free of NANB virus(es). However,
this is unlikely to be the case, and indeed, it is
thought that the manufacture of the IV IgG preparations
implicated in the outbreaks of NANB hepatitis may not
have included a known virucidal step and therefore
yielded an infective product when the initial plasma
pool was contaminated by a viraemic donor.
The outbreaks of NANB hepatitis are also related to
the use of large doses of IV IgG. Since the dose of IV
IgG used is 50 to 100 times higher, the infectivity
level may be more easily reached than with standard
intramuscular IgG.
At the present time, a suitable marker for NANB
hepatitis is not available and while chimpanzee
inoculation can be used to test for NANB hepatitis
transmission, this is expensive and time-consuming and
unreliable unless properly conducted (Prince, 1985).
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Furthermore, there are only a limited number 01
chimpanzees available throughout the world. Until more
reliable tests become available screening all plasma
donations for abnormally high ALT levels would decrease
the risk of NANB transmission (Hollinger, 1984).
However, this should not obviate the need for regular
and meticulous screening of the recipients for evidence
of hepatitis infection. Hepatitis infectivity is usually
indicated by elevated ALT or AST levels (two times the
upper limit of normal) over two consecutive monthly
samples, in the absence of other known causes of
elevated liver enzymes.
6.5 AIDS AND PLASMA DERIVED PRODUCTS
Today attention has shifted away from hepatitis-
transmission to the question of the transmissibility of
AIDS through plasma derived products. The risk of
gammaglobulin transmitting AIDS has generated some
concern. This is because gammaglobulin is a pooled
product from many donors which is not pasteurised.
However, although gammaglobulins are widely used there
has been only one reported case of a person not in a
high-risk group who has received immunoglobulin prior to
the onset of AIDS (MMWR, 1983). This patient received
immunoglobulin prophylactically for a needle stick
puncture from an unknown source. Furthermore, while HIV
antibody has been detected in lots of gammaglobulin and
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hepatitis B immune globulin, these lots have all been
culture negative for the virus (Tedder et al, 1985;
Gocke et al, 1986; Ikeda et al, 1986).
Intravenous gammaglobulin prepared by the reduction
and alkylation method, or pH 4/pepsin treatment method,
was found to contain antibodies against HIV using ELISA
and Western blot analysis. The gammaglobulin
preparations showed no signs of viral activity (by
monitoring for reverse transcriptase activity or virus
antigen expression). Recipients of large doses of the
preparations became transiently seropositive but the
antibody was transient and was not associated with
infection (Wood et al, 1986).
The isolation of retroviruses related to HIV from two
patients with 'common variable' hypogammaglobulinaemia
by Webster and his colleagues (1986) raised the
possibility of these viruses being transmitted by
contaminated IV IgG. However, since there have been no
other reports of clinical AIDS in patients receiving IV
IgG, they raised the possibility that these retroviruses
may be the cause of 'common variable'
hypogammaglobulinaemia. But there has been difficulty in
isolating similar viruses in other patients with 'common
variable' hypogammaglobulinaemia (Webster, personal
communication 1986).
In view of the widespread and frequent use of
gammaglobulin and other Cohn fraction II derivatives
2 l~7
such as hepatitis B immune globulin, and the lack of
clinical AIDS being manifest in their recipients, one
cannot consider it to be a significant risk for
transmitting this disease. The most likely explanation
of its safety relates to the cold ethanol preparation
used in Cohn fractionation being able to denature the
virus (Spire et al, 1984; Martin et al, 1985;
Piszkiewicz et al, 1985). It has been reported that 25%
ethanol inactivates HIV virus. In addition, the virus
probably precipitates during fractionation procedures
into fraction I and the cold insoluble fraction, thereby
sparing Cohn fraction II (Wells et al, 1986).
While it is now generally accepted that all plasma
pools used in the manufacture of blood products are
likely to contain viral contamination, attempts should
be made to limit the contamination to a minimum in order
to minimise the demands on any inactivation processes
during the manufacture of blood products. The most
efficient means of excluding infective donations is by
the use of assays for specific markers of potential
infectivity, e.g. hepatitis B antigen, HIV antibody,
hepatic enzymes. The exclusion of some infective
donations can also be achieved by persuading donors in
'high risk' groups, particularly homosexuals and
intravenous drug abusers, to abstain from donating blood
or plasma.
During the manufacture of IV IgG, further processinig
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of the IgG is required following the removal of ethanol
to reduce the level of spontaneous anti-complementary
activity and of vasoactive enzymes. Several of the
techniques used at this stage have recognised or
potential virucidal activity. These include beta-
propiolactone and ultraviolet irradiation (Prince et al,
1983), acid treatment (Andrewes et al, 1978) and limited
or complete proteolysis using pepsin at low pH (Tabor et
al, 1983).
6.6 FINAL CONCLUSION
In this thesis it has been shown that random
screening of donors for high levels of specific antibody
is not effective, being time- and labour-intensive and
costly. This has been confirmed for hepatitis B and CMV-
plasma procurement. The study on boosting donors with
tetanus toxoid for the procurement of tetanus plasma has
shown that donors can be hyperimmunised without an
excess of adverse reactions. This study has also
identified the donors most suitable for boosting with
tetanus toxoid prior to plasmapheresis. While similar
studies could be set up to examine the feasibility of
boosting donors with other vaccines for hyperimmune
plasma procurement, the availability of safe and
effective vaccines remains the crucial factor. Indeed,
while donors can be boosted with hepatitis B vaccine,
there is not a completely safe and effective CMV
2-iq
vaccine. The demonstration of an effective and safe
boosting policy with tetanus toxoid would therefore pave
the way to hyperimmunisation of donors for the
procurement of other specific hyperimmune plasma.
The studies on adverse reactions and risk of
hepatitis transmission have confirmed the safety of a
pH 4/mild pepsin treatment IV IgG product. Patients
with primary hypogammaglobulinaemia who have never
previously received any immunoglobulin replacement are
now given a small initial dose of IV IgG with or without
any prophylactic aspirin. Following the study on dosage
individualisation of IV IgG for each patient with
hypogammaglobulinaemia, the dose and frequency of
administration of IV IgG is now regularly monitored so
as to maintain the 'trough' serum IgG level as near the"
normal range as possible. This may be important as it is
likely that if normal serum IgG levels can be achieved
as soon as the diagnosis is made, permanent structural
organ damage is likely to be minimal.
There is no doubt that further, properly-conducted
studies in to whether patients with primary
hypogammaglobulinaemia benefit from achieving normal
serum 'trough' IgG level are required, and it is only
when these studies are completed that we will know if
the treatment of these patients is more complex than
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Date of Birth : 15.01.51
Age at diagnosis : 34 years
Diagnosis : Common Variable Immunodeficiency
Presenting symptoms : Painful lymphadenopathy
Recurrent infection







: 3.35 g/1Serum IgG











Weight loss and diarrhoea
Intractable giardiasis











Details and progress: Prestudy serum IgG is not low
because of prior treatment with other IV IgG
preparations. Well since on IV IgG. He is the subject of











Past medical history: Asthma
Idiopathic thrombocytopenia




mother has Hashimoto's thyroiditis
9 months
Before study
: 1.81 g/1Serum IgG




























Date of Birth :





















Details and progress: well since receiving
immunoglobulin replacement. Prestudy serum IgG is
not low because of previous IV IgG therapy. Three years
after regular IV IgG, she now has normal serum IgG
levels but probably has IgA deficiency with IgG 2






Past medical history: Recurrent sinusitis














Details and progress: well since receiving
immunoglobulin replacement. He experienced adverse
reactions during the initial IV IgG infusions but


























Details and progress : no obvious improvement despite
reasonable serum IgG levels; bronchiectasis remains a
problem and because of severe sepsis she is underweight.
PATIENT 8
Date of Birth :



























Details and progress: clinically free from




Date of Birth :





















Details and progress: clinically
infection and serum IgG better








Date of Birth :






















Details and progress: clinically free from severe
infection. She became rheumatoid factor negative when











Past medical history: Recurrent Otitis Media
Myringoplasty
Family history : nil of note






Details and progress: clinically free from severe
infection. His high serum IgG before the study is the
result of IgG replacement therapy with fresh frozen
plasma and at least two other IV IgG preparations.
PATIENT 12
Date of Birth


























Details and progress : clinically free from severe
infection. The severe proteinuria secondary to his
amyloid appears to have spontaneously resolved following



























Details and progress ; clinically free from severe
infection. Since receiving IV IgG he has gained 12
pounds in weight. Chest X ray findings are, however,




Date of Birth :










Malabsorption without villous atrophy
Recurrent mucosal ulcers of uncertain
aetiology
Jejuno-ileal strictures, ?Crohn's
Recurrent otitis media and sinusitis
Family history X-linked hypogammaglobulinaemia






Details and progress : In 1980, treatment with fresh
frozen plasma started because of low serum IgG levels
while on IM IgG. In 1981, investigations for weight loss
showed no treatable abnormality. In 1986, investigations
for abdominal pain, weight loss, and severe iron
deficiency anaemia revealed ulceration, tubular
narrowing, saculation and thickening of bowel wall
together with effacement of mucosal folds and a
cobblestone appearance most marked in the proximal
bowel. Resection of the diseased portion of the bowel
resulted in a 7 pound weight gain and normalisation of




Date of Birth : 14.04.67
Age at diagnosis : 6 months
Diagnosis : X-linked Hypogammaglobulinaemia
Presenting symptoms: Screened because brother is known
to have Hypogammaglobulinaemia
Past medical history: Diarrhoea due to total villous atrophy
Hypoparathyroidism
Family history : X-linked hypogammaglobulinaemia






Details and progress : Treatment with fresh frozen
plasma started because of low serum IgG levels while on
IM IgG explains reasonable serum IgG before study.
Hypoparathyroidism diagnosed in 1 985 and he is
maintained on 4 meg of one-alpha every day. He does not
have any stigmata of hypoparathroidism.
262
PATIENT 1 6
Date of Birth :
















Family history : nil of note






Details and progress: In 1979, investigations of a left
paravertebral mass resulted in a laparotomy revealing a
renal mass; the histology of which suggested a mycotic
aneurysm. Surgery was difficult and a left
ureteronephrectomy was performed. Treatment with fresh
frozen plasma started in 1980, and subsequently received
two IV IgG preparations. He needed increased diuretics
during IV IgG infusions because of his cardiac failure.
Since last studied in November 1985, he developed a
septicaemic illness and died in 1986.
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PATIENT 17
Date of Birth :




















Details and progress : She received two IV IgG
preparations prior to the study. She delivered a normal
male baby in 1985. The baby's serum IgG was normal
because of passively transferred IgG from a well
maintained serum IgG in the mother. Baby does not have
hypogammaglobulinaemia. She is now well and has had no
serious lung sepsis since on IV IgG.
PATIENT 18
Date of Birth :




















Details and progress : Treatment with intravenous




Date of Birth :























Details and progress: Treatment with IM IgG did not
improve her chronic bronchitis. She developed severe
salmonella septicaemia while pregnant and lost the baby
she was carrying. Since on IV IgG from August 1984, she
has been able to stop her prophylactic antibiotic
without any deterioration of her chest symptoms.
PATIENT 20
Date of Birth :



















Details and progress : Since treatment with IV IgG she
has not had any lower respiratory symptoms. She feels
much better and more active.
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PATIENT 21
Date of Birth : 31.10.34
Age at diagnosis : 29 years
Diagnosis : Common Variable Immunodeficiency
Presenting symptoms: Recurrent Chest Infections
Past medical history: Pyogenic Arthritis
Hypersensitive to IM IgG
Family history : nil of note








Details and progress : Since replacement therapy has
been changed from IM IgG to fresh frozen plasma, his
symptoms have vastly improved. While on IV IgG, he has
been able to stop his prophylactic antibiotics and has
experienced no deterioration.
PATIENT 22
Date of Birth :










Family history nil of note






Details and progress : He had received two IV IgG
preparations prior to the start of the study. He is
known to have a large intake of alcohol and this has
explained his occasional high serum ALT levels. He
remains free of serious infective problems.
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PATIENT 23
Date of Birth :






















Details and progress : She is free from serious
infections, but her main problem is epilepsy.
PATIENT 24
Date of Birth :





















Details and progress : His replacement therapy has been
changed from IM IgG to fresh frozen plasma because his
chest symptoms were deteriorating. However, while on IV
IgG, they remain unchanged.
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PATIENT 25
Date of Birth :












Family history : nil of note






Details and progress: In view of his severe
malabsorption, he was established on home total
parenteral nutrition. Investigations carried out in
Michigan (USA), revealed that he had defective cellular
immunity. He underwent cholecystectomy for cholecystitis
and cholelithiasis. A liver biopsy showed portal
triaditis with occasional granulomatous foci. Jejunal
biopsy showed villous atropy. He had gastric
achlorrhydria with absent parietal cell antibodies. In
1984 investigations of abnormal liver function tests
including a liver biopsy revealed that they were
secondary to an excess lipid in his parenteral nutrition
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work described in this thesis :
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chronic peritoneal dialysis catheter under local anaesthesia. Venous
blood was sampled regularly for measurement of plasma morphine
concentrations by radioimmunoassay.1 This method gives identical
values to those of high-performance liquid chromatography in
patients with renal failure.2 No further analgesic medication was
required since the single dose of morphine had a prolonged clinical
effect. Postoperatively the patient appeared sedated for 24 h and was
drowsy with constricted pupils for a further 3 days. She had no
abnormalities of hepatic function and took no other analgesic
medications; she was put on peritoneal dialysis 36 h after insertion
of the catheter.
The figure shows plasma morphine concentrations after the
single intravenous injection. Morphine was still detectable 19 days
after this dose, with an estimated half-life of 73-1 h and a systemic
clearance of23 ml/min. The half-life was much longer and clearance
much lower than for patients with normal renal function. Systemic
morphine clearance in patients undergoing lumbar laminectomy
had a mean of486 ml/min and range of 189-1051 ml/min.1
The remarkable prolongation of the clinical effect of the single
10 mg dose of morphine, paralleled by the long half-life and low
systemic clearance, led us to abandon the study. We do not feel that
further use of morphine premedication is acceptable in patients
with severe chronic renal failure and believe that this patient
illustrates the overriding relevance of renal mechanisms for
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1. Moore RA, Baldwin D, Allen MC, et al. Sensitive and specific morphine radioimmuno¬
assay with iodine label: Pharmacokinetics of morphine in man after intravenous
administration. Ann Clin Biochem 1984; 21: 318-25.
2. Moore RA, Sear J, Baldwin D, et al. Morphine kinetics during and after renal
transplantation. Clin Pharmacol Ther 1984; 35: 641-45.
non-a, non-b hepatitis and intravenous
immunoglobulin
Sir,—There have been two reports of non-A, non-B (NANB)
hepatitis in patients with hypogammaglobulinaemia given
immunoglobulin preparations treated to render them suitable for
intravenous use.1. We would like to report on our experience with
Scottish National Blood Transfusion ' Service intravenous
immunoglobulin (IVIG) over the past two years. This product is
prepared at the Service's Protein Fractionation Centre from a cold
ethanol fraction II which is subsequently ultrafiltered, treated by
mild pepsin proteolysis at pH 4, and freeze dried.3,4 The product
after reconstitution with water is a solution of 5% (5 g per 100 ml)
of human normal immunoglobulin. Patients with primary
hypogammaglobulinaemia receive 200-400 mg/kg every 2-5
weeks. Patients with autoimmune blood disorders (mainly immune
thrombocytopenic purpura) receive 2 g/kg divided over 2-5 days.
Treatment can be repeated every 2 months.
When Lane5 reported the possibility of NANB hepatitis in
hypogammaglobulinaemic patients receiving IVIG manufactured
at the Blood Product Laboratory, Elstree,5 we began a prospective
study ofclinical and laboratory evidence ofviral hepatitis in patients
with primary hypogammaglobulinaemia after treatment with
Scottish IVIG. Pre-infusion serum samples obtained at each
infusion of IVIG were sent for assay of alanine aminotransferase
(ALT).
Serial ALT values were available over a period of one year in
eleven patients and over 6-10 months in a further five. Nine
patients had been established on regulqj replacement with Scottish
IVIG for at least a year before the start of the prospective study.
Serum samples taken during that year had been stored at -70°C,
and the pre-infusion samples from these patients were retrieved and
examined for ALT activity.
No patient had any clinical evidence of viral hepatitis. Eleven of
the sixteen patients had ALT values in the normal range (up to 50
U/l). One patient had chronic liver disease secondary to total
parenteral nutrition before the start ofIVIG treatment, two patients
had two isolated ALT rises (neither above 70 U/l), and ALT values
were normal by the next infusion; one patient had a single rise in
ALT (60 U/l); and one patient had a transient ALT increase over a 4
week period with a peak value of91 U/l after 14 months oftreatment
with Scottish IVIG. All patients were clinically well and other
patients who had received the same batches of IVIG did not show
any change in serum ALT.
Neither the clinical picture nor the level ofserum ALT increase in
the above five patients resembles NANB hepatitis or the illness
described by Lever, Ochs, and their colleagues.1,2 Our patients have
remained well. Most clinicians will diagnose hepatitis if the ALT
level is above the normal range in two or more sequential blood
specimens taken 3-17 days apart and ifone value is at least twice the
upper limit of normal.6 None of our patients meet these criteria,
except for one with chronic liver disease.
Thirty-eight additional patients with various
immunohaematological disorders were enrolled in a prospective
study in 1984 to assess the clinical efficacy and safety ofhigh doses
of the Scottish IVIG. Serial blood samples were taken and tested for
ALT before treatment, every week for a month, then 2,3, and 6
months after treatment. Sixteen patients have completed 6 months'
follow-up.
/'Among the thirty-eight patients, two with viral infections had
abnormal ALT levels before treatment. ALT values in samples
taken 3 weeks after therapy were in the normal range. Another
patient was being treated with androgenic steroids. His ALT was 68
U/l immediately before the first infusion and a peak level of 102 U/l
was observed 2 days later. So far he has been followed up for 4 weeks
and his ALT remains about 60 U/l. This pattern ofALT elevation is
not in keeping with transmission of infection by the
immunoglobulin preparation because the peak enzyme activity was
within 2 days of the infusion. A fourth patient had a raised lactate
dehydrogenase level before IVIG was given and she had an ALT of
114 U/l in a single sample taken 4 weeks after treatment. The ALT
level was normal 1 week later. One patient had normal liver-
function tests and showed a transient rise in ALT (peak 60 U/l) 4
weeks after therapy. This rise coincided with a course of
cyclophosphamide. As in the study of the hypogamma¬
globulinaemic patients none of these cases showed any clinical
evidence to suggest viral hepatitis. J
We believe that Scottish National Blood Transfusion Service
IVIG does not cause hepatitis. While we have observed some minor
increases in serum ALT values of some of our patients, we do not
think that these were due to non-A, non-B hepatitis.
Edinburgh and South-East Scotland
Regional Blood Transfusion Centre,
Edinburgh EH3 9HB
Glasgow and West of Scotland
Regional Blood Transfusion Centre,
Carluke
C. L. S Leen"
P. L. Yap
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non-a, non-b hepatitis after intravenous
gammaglobulin
Sir,—We note the comments ofDr Brettle(Jan 5, p 51) regarding
our report of non-A, non-B (NANB) hepatitis in patients with
agammaglobulinaemia after intravenous gammaglobulin.
The first case of hepatitis occurred two weeks after the first
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Sarcoidosis and Primary Hypogammaglobulinaemia: a Report of two Cases and
a Review of the Literature
C.L.S. Leen, M.R.C.P. * J.C.J.L. Bath, F.R.C.P.(E)**, R.P. Brettle, M.R.C.P. ***, P.L. Yap,
Ph.D., M.R.C. Path.*
* Edinburgh & South-East Scotland Blood Transfusion Service, Royal Infirmary, Edinburgh, Scotland.
** Law Hospital, Carluke, Lanarkshire, Scotland.
*** City Hospital, Edinburgh, Scotland.
Abstract. We are aware of only four previous cases of Kveim positive sarcoidosis reported in
hypogammaglobulinaemic patients and we describe two further patients. Patients with hypogam¬
maglobulinaemia and a sarcoid-like syndrome or sarcoidosis have been reviewed. Similarities bet¬
ween sarcoidosis and a subgroup of late onset primary hypogammaglobulinaemia have been
highlighted. It is suggested that sarcoidosis in this patient population is probably commoner than
was previously thought, but the association between the two conditions remains unclear.
Key words. Sarcoidosis. Hypogammaglobulinaemia. Cellular immunity.
Introduction
Sarcoidosis is usually associated with nor¬
mal or elevated serum immunoglobulin levels
[1]. The observation of sarcoid-like
granulomas in patients with primary hypogam¬
maglobulinaemia has been reported previous¬
ly [2-12]: but we are aware of only four
reported cases where a definite diagnosis of sar¬
coidosis was confirmed by a positive Kveim test
[2, 5, 10, 12]. We would like to report two fur¬
ther caseis where sarcoidosis and late onset
primary hypogammaglobulinaemia coexisted
in the same patient.
Author's Address:
Dr. C.L.S. Leen M.R.C.P., Edinburgh & South-East
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Case reports
Case 1. G.McL. was relatively well apart
from recurrent otitis media and sinusitis until
1970 when, at the age of 23, he presented with
a febrile illness accompanied with vomiting. A
chest x-ray showed bilateral hilar lym-
phadenopathy. The Mantoux test was negative
to 1 unit of tuberculin PPD and a Kveim test
was positive. He did not receive any cor¬
ticosteroid. One year later he was found to have
hypogammaglobulinaemia on protein elec¬
trophoresis. His sarcoidosis remained active and
he continued to have respiratory infections with
radiological pulmonary changes. His serum im¬
munoglobulin levels were: IgG 2.0 g/1, IgM 0.12
g/1, and IgA could not be detected. In 1975 he
had an acute febrile illness with pleural effu¬
sions and E.C.G. abnormalities in keeping with
pericarditis. He was treated then with oral cor¬
ticosteroids and their withdrawal was delayed
because respiratory symptoms increased when
the dose was reduced.
92 Leen, Bath, Brettle, Yap
In 1976 intramuscular immunoglobulin
750 mg monthly was started with improvement
in respiratory symptoms and withdrawal of
steroids. In June 1980 following a further at¬
tack of pneumonia he developed severe herpes
zoster ophthalmicum resulting in temporary
paralysis of accomodation and of the fourth
cranial nerve. Iridocyclitis and punctate
keratitis followed the zoster infection but both
resolved eventually with topical therapy. At
review in July 1984 he complained of tiredness,
weight loss, constant productive cough with
mucopurulent sputum and recurrent flu-like
episodes. In August 1984, intravenous infu¬
sions of immunoglobulin (15 gm) were started
and continued at three weekly intervals. By
January 1985 he had gained 12 pounds in
weight, his cough and sputum were much
decreased and he felt fitter. Chest x-ray ap¬
pearances were unchanged since July 1984 with
considerable generalised mottling and coarse
reticulation present in the lung fields.
Case 2. R.B. This patient was well until
1978 when he presented with chronic intrac¬
table diarrhoea and weigth loss. A jejunal
biopsy showed partial villous atrophy, Giar-
dia lamblia in the lumen and increased lym¬
phocytes with reduced plasma cells in the
lamina propria. Serum immunoglobulin con¬
centrations were low (IgG 2.9 g/1, IgA and IgM
undetectable). There was slight lymphopenia
of 0.9 X 10 9/1 with 91% T cells and 9% B
cells [13]; isohaemagglutinins and antibodies
to E. coli were undetectable; but lymphocyte
transformation to phytohaemagglutinin and
concanavalin A and tests of neutrophil func¬
tion were normal [13]. A diagnosis of late onset
hypogammaglobulinemia with complicating
chronic giardiasis was made. Despite long
courses of metronidazole and mepacrine, weight
loss and diarrhoea continued, and therapy was
supplemented with immunoglobulin replace¬
ment in the form of plasma 15 mg/kg every
three weeks. This resulted in symptomatic im¬
provement, increased serum IgG of 6.2 g/1 and
weight gain of 17 kg.
Four months after the start of his im¬
munoglobulin replacement therapy he was ad¬
mitted to hospital with diabetic keto-acidosis
(2% glycosuria, ketonuria (+ + +), blood
glucose 31.2 mmol/1; bicarbonate 12 mmol/1).
He remained relatively well on twice daily in¬
sulin injections until September 1980 when he
complained of one month history of drenching
night sweats, general malaise, headaches and
vague epigastric discomfort. Positive findings
on examination were a temperature of 37.5 C
and moderate hepatosplenomegaly.
Haemoglobin, white cell count and ESR were
normal. Liver function tests were slightly ab¬
normal with serum ALT levels ranging between
41 and 67 U/L and Alkaline Phosphatase bet¬
ween 103 and 115 U/L. Chest x-ray and an ab¬
dominal lymphangiogram were likewise nor¬
mal. Stool examination revealed many Giardia
intestinalis cysts. Mantoux test to 1 unit and 10
units of tuberculin PPD was consistently
negative. Throat swabs, early morning urine
specimens, mid-stream specimens of urine,
blood cultures, skin swabs and marrow cultures
were also negative (including alcohol and acid
fast bacilli studies). Hepatitis B surface antigen
was negative. Liver biopsy and iliac trephine
biopsy were normal with no evidence of lym¬
phoma or granuloma formation. No firm
diagnosis was reached, but his symptoms settl¬
ed spontaneously after he received further treat¬
ment with metronidazole for giardiasis.
He was admitted again to hospital in 1982
for treatment of a right basal pneumonia. A
prominent shadow below the aortic knuckle was
noted in his chest x-ray. Repeat chest x-ray a
few months later revealed enlargement of hilar
lymph glands bilaterally and of the left
paratracheal group of nodes without pulmonary
infiltration. Hepatosplenomegaly and enlarge¬
ment of the right scalene node were found on
physical examination. Histological examination
of the right scalene node biopsy showed
numerous non-caseating granulomas with giant
cells. The appearances were consistent with sar¬
coidosis. A Kveim test was performed 18
months later to seek further evidence for sar¬
coidosis and was positive. T and B lymphocyte
numbers were normal but lymphocyte transfor¬
mation with phytohaemagglutinin, con¬
canavalin A and pokeweed mitogen were
severely depressed whereas they were completely
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normal previously. There is no family history
of sarcoidosis or of insulin dependent diabetes,
or of increased susceptibility to infection.
Comments
It is quite possible that sarcoidosis and
hypogammaglobulinaemia developed
simultaneously in the first patient although
serum immunoglobulin levels were not
measured until one year after sarcoidosis was
diagnosed. The earlier history of recurrent
otitis media and sinusitis would suggest that
the primary hypogammaglobulinaemia may
have preceded sarcoidosis. The second patient
is very unusual in that he developed insulin
dependent diabetes mellitus in the total absence
of serum autoantibodies and subsequently suf¬
fered from sarcoidosis. The clinical features
that are consistent with the diagnosis include
hilar lymphadenopathy, splenomegaly, non
caseating granulomas in the scalene node, non
reactive tuberculin test, depressed lymphocyte
proliferation and a positive Kveim test. The
only unusual finding is the very low level of
serum immunoglobulins consistent with
primary hypogammaglobulinaemia. The defect
in his lymphocyte functions in vitro is consis¬
tent with both common variable hypogam¬
maglobulinaemia [14], and sarcoidosis [15].
Review of literature
Although 85% of patients with sarcoidosis
have increased levels of serum IgG, a syndrome
resembling sarcoidosis with hypogam¬
maglobulinaemia has been described previous¬
ly. Prasad first reported in 1954 the case
of a 30 year black woman with hypogam¬
maglobulinaemia, hypersplenism, and
numerous non caseating granulomas involving
lymph nodes, liver and spleen. Although no
Kveim biopsy was performed, Zinneman,
when reviewing the same patient in his series
of 3 patients with hypogammaglobulinaemia
thought that she had sarcoidosis. The first well
documented hypogammaglobulinaemia patient
with a positive Kveim test confirming sar¬
coidosis was by Bronsky, although of the three
patients in the MRC series published in 1971,
there was one who was reported to have
sarcoidosis following a positive Kveim test in
1960. In 1970, Sharma and James found
widespread granulomas in the liver and
scalene nodes of a patient with hypogam¬
maglobulinaemia. Other features consisted of
skin anergy to tuberculin, Candida albicans,
and dinitrochlorobenzene, and depressed lym¬
phocyte transformation to phytohaemag-
glutinin. Because of the paucity of clinical
features, and the negative Kveim test, Sharma
and James concluded that the patient did not
have sarcoidosis, and that the associated
granulomas might have been due to an
unknown immunologic mechanism. Since then
there have been numerous reports of sar¬
coidosis or of a sarcoid- like syndrome in pa¬
tients with hypogammaglobulinaemia, Table I.
Crofts's patient is particularly interesting
in that she had selective IgA deficiency
associated with raised serum IgG at the time
the diagnosis of sarcoidosis was made, and it
was only after splenectomy that she developed
severe panhypogammaglobulinaemia and
cellular immunodeficiency. Crofts thought that
the post operative development of IgG and
IgM deficiencies could have been related to
splenectomy in an already compromised im¬
mune system, although selective IgA deficiency
can develop into panhypogammaglobulinaemia
[9]. The abnormal mononuclear cellular
response would be consistent with sarcoidosis.
Interestingly, Seigler diagnosed sarcoidosis in
two patients with selective IgA deficiency [16].
Discussion
Reports in the literature seem to indicate
that there may be two different clinical entities:
sarcoidosis and a sarcoidlike illness in the
hypogammaglobulinaemic population. This is
not surprising as many features that are com¬
mon to sarcoidosis e.g. hypersplenism,
granulomas and depressed cellular immunity
may be encountered in the patient with
hypogammaglobulinaemia [9, 18, 14]. Asherson
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Table I
Clinical features of sarcoid-like syndrome in primary hypogammaglobulinaemia
AGE
(Yrs.)













et al 1954P1 — Yes Yes — — Spleen, liver nodes
25 M Hill 196015) + ve - Yes - - Nodes
39 M Hill 196315) - - Yes - - Nodes
37 F Bronsky
et al 196513) + ve Yes Yes — — ve Skin & nodes Bilateral hilar nodes
35 F Hill 196515) — ve Yes Yes - - Nodes and liver




test positive to Mumps and
Streptokinase-Streptodornase.
35 F Sharma &
James 1970I6) — ve Yes Yes Yes — ve Liver Abnormal skin test to Candida
albicans dinitrochlorobenzene.
47 M Seigler 1978U6] - - Selective
IgA initially
- - - Hilar nodes, pulmonary mottl¬
ing, arthritis, diabetes mellitus.
21 F Seigler 1978)16) — ve — Selective
IgA
— — ve Liver skin Renal tubular acidosis, hyper-
calcaemia, nephrocalcinosis,
nephrolithiasis.
30 F Asherson &
Webster 1980)9) — ve Yes Yes - — ve Liver Hilar nodes, positive tests to
DNB.
48 F Asherson &
Webster 1980)9) — ve - Yes - — ve Transbronchial
biopsy
Reticular pattern in lung fields.
Positive skin test to DNB.
? M Asherson &
Webster 1980)9) — ve - Yes - — ve Transbronchial
biopsy
Asthma, positive skin test to
DNB.
16 M Perks &
Petheram 1978F) — ve Yes Yes Possible
clinically
— ve Skin, lung, pleura
& liver
Eyes involvement.
25 F Perks &
Petheram 1978)7' — ve Yes Yes Yes — ve Scalene nodes Raised serum angiotensin con¬
verting enzyme.
43 M Edelstein
et al 197818) — Yes Yes Probably — ve Nodes, spleen
23 F Crofts et al 198300) + ve Yes Selective
IgA initially
Yes - ve. Spleen, liver nodes IgA deficiency preceding pan-
hyp ogammaglobulinaemi a.
Repeat Kveim normal later.
12 F Friedman
et al 198300 - Yes Yes Yes — ve Liver, spleen Negative skin test to Candida
streptodornase, honeycomb pat¬
tern in lung fields, decreased
serum C4; hypersplenism.
72 F Lee 1984021 + ve Yes Yes — — Skin Leucopenia, haemolytic
anaemia, uveitis, raised serum
angiotensin converting enzyme.
33 M Present Case + ve Yes Yes Yes — ve Scalene node Diabetes Mellitus.
23 M Present Case + ve No Yes — — ve — Severe Herpes Zoster with
iridocyclitis.
* IgG, IgA and IgM except where otherwise specified. ** CMI = cell mediated immunity.
Figures in brackets represent reference number.
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noted splenomegaly in 55% in his series of 40
patients with common variable hypogam¬
maglobulinaemia and 3 patients in the same
series had sarcoid granulomas. Sarcoid like
granulomas in patients with hypogam¬
maglobulinaemia may represent an abnormal
interaction between macrophage and indigesti¬
ble antigen possibly because of the underlying
immune defect [17].
Cunningham-Rundles [14] demonstrated
that some patients with late onset primary
hypogammaglobulinaemia have a profound loss
of both B and T lymphocyte function as studied
in in vitro lymphoproliferative assays. Indeed,
most of the patients in this review showed
evidence of negative tuberculin reaction and 5
patients at least [6, 7, 11, and the two present
cases] had documented evidence of abnormal
in vitro T cell transformation. Whether this is
also needed for granuloma formation in a
positive Kveim test in addition to the underly¬
ing defect in the humoral system is unclear.
The Kveim test is widely accepted as a
reliable and clinically useful aid to the diagnosis
of sarcoidosis [19]. False positive reactions are
rare, and as low as 1-2% [20, 21] and a positive
test can be regarded as virtual proof of active
sarcoidosis. However, a positive test can only
be obtained in 75% of cases with clinical
evidence of sarcoidosis [22]. A negative Kveim
does not exclude a diagnosis of sarcoidosis, if
the clinical features are typical of the syndrome.
It can therefore be argued that sarcoidosis in
patients with hypogammaglobulinaemia is com¬
moner than is currently believed, and that near¬
ly all the patients in this review with non reac¬
tive Kveim had either a clinical syndrome
similar to sarcoidosis or had an atypical
form of sarcoidosis. Nonetheless, until these
two conditions are better understood, the
association between sarcoidosis and hypogam¬
maglobulinaemia must remain obscure.
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Immune Hepatitis B Plasma Procurement
C. L. S. Lcen, R. M ilson. F. L. Yap. D. B. L. McClelland
Edinburgh and S. E. Scotland Blood Transfusion Service. Regional Centre, Royal Infirmary,
Edinburgh. UK
Abstract. The requirement for hepatitis B immunoglobulin for passive immunisation
persists despite the availability of a safe hepatitis B vaccine, and there is therefore a need for
immune plasma for immunoglobulin production. We have screened a large number of blood
donors to identify potentially suitable hepatitis B immune plasma donors. The logistics of
this have been examined, and the programme was found to be inefficient and labour-
consuming. A suitably designed programme of active immunisation with hepatitis B vaccine
should provide a more effective means of obtaining plasma.
Introduction
Plasma with high titres ofantibody against
hepatitis B (HBsAb) for the manufacture of
hepatitis B immunoglobulin (HBlg) is nor¬
mally collected from suitable donors who
have been previously exposed to hepatitis B
infection. Our present plasma procurement
system relies on large-scale screening of the
blood donor population to find suitable
donors to be recruited for plasmapheresis. In
a previous communication [1], we have
found that the prevalence of hepatitis B anti¬
body in the Scottish population is quite low
and that screening of the general blood donor
population is a large exercise which is time-
and labour-consuming. Furthermore, the se¬
rum level of antibody to hepatitis B surface
antigen is not always maintained, leading to a
loss of hepatitis B immune plasma donors.
and as a consequence such screening exer¬
cises may have to be repeated at regular inter¬
vals. We report the results of such a screening
programme in South East Scotland and
examine its effectiveness as a means of iden¬




Between tune and October 1983 all blood dona¬
tions collected from the normal volunteer blood donor
population by the Edinburgh and South East Scotland
Regional Blood Transfusion Centre were screened for
the presence of hepatitis B surface antibody (HBsAb).
EIBsAb was subsequently quantified in the positive
samples.
Donors with HBsAb levels of 10 IU/ml or greater
were identified and approached with a view to recruit¬
ing them for plasmapheresis.
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The criteria for suitability for plasmapheresis
were: (I) scrum HBsAb level of 10 Ill/ml or greater: (2)
age less than 50 tears; (3) minimum body weight of
50 kg: (4) good venous access; (5) no major illnesses:
(6) absence of HBsAg: (7) availability.
The recruited donors were plasmapheresed at
intervals varying between once evert 4 and once evert
12 weeks, and the volume ofeach plasma donation was
recorded by weighing. Before each plasmapheresis,
quantitation of HBsAb level was carried out and liver
function tests and absence of hepatitis B surface anti¬
gen were monitored.
Biochemical Assessment
Venous blood samples were collected at each plas¬
mapheresis for liver function tests by Sequential Mul¬
tiple Analysis with computer system SMAC 2.
Screening and Quantitation of HBsAb Level
Screening of the blood donations was carried out
using a solid-phase sandwich immunoassay adjusted
to detect samples with hepatitis B antibody level above
1 IU/ml [I]. The antibody level in positive sera was
measured using AUSAB (Abbott Laboratories. Chica¬
go. 111.) radioimmunoassay. A laboratory standard,
calibrated against a WHO standard obtained from the
Amsterdam Red Cross Central Laboratory, was di¬
luted in 0.1 MTns-HCl. pH7.5. containing 50% nor¬
mal human serum (HBsAg/anti-HBs-negative) to val¬
ues of 0.32. 0.16. 0.08. 0.04. 0.02. and 0.01 IU/ml.
Anti-HBs-containing sera were diluted 1:10, 1:100.
1:1.000. and 1:10.000. Count rates were automatically
processed by an NE 1612 gamma counter (Nuclear
Enterprises. Edinburgh. Scotland) programmed to
construct a standard curve against which to compare
appropriate test serum dilutions.
Assessment ofHepatitis B Status
Venous blood samples were assayed for hepatitis B
surface antigen by radioimmunoassay (Blood Prod¬
ucts Laboratory. Elstree, UK).
Results
Of the 29. 265 serum samples that were
screened between June and October 1983,
129 samples contained more than 1 IU/ml of
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Fig. 1. HBsAb level distribution.
129 positive serum samples showed the dis¬
tribution according to figure 1.
A total of 19 donors had HBsAb levels of
10 IU/ml or greater with a range of 10.0-
116.0 (mean 15.2) IU/ml. Of these 19 newly
identified donors that were approached. 10
agreed to be recruited for regular plasmapher¬
esis. One donor had to be withdrawn because
routine liver function tests showed evidence
of chronic liver disease. Twelve months after
the screening programme only 2 out of the
newly recruited 9 were still donating hyper¬
immune hepatitis B plasma. Of those lost, 5
moved elsewhere, and in 2 cases the HBsAb
level had fallen and remained consistently
below 10 IU/ml.
No donor developed abnormal alanine
aminotransferase (ALT) values during the
studv.
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August 1980 10.095 IO -c 0.28 0 0 0 0
October 1980
to
December 1980 1 1.849 47 0.39 3 0.025 0 1
February 1981
to
Mat 1981 16.23! 58 0.35 4 0.025 0 0
May 1981
to
September 1981 3.210 10 0.31 1 0.031 0 1
September 1981
to
August 1982 28.384 46 0.16 8 0.028 1 5
June 1983
to
October 1983 29.265 129 0.67 26 0.088 7 9
Quantity of Plasma Collected
A total of 30.5 litres of hyperimmune hep¬
atitis B plasma was collected from the 9 newly
recruited donors over the 12 months follow¬
ing recruitment (0.8-6.5 litres per donor).
The mean volume of plasma per donor col¬
lected was 3.4 litres. A total of 424.380 IU of
HBsAb was collected with a mean plasma
concentration of 13.9 IU/ml of HBsAb.
Discussion
Hepatitis B immunoglobulin is used in the
prevention of hepatitis B infection following
accidental exposure to the virus and in
infants born to mothers who are chronic car¬
riers of the virus. The requirement for this
immunoglobulin is likely to continue or
increase in view of the increasing incidence of
hepatitis B infection [2] despite the availabil¬
ity of a safe hepatitis B vaccine. As a result, we
developed a low-cost radioimmunoassay for
the screening of donors [1] and we have ana¬
lyzed the long-term value of random screen¬
ing of donors for high-titre HBsAb plasma. Of
all the donors identified following the screen¬
ing of 29.265 blood donations, only 2 were
still donating regularly 12 months after they
had been recruited.
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Our experience in recent years is that eve¬
ry year on average a third of donors from the
HBsAb plasmapheresis panel become unsuit¬
able because of falling antibody level, or
because they har e moved elsewhere. There¬
fore. to maintaining a constant panel of say
15 donors it would be necessary to repeat the
screening programme at less than 3-yearly
intervals. This present system therefore ap¬
pears to be a very inefficient way of identify¬
ing and recruiting hepatitis B plasma do¬
nors.
In previous years, five other screening
campaigns had been carried out in Edin¬
burgh: the vers poor recruitment confirms
our past experience (table I).
We believe that it is of great importance
that other methods for procuring HBsAb
plasma for the manufacture of HBIg be exam¬
ined. In particular, now that a safe hepatitis B
vaccine is available, the immunisation of
suitable donors should be considered. How¬
ever. while it is generally very difficult for
individuals to achieve high enough antibody-
levels suitable for plasmapheresis (greater
than 10 IU/'ml) following a primary course of
immunisation with hepatitis B vaccine [3. 4],
preliminary studies in the North London
Blood Transfusion Service have demon¬
strated that high enough antibody levels can
be reached in individuals who have pre-exist¬
ing naturally acquired hepatitis B antibody
by boosting. A consistent 10-fold rise and
in certain cases a 60-fold rise in antibody-
levels following boosting with the Merck.
Sharp & Dohme hepatitis B Vaccine has been
demonstrated [5], Therefore, we suggest that
boosting individuals with pre-existing natu¬
rally acquired hepatitis B antibody be exam¬
ined as a means of recruiting suitable hepati¬
tis B immune plasma donors.
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Serum ALT Levels in Patients with Primary
Hypogammaglobulinaemia Receiving Replacement Therapy with
Intravenous Immunoglobulin or Fresh Frozen Plasma
C.L.S. Leena, P.L. Yapa, G. NeilP, D.B.L. McClellanda, A. Westwoodb
"Edinburgh and South East Scotland Blood Transfusion Service, Regional Centre, Royal Infirmary;
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Abstract. The intravenous immunoglobulin (IV. IgG) preparation used in this study is manufactured by the
Scottish National Blood Transfusion Service (SNBTS) by the pH 4/mild pepsin method. Recent reports suggest that
non-A, non-B hepatitis may be transmitted by certain intravenous immunoglobulin preparations. Serum ALT levels
were therefore measured prospectively in 16 patients with primary hypogammaglobulinaemia who received an
intravenous immunoglobulin replacement therapy (SNBTS IV IgG) over a period ranging from 6 to 25 months.
Retrospective analysis of serum ALT levels was also carried out in 8 patients with primary hypogammaglobulinaemia
who received fresh frozen plasma (FFP) for periods ranging from 8 months to 13 years. There was no evidence of
non-A, non-B hepatitis transmission by either SNBTS IV IgG or by FFP in all the patients studied.
Introduction
Immunoglobulin preparations generally have a good record for
saftey with respect to the transmission ofviral hepatitis [ 1 ]. However,
there have been reports ofnon-A, non-B (NANB) hepatitis in patients
with primary hypogammaglobulinaemia receiving intravenous im¬
munoglobulin (IV IgG) preparations that have been treated so as to
make them safe for intravenous use [2-4], raising the possibility that
NANB hepatitis viruses may not always be inactivated or removed
during the manufacture of these immunoglobulin preparations. We
report the results of a retrospective evaluation of serum ALT levels in
patients with primary hypogammaglobulinaemia receiving an immu¬
noglobulin replacement in the form of fresh frozen plasma (FFP), and
a prospective evaluation of serum ALT levels in such patients receiv¬
ing intravenous immunoglobulin treated by mild pepsin proteolysis
at pH 4. Part of this data has been presented in a preliminary
communication [5],
Patients, Materials and Methods
Patients
All 17 patients had proven primary hypogammaglobulinaemia.
Four (cases 8,9, 10 and 15) were X-linked and the remainder had late
onset primary hypogammaglobulinaemia. Sixteen of the preceding
patients who were receiving IV IgG were enrolled in the prospective
trial. The patients' ages ranged from 11 to 49 years.
Fresh Frozen Plasma
Plasma was collected for each patient by plasmapheresis of 2 or 4
dedicated donors to minimise the risks of transmitting infection
including NANB hepatitis. A dose of 15 ml/kg body weight at 2-4
weekly intervals was used. Plasma donors met the standard medical
and serological requirements for blood donors including normal
serum ALT levels. The duration of FFP replacement therapy in the 8
patients in the retrospective study ranged from 8 months (case 8) to
13 years (case 14).
IV IgG Preparation
The IV IgG preparation used in this study is prepared at the
Protein Fractionation Centre of the Scottish National Blood Trans¬
fusion Service (SNBTS) from a cold ethanol (Cohn) fraction II of
plasma collected from volunteer Scottish blood donors. The cold
ethanol fraction II is subsequently ultrafdtrated, treated by mild
pepsin proteolysis at pH 4 and freezedried [6, 7], The product after
reconstitution with water is a solution of 5% (5g/100 ml) human
normal immunoglobulin. Patients received 200-400 mg/kg of
SNBTS IV IgG every 2-5 weeks. The duration of SNBTS IV IgG
treatment ranged from 6 to 25 months.
Other Immunoglobulin Preparations
Seven of the patients in the study received other intravenous
immunoglobulin preparations (Gamimune, Cutter Laboratories;
Sandoglobulin, Sandoz) in an earlier evaluation of immunoglobulin
therapy [8], and 13 of the patients received standard intramuscular
























1983 13p 8f 1988
























1982 13p 12f 1985
f^-'s//s/////Z
1985




^ IgG ISandozIV IgG I CutterIV IgG
immunoglobulin manufactured by Cohn fractionation at the SNBTS
Protein Fractionation Centre, prior to the study period (fig. 1).
ALT Assays
The majority of the ALT levels was measured either by an enzy¬
matic (kinetic) method on a Multistat III centrifugal analyser using a
Boehringer ALT (OPT) kit or by sequential multiple analysis with
Computer System (SMAC 2), Technicon Instrument Association. In
a small number of instances, ALT levels were measured at the
patients' local hospital clinical chemistry laboratories using standard
automated methods. The normal range of serum ALT levels is 11-50
U/l.
Hepatitis B Serology
Venous blood samples were tested for hepatitis B surface antigen
by radioimmunoassay prior to the first SNBTS IV IgG infusion.
Patients were retested not less than 6 months after the first infusion
and in certain cases again at 6-12 monthly intervals. Blood samples
were also tested for antibodies to hepatitis B surface, core and *e'
antigens.
Study Design
Serum ALT values in the patients who had received FFP therapy
were obtained over periods of 6-29 consecutive months in 8 patients.
The case records were examined first, and where no ALT results were
recorded, pre-infusion serum samples stored at -150 °C in the vapour
phase of liquid nitrogen were retrieved for ALT assays.
All 16 patients receiving SNBTS IV IgG had serum samples taken
before and after each infusion of immunoglobulin for estimation of
immunglobulin and ALT levels. The following serum samples were
available for analysis:
(a) from December 1983, ALT levels in all serum samples were
measured prospectively; (b) before December 1983, ALT levels were
obtained retrospectively from the patients' case records; (c) where
there were no records of the serum ALT having been determined
previously, pre-infusion serum samples (stored frozen at -15CTC)
were retrieved and ALT levels measured.
Prospective data on ALT levels were therefore available in 11
patients for 13-15 consecutive months and in a further 5 patients for
5-11 consecutive months.
Blood samples from 7 patients (cases 1, 3, 6, 8, 9, 10, 11 and 14)
were collected in Edinburgh, and the sera were separated within 24 h
after collection. Blood samples from 9 patients (cases 2,4,5,7, 12, 13,
15, 16 and 17) were collected outside Edinburgh, as these patients
received their immunoglobulin infusion at their local hospital and
the blood samples were sent by post; the sera were separated imme¬
diately on arrival (usually within 24-72 h of collection) and kept at
4*C until assay.
A patient was diagnosed as having hepatitis if the ALT was above
the normal range (50 U/l) in two or more sequential blood samples
taken within a 3- to 17-day interval, and if one of these levels was at
least twice the upper limit of normal (100 U/l). An episode of
hepatitis was considered to be probably ofviral aetiology if there was
no other identifiable cause for the raised ALT [9].
Validity ofStored Samples
Serum was collected from patients with liver disease of non-
infective aetiologies and sent for ALT assay. Aliquots of the sera were
stored at -20 °C and at -150 °C for at least 6 months before they were
assayed for ALT activity.
Fig. 1. Types of Immunoglobulin in replacement therapy received
by cases 1-17. The numbers above the hatched lines indicate the
number of samples in which ALT levels were determined, c = ALT
values obtained from patients' case notes; f = ALT values obtained
on samples stored at -150°C; p = ALT values obtained in prospective
study. Sandoglobulin and Gamimune are indicated as Sandoz IV IgG
and Cutter IV IgG, respectively.
Results
Validity of the Stored Sera
ALT values of samples stored for at least 6 months at
-20°C and at -150°C were compared with the ALT values
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Fig. 2. Serum ALT values of samples in which ALT levels were
determined immediately after collection or after storage at -150"C
and -20 °C for 6 months. The horizontal broken line indicates the
upper limit of the normal range for serum ALT values; the diagonal
broken line indicates changes in ALT levels in a sample with an initial
ALT value of 187 U/l.
measured at the time of sample collection. It was found
that serum ALT activity decreased after storage at -15 0 °C
and at -20°C for up to 6 months. The decline in ALT
activity was minimal for samples stored at -150°C in
contrast to samples stored at -20 °C, when significant
decreases in serum ALT activity were noted (fig. 2).
ALT Levels during FTP Therapy
Among the 8 patients who had received FFP therapy in
the study, 100 serum ALT levels were available from the
case notes: 25 samples (from 3 patients) had levels above
50 U/l, 2 from case 1 (67 and 55 U/l), 7 from case 9 (range
53-113 U/l) and 16 from case 10 (range 52-203 U/l).
From an additional 65 frozen serum samples sent for ALT
measurement, only 3 were abnormal, all from case 1(114,
60 and 69 U/l). Therefore, of 165 serum ALT values
available for analysis, 28 from 3 patients) were abnormal
(fig. 3a, e, f)-
ALT Levels during SNBTSIV IgG Therapy
A total of 249 serum samples were obtained and
assayed for ALT levels immediately prior to each infu¬
sion. All but 7 were in the normal range (10-50 U/l). The 7
samples with abnormal values were from 4 patients: case
3 (91 and 53 U/l), case 9 (60 LI/1), case 15 (70 U/l) and case
17 (96, 84 and 234 U/l) (fig. 3b, e).
An additional 60 scrum samples were retrieved from
-150°C storage and examined for ALT activity. Only 4
were abnormal, 2 from case 1 (54 and 69 U/l) and 2 fium
case 5 (75 and 58 U/l).
A further 5 normal ALT values were noted on review
of the case notes.
Therefore, of a total of 314 serum ALT values, 11
(from 6 patients) were above the upper limit ofnormal (50
U/l).
Hepatitis B surface antigen was negative in all the
specimens tested.
Relationship of raised ALT Values to the Clinical
Condition of the Patients
FFP Therapy. Three out of eight patients studied
developed raised serum ALT values during FFP therapy
that could be consistent with NANB hepatitis. However,
in each case there were more probable explanations for
the abnormal ALT. One patient (case 1) was diagnosed as
suffering from sarcoidosis which was active at the time
the ALT was raised [19], Another patient (case 10) was
clinically unwell with recurrent episodes of septicaemia
and had a cholestatic pattern of liver function tests (al¬
kaline phosphatase of 3,351 U/l). The last patient (case 9)
had multiple problems associated with hypogammaglo¬
bulinemia including severe malabsorption with weight
loss and recurrent chest infections.
SNBTS IV IgG. Out of a total of 314 blood samples, 11
abnormally raised ALT values were observed occurring in
6 of the 16 patients during SNBTS IV IgG therapy. No
markers of hepatitis B infection were detected in the
patients at any time.
Figures 3c, d and g illustrate 3 patients (cases 4, 8 and
16) with normal serum ALT levels during therapy with
FFP and SNBTS IV IgG.
Further details of the 6 patients (cases 1,3,5,9, 15 and
17) who developed raised ALT levels are shown below.
Case I had raised serum ALT levels during FFP ther¬
apy (see above), secondary to active sarcoidosis, and it is
likely that the two raised serum ALT values (54 and 69
U/l) were the result of his sarcoidosis.
Case 3 had received SNBTS IV IgG since April 1983.
In April 1984, before her 18th infusion of SNBTS IV IgG,
she was found to have a high serum ALT of 91 U/l while
remaining clinically very well. Three weeks later her
serum ALT was 44 U/l. No cause for the raised ALT was
found, and in particular there was no history of drug or
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alcohol ingestion; hepatitis B surface antigen as well as
other virological markers of hepatitis were absent.
Case 5 received Sandoglobulin and Gamimmune for 3
months each prior to the study period. His hypogamma-
globulinaemia is associated with malabsorption second¬
ary to villous atrophy, frequent respiratory and gastroin¬
testinal infections requiring treatment with numerous
antibiotics including erythromycin for intractable Cam¬
pylobacter enteritis. Two abnormal ALT values (75 and 58
U/l) were observed when the frozen samples were ana¬
lysed. Retrospective analysis of the case records suggest
that he was not unwell at the time of the abnormal ALT
levels and that there was no apparent cause for the abnor¬
mal ALT.
Case 9 had documented abnormal serum ALT values
during FFP therapy. At the time of the single abnormal
ALT level (60 U/l) which followed his 15th SNBTSIV IgG
infusion, he was asymptomatic.
Case 15 was diagnosed in 1966. After years of treat¬
ment with intramuscular gammaglobulin he received
FFP followed by Sandoglobulin and Gamimune (for 3
months each) before treatment was commenced with
SNBTS IV IgG in April 1983. A single raised ALT value
(70 U/l) was noted in February 1984. Four days elapsed
between the collection of the sample and the separation of
the serum, and all subsequent serial ALT values have
been normal. An additional factor in this case is that the
attending physician reports that this patient has a large
regular alcohol consumption.
Case 17 had been on total parenteral nutrition since
1980 because of intractable diarrhoea with severe malab¬
sorption. His medical history included chronic cholecys¬
titis and cholelithasis treated by cholecystectomy in 1980
and since 1981 had documented abnormal liver function
tests including raised ALT ranging from 50 to 234 U/l. A
liver biopsy in 1980 showed mild chronic portal triaditis
with occasional granulomatous foci. A repeat liver biopsy
in 1984 had similar features, and in particular there were
no features to suggest NANB hepatitis. His abnormal
liver function tests were considered by his gastroentero-
logist to be a consequence of his underlying disorder and
of an excess intralipid content in his total parenteral
nutrition regime [10, 11],
Discussion
Many serum enzymes may remain stable for some time
when stored at -20°C. Serum ALT has also been shown to
be stable for 3-4 days at room temperature and up to 7
days if kept refrigerated at 4°C [12, 13]. Our data suggest
that while there seems to be a fall in serum ALT activity
after storage at -150°C for 6 months, the fall is minimal in
contrast to a storage at -20 °C (fig. 2). It also seems
unlikely that any serum sample with significantly raised
ALT values (100 U/l or greater when considering hepati¬
tis) would have been missed because they had been stored
at -150°C for 6 months.
Three ofour patients receiving FFP have been noted to
have raised serum ALT levels. Although the magnitude of
their serum ALT rise is consistent with hepatitis, there has
been an obvious cause for their abnormally raised ALT; 1
had active sarcoidosis, and the remaining 2 were very ill
with infection including recurrent septicaemia in 1
patient. In addition, there were no features to suggest
NANB hepatitis.
None of our patients during SNBTS IV IgG therapy
would fulfil the criteria for hepatitis, except for the
patient with known liver disease. Only a small proportion
of patients receiving regular IV IgG infusions had any
ALT abnormalities. The pattern and magnitude of distur¬
bance of liver function tests was not that of NANB hep¬
atitis. In 5 of the 6 patients with raised ALT levels during
IV IgG treatment there appears to be an explanation other
than NANB hepatitis. Only 1 patient had an unexplained
elevated ALT level (peak ALT of 91 U/l) which became
normal within 3 weeks, but by definition [9] she did not
have hepatitis and was clinically well throughout. Fur¬
thermore, neither the clinical picture nor the level of
serum ALT rise in these patients resemble that of NANB
hepatitis or the illness described by Lever and Ochs
[2, 3],
Conventional immunoglobulin preparations virtually
never transmit viral infections [14-16]. However, several
recent reports [2, 3] indicate that some immunoglobulin
products designed for intravenous administration may
not be as safe as the conventional intramuscular product.
It is probable that production methods influence the
safety of intravenous preparations in terms of transmis¬
sion of viral infections. In particular, the presence or
absence of further processing to reduce the level of spon¬
taneous anti-complementary activity and of vasoactive
enzymes following the removal of ethanol may be impor¬
tant. Not all of these procedures are thought to be viru¬
cidal. Neither of the two intravenous preparations known
to have transmitted NANB hepatitis [2, 3] were subjected
to a recognised virucidal finishing treatment, e. g. acid
treatment (pH 4.0) or Beta-propiolactone and ultraviolet
irradiation [17], Our data show that SNBTS IV IgG which
is processed for intravenous use by the pH 4/pepsin
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Fig. 3a-g. ALT values in 7 patients
receiving different types of immuno¬
globulin therapy. ALT values were eith¬
er determined in samples assayed with¬
in 72 h of collection (X) or after storage
at -150'C (•). The horizontal broken
line indicates the upper limit of the nor¬
mal range for ALT levels; the hatched
horizontal areas indicate the type of
immunoglobulin therapy received by









































method [18] and FFP obtained from 2-4 properly
screened dedicated donors do not transmit NANB hepa¬
titis.
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Summary
Three of 20 patients with primary hypogammaglobulinemia developed Salmonella gastro¬
enteritis. Two of them who also had low concentrations of serum IgG and pernicious anaemia
were clinically septicaemic. Patients with primary hypogammaglobulinemia have previously
been thought not to be more susceptible to Salmonella infection but a combination of low gastric
acidity and impaired humoral immunity may predispose them to such infection.
Introduction
Late-onset primary hypogammaglobulinaemia (PH), also known as common
variable immunodeficiency, is a rare condition characterised by a deficiency of
the three main classes of immunoglobulins and an absence of IgA in intestinal
secretions. Affected patients are prone to recurrent bacterial infections. They
also have a high incidence of diarrhoeal illness which is not always attributable
to an increased susceptibility to infection. More specifically, these patients are
not believed to be more susceptible to salmonellosis1 although they suffer from
Giardia and other parasitic infestations as well as Campylobacter infection.
In 20 patients with late onset PH, we observed an unusually high incidence
(three of 20) of salmonella infection.
CASE REPORTS
Patient 1
At the age of 28 years, while pregnant in 1975, this patient was found to have
hypogammaglobulinaemia because of absent isohaemagglutinins. Her
immunological profile is shown in Table I. Treatment began with a small
intramuscular dose of immunoglobulin which was increased in 1979 to 4 5 g
monthly in divided doses. In 1978, she developed anaemia and malabsorption
associated with giardiasis. She remained anaemic despite appropriate treatment
and pernicious anaemia was diagnosed by means of the Schilling test. Antibodies
Address for correspondence: Dr C. L. S. Leen.
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Selection of Plasma Donors Suitable for Tetanus Boosting
C. L. S. Leen, G. R. Barclay, D. B. L. McClelland
Edinburgh and Southeast Scotland Regional Transfusion Center, Royal Infirmary, Edinburgh, UK
Abstract. As a result of a comparative trial examining the immunogenicity and clinical reactivity of two tetanus
vaccines, 33 donors with high antibody levels were plasmapheresed over 6 months for the collection of tetanus
hyperimmune plasma. Serial antibody assay results and the frequency of adverse reactions were analysed to define
the donors most suitable for an immune plasma programme. A high proportion of boosted donors were withdrawn
from plasmapheresis because of poor persistence of antibody levels. Donors most suitable for boosting appear to be
males under 25 years old with a tetanus antibody level of around 8 IU/ml prior to boosting.
Introduction
Tetanus immune globulin is manufactured from plas¬
ma collected from human donors who have high levels of
tetanus antibody. These donors are usually selected short¬
ly after receiving a course of tetanus immunization or a
tetanus boost following trauma. However, this method of
recruiting donors is not entirely satisfactory because not
all donors achieve suitably high antibody levels (greater
than 10 IU/ml) after immunization. Some plasma-collect¬
ing organisations therefore boost selected donors to ren¬
der them suitable for donating hyperimmune tetanus
plasma [1, 2],
Following a study comparing two differently purified
tetanus absorbed vaccines in volunteer blood donors [3],
33 donors with high tetanus antibody were plasmapher¬
esed for up to 6 months. The results of the vaccine trial
and subsequent plasmapheresis were examined to define
the characteristics of donors most suitable for a pro¬
gramme of hyperimmunization with tetanus toxoid. In
particular, we examined the factors that influenced the
incidence of adverse reactions to tetanus boosting, as well
as those that determined the persistence of antibody lev¬
els suitable for plasmapheresis.
Volunteers, Materials and Methods
205 volunteer blood donors (mean age 32.9 years, range 18.7—
64.8 years) participated in the trial [3], The participants were ran¬
domised with respect to age, sex and pre-immunization tetanus
antibody levels. Following boosting with 0.5 ml of one of the two
tetanus vaccines (conventional tetanus vaccine or immune-purified
tetanus vaccine), the vaccinees were asked to complete a daily cal¬
endar record for 7 days to report the occurrence and severity of local
reactions at the site of injection (pain, redness, tenderness and lump),
and systemic reactions (headache, feverishness and malaise). Vacci¬
nees also recorded their oral temperature daily for 7 days after
immunization.
After the completion of the trial, donors were invited to be
plasmapheresed if they fulfilled the following criteria: (1) serum
antibody level of 10 lU/ml or greater, (2) age less than 50 years, (3)
body weight greater than 50kg, (4) good venous access, (5) no major
illnesses, (6) absence ofhepatitis B surface antigen, (7) availability. 36
donors were invited to donate plasma. The frequency of plasmapher¬
esis varied from once every 4 weeks to once every 12 weeks depending
on availability. Donors whose tetanus antibody levels dropped below
10 IU/ml on two successive occasions were withdrawn from the
plasmapheresis panel.
The serum tetanus antibody levels were measured using an ELISA
method shown to correlate well with mouse protection assay [G. R.
Barclay, unpublished].
All volunteers gave informed consent to participation in the
study, and the protocol was approved by the Ethical Committee of the
Scottish National Blood Transfusion Service.
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Total 57 (100) 76 (100) 50 (100) 21 (100) 204
Figures in parentheses indicate percentage.
Table II. Sex and antibody response











Total 105 (100) 99 (100) 204
Figures in parentheses indicate percentage.
Table III. Antibody increase
Pre-immunisation antibody level, IU/ml
0 0-2 2-4 4-8 >8




immunisation 89 (75) 31 (94) 22 (96)
Increase in anti¬
body, IU/ml
Mean 8.76 8.44 9.50
±SD 10.60 7.21 6.46
Figures in parentheses indicate percentage.
Statistics
Statistical analyses were carried out using Spearman rank corre¬
lation for relationships between two continuous variables and anal¬
ysis of frequency was carried out by a Yates-corrected chi-square test
using a 2x2 table and 1 degree of freedom.
Results
The two vaccines were found to be similar with respect
to the frequency of reactions encountered in the vaccines
and to their immunogenicity [3]. For the purposes of data
presentation and analysis in this study, we have not made
any distinction between the two vaccines.
Effect ofAge, Sex and Pre-immunization Tetanus
Antibody Level on Antibody Level at 2 Weeks after
immunisation
There was a significant correlation between age and
antibody level assayed 2 weeks afterimmunization (r =
-0.30, p<0.001) and between age and increase in antibo¬
dy level defined as the difference between post- and
pre-immunization antibody levels (r = -0.24, p<0.001;
table I).
There was no significant sex difference in the magni¬
tude of antibody increase (table II).
The magnitude of antibody increase was independent
of the pre-immunization antibody level (table III).
Effect ofPreimmunization Antibody Level, Sex and
Age on Incidence ofReactions to Vaccine
The sum of the number of days on which the vaccinees
experienced any moderate or severe symptoms was used
for the analysis of adverse reactions. There was no signif¬
icant correlation between pre-immunization antibody
level and overall reactions; however, the data suggest that
there may be an unusually high incidence of reactions
amongst vaccinees with antibody levels which were
detectable but less than 2.0 IU/ml (table IV). Males had
significantly fewer reactions than females (p<0.01;
table V), but there was no evidence that age had any effect
on the incidence of adverse reactions.
When the individual reactions were analysed, there
was a significantly higher incidence of moderate or severe
tenderness and redness among females (p<0.01). There
was also a correlation between pre-immunization anti¬
body level and pain (r = 0.21; p<0.01) and between pre-
immunization and frequency of tenderness (r = 0.20;
p<0.01). The incidence of individual reactions was also
analysed in vaccinees grouped according to their pre-
immunization tetanus antibody levels. While there was a
significantly higher incidence of moderate and severe
pain at the injection site in subjects with a pre-immuni¬
zation antibody level above 8 IU/ml (x2 = 4.15, p<0.05),
the increased incidence of moderate and severe tender¬
ness in that group was not statistically significant
(X2 = 3.80, p>0.05) when compared with the group with
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Table IV. Correlation between pre-immunisation antibody level
and reaction to vaccination
Reaction Pre-immunisation antibody level, IU/ml
0 0-2 2-4 4-8 >8
(n = 118) (n-33) (n-23) (n = 21) (n-9)
Local reactions
Redness 17(14) 9 (27) 5(22) 3(14) 2(22) 1
Pain 3(2) 1 (3) 2(9) 3(14) 2 (22)* J
Tenderness 9(8) 11 (33)** 1 (4) 5(24) 3 (33)
C.
o




Systemic reactions i 5sE ,
Temperature 4(3) 4(12) 1 (4) 1 (5) 0 I E£ 3
Headache 13(11) 9 (27)* 3(13) 2(10) 2 (22) a°
Feverishness 2(2) 4(12) 1 (4) 2(10) 1 (11) £ A'3 >.
No moderate or 11




tion 23 (20) 19 (59) 4 (17) 8 (38) 4 (44)






EH 0-2 (n=15) □ 4-8 (n= 8)




Fig. 1. Distribution of plasma donors with post-immunization
tetanus antibody levels greater than 10 IU/ml who were still donating
in the 6 months following immunization. Donors are allocated to
groups according to their pre-immunization tetanus antibody lev¬
els.
Table V. Frequency of reactions among sexes
Male Female
(n= 105) (n = 99)
Local reactions
Redness 11 (10) 25 (25)*
Pain 3(3) 8(8)
Tenderness 8(8) 21 (21)*
Lump 46 (44) 57 (58)
Systemic reactions
Temperature 2(2) 8(8)
Headache 15(14) 14 (14)
Fever 3(3) 7(7)
Total reactions
(pain, tenderness, fever, headache) 22 (21) 36 (36)*
Figures in parentheses indicate percentage.
*p<0.01.
Fig. 2. The sex distribution of donors with post-immunization
tetanus antibody levels greater than 10 IU/ml during the first 6
months following immunization.
Interestingly, the group with detectable pre-immuni-
zation antibody levels of less than 2 IU/ml showed the
highest frequency of reactions which in many cases were
significant as compared to the group without detectable
pre-immunization antibody.
Volume ofHyperimmune Plasma Collected
36 donors (23 men and 13 women) with high post-
immunization antibody levels were recruited for plasma¬
pheresis. Three donors were withdrawn from plasma¬
pheresis: 2 men were unavailable to attend regularly
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because of business commitments and 1 woman devel¬
oped a medical condition unrelated to immunization or
plasmapheresis. By 6 months after immunization, plas¬
mapheresis had been stopped in 21 of the 33 remaining
donors (62%) because their antibody levels had fallen
below 10 IU/ml. The volume of plasma collected in the 6
months following immunization was 54.5 litres. This
contained a total of 1,201,400IU of tetanus antibody with
a mean antibody concentration 22.0 IU/ml.
Characteristics ofDonors with Persistently High
Antibody Levels
There was no clear relationship between the persis¬
tence of antibody level above 10 IU/ml and the interval
since the last tetanus boost, but 75% of donors with
pre-immunization antibody levels above 8 IU/ml ap¬
peared to maintain an antibody level above 10 IU/ml
after boosting for at least 6 months (fig. 1).
Of the 21 men and 12 women who were regularly
plasmapheresed, 9 men (43%), and 3 women (25%) still
possessed antibody levels above 10 IU/ml after 6 months
of plasmapheresis (fig. 2).
Discussion
The frequency of unselected blood donors who have a
tetanus antibody level above 10 IU/ml is very low, rang¬
ing from 1.5% [4] to 2.8% [5] so that random screening is
an inefficient method of finding immune plasma donors.
A programme of hyperimmunization of plasma donors
with tetanus toxoid can overcome the difficulty in recruit¬
ing tetanus antibody plasma donors [1, 2], However,
before such a programme is set up, it is important to
identify donors who are unlikely to suffer from severe
adverse reactions and who can be expected to produce
good antibody levels for a long time after boosting.
Our results do not show any statistical difference
between the sexes in terms of antibody response to teta¬
nus toxoid. However, the increase in antibody level fol¬
lowing boosting with tetanus toxoid was significantly less
in those over the age of 40 years. The reduced antibody
response with increasing age has previously been ob¬
served [6, 7],
It is generally difficult to compare reaction rates
between different tetanus vaccine studies because of dif¬
ferences in the vaccinees and in the methods of assessing
adverse reactions [8]. Published reports show that women
are more susceptible to reactions than men [9, 10], and
that there is a higher frequency of reactions in persons
with high levels of pre-immunization tetanus antibody
[11, 12], In this study, we have confirmed that women are
more likely to experience adverse reactions than men. We
have also found a trend towards a higher frequency of
adverse reactions with increasing pre-immunization anti¬
body levels, but this was only significant for moderate and
severe pain in the group of vaccinees with a pre-immuni¬
zation antibody level above 8 IU/ml as compared with the
group with undetectable pre-immunization antibody lev¬
el. Our results also suggest unexpectedly that the highest
and most significant incidence of reactions in individuals
with pre-immunization anti-tetanus antibodies is in the
group with pre-immunization antibody levels between 0
and 2 IU/ml. This finding has not been previously report¬
ed. Since this increased frequency was observed equally in
recipients of either immunopurified or conventionally
purified vaccine [3], it may not be related to vaccine
preparation [8], We favour the interpretation that these
reactions may be an Arthus-type phenomenon [9], where
it is possible that in this antibody range, the ratio of
antibody to antigen in some subjects was such that
immune complexes were formed and caused the reac¬
tions.
Although among the donors with persistently high
tetanus antibody levels (above 10 IU/ml) 6 months after
boosting, there was a preponderance of men and of
donors with a pre-immunization antibody level above
8 IU/ml, it is difficult to draw any definite conclusion as
the numbers are small. Furthermore, it is not surprising
that following boosting, individuals with high pre-immu¬
nization antibody levels would maintain a high antibody
level longer than those with lower pre-immunization anti¬
body levels.
This study confirms that boosting of volunteer donors
for the production of plasma containing high levels of
tetanus antibody produces only minor reactions and that
individuals with high tetanus antibody levels can be
hyperimmunized without an excess of adverse reactions.
Boosting is therefore appropriate in situations where it is
difficult to recruit adequate plasma donors for tetanus
antibody. Our data show that the donors most suitable for
hyperimmunization with tetanus toxoid are likely to be
young males preferably under 25 years of age, with a
pre-immunization tetanus antibody level of around
8 IU/ml.
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Increase of Serum Immunoglobulin Level into the Normal Range in
Primary Hypogammaglobulinaemia by Dosage Individualisation of
Intravenous Immunoglobulin
C. L. S. Leen, P. L. Yap, D. B. L. McClelland
Edinburgh and South East Scotland Regional Transfusion Centre, Royal Infirmary, Edinburgh, Scotland
Abstract. The effect of varying the dose or the frequency or of both dose and frequency of immunoglobulin
administration was evaluated in 17 patients with primary hypogammaglobulinaemia treated with Scottish National
Blood Transfusion Service intravenous immunoglobulin (SNBTS IV IgG), an intravenous immunoglobulin prepara¬
tion manufactured by the pH 4/mild pepsin method. Individualised dosage of SNBTS IV IgG resulted in trough
serum IgG levels of greater than 4.0 g/1 in 13 of the 17 patients studied. 6 of the 17 patients had trough serum IgG
levels in the normal range (5.0 g/1). In 2 patients, more frequent infusions were required to achieve normal trough
serum IgG levels because of their clinical conditions. In 1 of these 2 patients, the frequency could be reduced to three
weekly when the gastrointestinal loss of IgG was reduced. There was a low incidence of adverse reactions (6.4%)
which occurred mainly during the initial infusions. Most patients benefited from an increased serum IgG level, but
the frequency of diarrhoea was unaffected. One patient with severe bronchiectasis continued to suffer from respira¬
tory infections despite normal serum IgG levels.
Introduction
In patients with primary hypogammaglobulinaemia,
immunoglobulin replacement therapy has largely been
limited until recently to the administration of either
intramuscular immunoglobulin or of fresh frozen plasma.
The dose of IgG administered to patients with hypogam¬
maglobulinaemia (25-50 mg/kg/week) has been based on
the clinical trial held by the MRC [1]. However, the
increments in serum IgG level achieved in patients
treated with this dose of IgG are highly variable and IgG
levels hardly ever rise into the normal range. The intra¬
venous administration of large quantities of immuno¬
globulin has now been shown to be both safe and well
tolerated in the patients with primary hypogammaglobu¬
linaemia [2-4]. As a result, clinicians have attempted to
achieve higher serum IgG concentration in their patients
with a view to reducing the incidence of infections. Most
trials have used larger doses of IgG per infusion but the
intervals between infusions have been kept fixed at either
3 or 4 weeks [5-7], The optimal dose schedule has there¬
fore not been established.
As part of a larger study evaluating the safety and
efficacy of a new intravenous immunoglobulin prepara¬
tion [Leen et ah, in preparation], we have tried to indi¬
vidualise the dose of infused IgG in order to increase into
the normal range the trough serum IgG concentration of
our patients with primary hypogammaglobulinaemia. We
report our results based on varying either the dose of IgG
infused or the frequency of infusions, or varying both the
dose and frequency of IgG infusions.
Materials and Methods
Patients
A total of 17 patients (age range 11-50; 11 male, 6 female) (from
February 1983 to May 1985) received Scottish National Blood Trans¬
fusion Service intravenous immunoglobulin (SNBTS IV IgG) for at
least 6 months. The duration of treatment was over 12 months in 13
of the 17 patients, over 18 months in 10 and over 2 years in 8. Twelve
suffered from late onset primary hypogammaglobulinaemia (com¬
mon variable immunodeficiency) and 5 from X-linked primary
hypogammaglobulinaemia. All patients had a history of recurrent
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Table I. Clinical details of individual patients
Patient Age at com¬ Diagnosis Other diagnoses1 Clinical IgG at IgG before IgG after Treatment during 3
mencement outcome2 diagnosis study study months before study
of study (improve¬ g/1 g/1 g/1
years ment)
chest GI
1 29 CVI IDDM yes n.a. 2.9 5.47 5.28 FFP 1 litre/3 weeks
sarcoidosis
2 21 CVI NLH yes no 1.49 2.5 5.28 IM IgG 1.5g/week
3 25 CVI giardiasis yes n.a. 1.0 4.34 8.4 IV IgG Gamimune
meningitis 0.2 g/kg/3 weeks
4 22 CVI - 2.3 1.53 4.7 nil
5 29 CVI bronchiectasis no n.a. 3.0 8.08 4.40 FFP 800-1,500 ml/
3 weeks
6 41 CVI villous atrophy yes no 1.1 2.73 7.2 IV Gamimune
ileal strictures 0.2 g/kg/3 weeks
7 29 CVI - yes n.a. 0.7 6.24 3.8 IV Gamimune
0.2 g/kg/3 weeks
8 41 CVI sarcoidosis yes n.a. 1.7 0.97 4.05 IM IgG 750mg/month
9 19 X-linked NLH yes no undetectable 1.46 3.05 IV Sandoglobulin
bronchiectasis 0.3 g/kg/2 weeks
10 16 X-linked villous atrophy yes no 1.5 3.22 2.8 FFP 400 ml every
hypoparathyroidism 3 weeks
11 11 X-linked renal artery yes n.a. undetectable 2.24 4.7 IV Sandoglobulin
aneurysms 0.2g/kg/2weeks
12 21 CVI - yes n.a. 2.3 3.36 4.8 IV Gamimune
0.2 g/kg/3 weeks
13 37 CVI Bell's palsy yes no - 1.57 4.78 IM IgG 1.5g every 10
giardiasis days
varicella zoster
14 50 CVI - yes n.a. 1.8 1.8 4.4 nil
15 23 X-linked - yes n.a. - 3.92 3.53 IV Gamimune
0.2 g/kd/3 weeks








CVI = Common variable immunodeficiency; X-linked = X-linked primary hypogammaglobulinaemia; NLH = nodular lymphoid hyper¬
plasia: FFP = fresh frozen plasma; IM IgG = intramuscular immunoglobulin; IV Gamimune = intravenous immunoglobulin preparation
(Cutter Labs); IV Sandoglobulin = intravenous immunoglobulin preparation (Sandoz); IDDM = insulin-dependent diabetes mellitus.
1 All patients had a history of recurrent upper respiratory tract infections before the commencement of immunoglobulin replacement
therapy.
2 Clinical outcome of IV IgG therapy, defined as improvement in either respiratory or gastrointestinal symptoms compared with
symptoms while on IM IgG therapy or on no IgG replacement therapy (n.a. = evaluation not applicable as patient did not have gastro¬
intestinal symptoms).
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bacterial infections with low serum IgG levels measured on at least
two occasions at the time of diagnosis. All but 2 were already estab¬
lished on immunoglobulin replacement therapy before entry to the
study. Further clinical details of individual patients are shown in
table I.
Local hospital ethics committee consent, the consent of the
patient's physician, and informed written consent from the patient
were obtained prior to the study.
SNBTSIV IgG
The intravenous immunoglobulin used in this study (SNBTS IV
IgG) is prepared at the Protein Fractionation Centre of the Scottish
National Blood Transfusion Service (SNBTS) from a cold ethanol
(Cohn) fraction II which is subsequently ultrafiltered, treated by mild
pepsin proteolysis at pH 4 and freeze dried [8, 9]. The product after
reconstitution with water is a solution of 5% (5 g/100 ml) human
normal immunoglobulin.
Method ofInfusion
Infusion Dose and Rate. A total SNBTS IV IgG dose of 200 mg/kg
body weight was administered on most occasions. In 2 patients, cases
9 and 10, where the trough serum IgG level, i.e. immediately prior to
IgG infusion, was not maintained above 3 g/1 the infusion dose was
steadily increased to 540 and 400 mg/kg, respectively.
In most patients the infusion was administered at a rate of 120 mg/
kg/h. In patients who had never received any immunoglobulin replace¬
ment initially, this rate was reduced in the first infusions. The infusion
rate was increased to 240 and 264 mg/kg/h for cases 10 and 9 without
any adverse reactions.
Frequency of Infusion
Infusions were initially administered at 3-weekly intervals except
in 3 patients (cases 9, 10, and 11) who received their infusions at
2-weekly intervals. Infusion frequency was modified according to the
patient's clinical state while aiming to maintain a serum trough IgG
level as near to the lower limit of normal as possible.
The infusion frequency was reduced from 3-weekly to 4-weekly
(or even less frequently) if the trough serum IgG was above 4.0 g/1
(normal range 5.0-13.0 g/1) and if the patient remained free from
infection. If, however, the patient was clinically unwell and the trough
serum IgG was below 3.0 g/1 the frequency of infusion was increased
to 2-weekly intervals. If the trough serum IgG was still below 3.0 g/1,
the infusion dose was doubled or given at weekly intervals. Finally, if
there was still no response a doubled infusion dose was administered
at weekly intervals. The frequency of infusion therefore ranged from
1 week (cases 6, and 9) to 12 weeks (case 3).
A total of 517 infusions from 24 batches of SNBTS IV IgG were
administered to the 17 patients over the study period.
Methods ofAssessment
The oral temperature, pulse and blood pressure were monitored
during the initial infusion at 0, 15, 30,45, and 60 min and half-hourly
thereafter until the end of the infusion. At later infusions when it was
clear that patients tolerated their infusions, the recordings were less
frequent.
Venous blood samples were collected from the infusion site at the
commencement of the infusion and at the end of the infusion either
from the opposite arm or from the infusion site after it had been
flushed with 10 ml ofblood. Serum IgG levels were assayed in the pre-
and post-infusion samples.
IgG was measured by laser nephelometry [10]; the normal range
for serum IgG concentrations (5.0-13.0 g/1) was determined by the
measurement of IgG levels in 350 normal blood donors.
An attempt was made to evaluate the half-life of the infused IgG
in SNBTS IV IgG in selected patients by collecting sequential samples
from the patients after their first infusion. Assuming that the metab¬
olism follows first-order kinetics, the half-life is proportional to the
slope of the beta-phase and is determined by the formula:
Half-life = ln 2/k = 0.693/k,
where k is the slope of the beta-phase determined by linear regression
analysis [11, 12],
Results
Serum IgG Concentrations following
SNBTS IV IgG Therapy
Sequential Serum IgG Concentrations
Figures 1-6 demonstrate sequential serum IgG levels
before and after each infusion in selected patients. Pre-
infusion samples give an indication of the trough level or
lowest serum IgG level following SNBTS IV IgG infusion
while post-infusion samples collected immediately fol¬
lowing the immunoglobulin infusion are a reflection of
the highest level that might be achieved following SNBTS
IV IgG infusion.
In 13 of 17 patients who had received SNBTS IV IgG
for more than 6 months, the serum trough IgG level was
above 4.0 g/1 within 8 months of the commencement of
SNBTS IV IgG replacement therapy. In 4 of 5 patients
who had received intramuscular IgG, the trough serum
IgG level was higher than 4.0 g/1 within 3 months of their
initial infusion. Of the 2 patients who had never received
any form of replacement therapy previously only 1
achieved a trough IgG concentration greater than 4 g/1
within the first 3 months but both achieved that level
within 8 months from the first infusion. Six of the 17 had a
serum trough IgG level of greater than 5.0 g/1 within
6 months of treatment.
Of the 10 patients who received treatment for at least
18 months, half of them maintained a trough serum
IgG level of greater than 5.0 g/1 for at least a year while
80% maintained their trough IgG above 4.0 g/1 for at
least 12 months. Seven maintained the trough IgG above
5.0 g/1 for more than 3 months and 8 for more than 2
months.
Seven patients started treatment with SNBTS IV IgG
from early 1983 and their sequential serum IgG levels
IgG Level with Individualised IV IgG Dosage 281
show the cumulative effect of intravenous immunoglob¬
ulin therapy as shown in case 11 (fig. 5). Two patients with
bronchiectasis maintained their serum IgG level within
the normal range. Some of the high serum IgG levels
prior to commencing SNBTS IV IgG therapy were due to
preceding therapy with fresh frozen plasma or another
intravenous immunoglobulin preparation (e.g. case 3,
fig. 1).
Effect of Increasing Dose
Two patients with X-linked primary hvpogammaglo-
bulinaemia (cases 9 and 10) who had persistently low
serum IgG levels and who could not attend for infusions
more often than once every 2 weeks had their infusion
dose increased to 540 and 400 mg/kg. An increment in the
serum IgG level was observed in only 1 patient (case 10,
fig. 4). Attempts at further increasing the serum IgG level
in case 9 consisted of increasing the infusion frequency
(see below).
Effect of Increasing Frequency of Infusions
In 3 patients, IgG replacement therapy was carried out
once every 2 weeks because of their low serum IgG despite
previous replacement therapy with other intravenous
immunoglobulin preparations (cases 9 and 11) and with
fresh frozen plasma (case 10). In 1 further patient (case 6)
the frequency of infusion was gradually increased to once
weekly when he suffered from recurrent gastro-intestinal
infections.
The serum IgG level in case 11 increased from 2.2 g/1 to
greater than 4.0 g/1 after 3 months (fig. 5). The serum IgG
level in case 10 who was receiving 800 ml of fresh frozen
plasma every 3 weeks decreased from 3.2 g/1 to around
2.0 g/1 (fig. 5) while on intravenous IgG replacement regi¬
men of 200 mg/kg every 2 weeks, presumably because of
an actual decrease in total IgG infused via the latter
replacement regimen. However, his serum IgG level grad¬
ually improved when his infusion dose was doubled.
There was no significant increase in trough serum IgG
level noted in case 9 (fig. 3). However, when his clinical
state worsened attempts at further increasing his serum
IgG levels were made by weekly infusions of IgG (see
below).
In 1 patient (case 6), the serum IgG level reflected the
severity of his gastro-intestinal disease (fig. 2). His serum
IgG initially fell when he had diarrhoea. Increasing the
frequency of SNBTS IV IgG from 3-weekly to 2-weekly
and then to weekly intervals brought his trough serum IgG
level into the normal range. However, with a worsening of
his gastro-intestinal symptoms, his serum IgG level fell
again despite the increased frequency of the immunoglob¬
ulin administration. Following resection of the strictured
and ulcerated segment of ileum found at laparotomy, his
serum IgG levels were once again in the normal range
while receiving replacement therapy at 3-weekly inter¬
vals. Histological examination of the resected bowel
showed ulceration and lymphoid hyperplasia without any
evidence of lymphoma or of Crohn's disease.
Effect of Increasing Infusion Dose and Infusion
Frequency
One patient with X-linked primary hypogammaglobu-
linaemia (case 9) had his infusion dose as well as his
infusion frequency increased when his clinical condition
deteriorated. He had persistently low levels despite an
increased dose of SNBTS IV IgG (300 mg/kg) and in
frequency of treatment to fortnightly intervals. He has a
combination of structural lung damage and gastro-intes¬
tinal disease as a result of recurrent infections. The infu¬
sion dose was increased to 540 mg/kg every 2 weeks
without any significant increase in trough serum IgG
concentration. However, at a later date, while an inpa¬
tient in hospital because of abdominal pain, he received
540 mg/kg at weekly intervals and his trough serum
immunoglobulin level rose to 4.05 g/1 (fig. 3).
Effect of Reducing Infusion Frequency
In 5 patients (cases 1, 3, 7, 12, and 17), the trough
serum IgG level was maintained above 4.0 g/1 when the
frequency of infusion were increased to once every 4
weeks. With an infusion frequency of once every 4 weeks,
patients (cases 1, 3, and 12) maintained their trough
serum IgG level above 5.0 g/1. Figure 6 illustrates the
effect of maintainance of serum IgG level with reduction
in the frequency of infusion.
In 4 patients a trough serum IgG level of greater than
4.0 g/1 was still achieved when the frequency of infusions
was further reduced to once every 5 weeks (cases 1, 3, 7,
and 12).
One patient (case 3) maintained a high trough serum
IgG level of 8.49 g/1 16 weeks since her last infusion of
SNBTS IV IgG of 200 mg/kg; the last but one infusion
having been carried out 12 weeks previously (fig. 1).
Half-Life of Infused IgG
Half-life values ranged from 15 to 53 days. No attempt
was made to repeat the half-life measurements after a
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Fig. 1-6. The data of serum IgG measurement is shown on the
horizontal axis and serum IgG concentrations on the vertical axis.
The lower limit of the normal range for serum IgG concentrations
(5 g/1) is shown by a horizontal broken line and the infusion dose and







Adverse reactions were associated with 33 of 517
SNBTS IV IgG infusions (6.4%), and were mostly mild.
Three adverse reactions were moderately severe, and
occurred in the initial two infusions in 2 patients who had
never previously received any form of immunoglobulin
replacement.
Complement studies (total haemolytic complement
CH50, C3. and C4) did not show any changes to suggest
complement activation during any of the infusions
including those where adverse reactions had been
recorded.
Clinical Efficacy
The clinical outcome of our patients in this study is
documented in table I. Of the 13 patients with serum IgG
levels above 4 g/1, all but 1 (case 5) experienced a reduc¬
tion in the number of respiratory infections; case 5 had
long-standing severe bilateral bronchiectasis. Case 16
with bronchiectasis continued to suffer from respiratory
infections when his serum IgG level fell from 6.0 g/1 while
receiving treatment with fresh frozen plasma to 2.7 g/1
following treatment with IV IgG.
The frequency of diarrhoea in 3 further patients (cases
2, 6, and 13) was unaffected when their serum IgG
increased to above 4 g/1. Cases 9 and 10 with X-linked
hypogammaglobulinemia suffered from chronic diar¬
rhoea despite serum IgG levels of 3.05 and 2.8 g/1, respec¬
tively. Finally, case 17 received total parenteral nutrition
because of malabsorption, and therefore was free from
diarrhoea.
Discussion
Immunoglobulin replacement therapy for patients with
primary hypergammaglobulinaemia has mainly been in the
form of intramuscular injections. In the current recom¬
mended doses of immunoglobulin used (25-50 mg/
kg/week) a proportion of such patients still suffer from
recurrent infections and develop structural damage over a
period ofyears [13], We conducted this study to see if it was
possible to maintain serum IgG concentrations at a normal
or near normal level over a long period of time using an
intravenous immunoglobulin preparation.
Patients with primary hypogammaglobulinaemia
usually have serum IgG of 2 g/1 or less before treatment.
With intramuscular immunoglobulin therapy at 25 mg/
kg/week, the response is variable but the serum IgG levels
are only raised by 1-2 g/1 with the occasional patient
showing no increment in IgG level at all. The serum IgG
levels achieved in individual patients are variable and
argue strongly against the practice of administering the
same dose of IgG to all immunodeficient patients [14],
The half-life of infused IgG is very variable among such
patients, and clinical observations have suggested that it
is shorter during intercurrent infection [15]. There is
therefore a need to individualise the dosage of infused
IgG in patients with hypogammaglobulinaemia.
Attempts to individualise treatment dosage should
achieve a high enough trough serum IgG level to minimise
the incidence of infection, using the minimal quantity of
IgG required due to cost and with a minimum number of
infusions to enable the patient to lead as normal a life as
possible. However, there is conflicting data on the opti¬
mal serum IgG level that such patients need to maintain
in order to minimise the risk of infection. In one study by
Janeway and Rosen [16], a serum IgG level of about 2 g/1
markedly reduced the incidence of serious infections. In
contrast, Joller et al. [17] have concluded that a minimal
serum IgG concentration of about 3 g/1 in patients with
hypogammaglobulinaemia is associated with an accepta¬
bly low risk of acute infections. As no definitive clinical
trials have been set up to determine the optimum IgG
level for protection against infection and other complica¬
tions of hypogammaglobulinaemia most clinicians aim to
achieve a near normal serum IgG level in their patients
since it is likely that the nearer to normal the serum IgG
level, the lower the incidence of infection.
Previous studies have attempted to individualise the
dose of immunoglobulin to achieve a satisfactory serum
IgG concentration but only one study increased the fre¬
quency of IgG infusions. Morell et al. [18] demonstrated
that the administration of 300 mg/kg/month to patients
with antibody deficiency could increase and maintain
their serum IgG level between 3.0 and 5.0 g/1. Higher
serum levels can be achieved by disproportionately larger
doses of IgG administered at short intervals, and sus¬
tained therapeutic IgG levels can be obtained with
500 mg/kg of IV IgG [19]. However, while most studies
have shown satisfactory increments in serum IgG levels
following administration of 300 mg/kg/month, there are
still patients who have persistently low serum IgG levels
[5]. In one study, Schiff et al. [7] used the half-life of
infused IgG to determine the dose required to maintain
trough IgG levels above 2.0 g/1 in his patients with humo¬
ral immunodeficiency. There was no reduction in the
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number of infective episodes when the patients received
the higher dose of IgG, but this was probably because the
trough serum IgG level achieved was only around 2.0 g/1
[7].
We have found that the serum IgG levels achieved with
SNBTSIV IgG therapy at a dose of 200 mg/kg 2 or 3 times
weekly were excellent with trough levels in the normal
range (greater than 5 g/1) for over a year in 50% of our
patients. Moreover, by increasing the infusion dose or by
reducing the interval between two infusions or by a com¬
bination of the two we have managed to achieve and
maintain substantial increments in the trough IgG level in
our patients. Sequential serum IgG levels in case 6 dem¬
onstrate the increased losses of infused IgG in the gastro¬
intestinal tract. In such patients adequate levels can be
maintained in the near normal range with frequent infu¬
sions of IgG with the usual dose of 200 mg/kg. Similar
increases could also be achieved in patients by using very
high doses; the equivalent of 8 times the usual dose of IV
IgG as in case 9. When the intervals between infusions were
increased from 3 to 5 weeks in 6 selected patients the
trough serum IgG level was maintained at above 4.0 g/1.
One patient (case 3) maintained her serum IgG level in the
normal range for 16 weeks after her last infusion. Although
she had primary panhypogammaglobulinaemia with a
history of recurrent bacterial infections associated with
very low IgG levels, it is possible that she is now producing
antibodies. Further investigations are in progress.
In summary, 76% of our patients achieved a trough
serum IgG level of at least 4.0 g/1 within 8 months of the
start of SNBTS IV IgG and 80% of patients maintained
their trough serum IgG level above 4.0 g/1 when they
received SNBTS IV IgG in a dose of 200 mg/kg every 4-5
weeks. In patients with large immunoglobulin losses, nor¬
mal trough serum IgG levels can be safely achieved with
the use of larger doses of SNBTS IV IgG by increasing the
infusion doses or the frequency of infusions or by increas¬
ing both the frequency and dose of infusions. While most
of our patients including those with mild to moderate
bronchiectasis improved during the study, we have been
unable to influence the frequency of diarrhoea in our
patients, and 1 patient with long-standing severe bilateral
bronchiectasis continued to suffer from recurrent pyo¬
genic respiratory infections.
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Summary
Tetanus toxoid purified by antibody-affinity chromatography, was compared with
conventionally purified material in a double-blind trial in 205 healthy blood donors.
There was neither any difference in immunogenicity as assessed by enzyme-linked
immunoassay nor in side-reactions between the two vaccines. This study confirms that
side-reactions to tetanus toxoid are not eliminated by purifying it.
Introduction
Local and mild systemic side-reactions after administration of tetanus toxoid
are quite common.1 Furthermore, the frequency and severity of such reactions
increases with the number of doses given.2 These reactions may be due to
hypersensitivity to the toxoid or to proteins of Clostridium tetani which
co-purify with toxoid during the precipitation process used in its conventional
preparation. It was, therefore, thought possible that a purer toxoid might be
less reactive.
A purified tetanus toxoid containing fewer contaminant proteins has been
prepared by antibody-affinity chromatography. This study was designed to
compare the purified with conventional toxoid in terms of the antitoxin
response and clinical reactivity in adult vaccinees.
Methods
Vaccinees
A total of 205 healthy adult volunteers of both sexes aged 18-64 years were
recruited from blood donors attending the Scottish National Blood Transfu¬
sion Service, Edinburgh. Exclusions from the study were: (i) administration
of Tetanus Immune Globulin within 6 weeks before the study; (ii) adminis¬
tration of tetanus toxoid within 12-months before the study; (iii) pregnancy;
and (iv) subjects who had experienced a severe reaction to a previous dose of
tetanus vaccine. Vaccination and reaction histories were determined by
interview. Initial venous blood samples were provided for assay of tetanus
antitoxin. Volunteers, matched for age and sex (Table I) and, with six
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Table I Characteristics of recipients of conventionally purified (CPT) and
antibody-affinity-purified (AAPT) tetanus toxoid vaccines
CPT AAPT
No. in group (% males) 102(50%) 103 (51%)
Mean age (range) in years 34(18-64) 32(18-64)
exceptions, tetanus antitoxin titres, were randomly assigned to receive con¬
ventionally purified toxoid (CPT) (n = 102) or antibody-affinity purified
in — 103) toxoid (AAPT). A single 0-5 ml dose of vaccine was administered
by means of a syringe and needle to each volunteer by deep subcutaneous
injection. All doses were selected by reference to a list assigning volunteers'
names to treatment numbers. Doses were, therefore, administered on a
double-blind basis.
All volunteers gave informed consent to participation in the study. The
protocol was approved by the Ethical Committee of the Scottish National
Blood Transfusion Service.
Vaccines
CPT (Absorbed tetanus vaccine, Wellcome lot IPPT 31) contained 10 Lf of
tetanus toxoid (1770 Lf/mg protein N) and had an immunising potency of 80 2
IU/dose. AAPT (Wellcome lot IPPT 27) contained 10 Lf of tetanus toxoid
(2317 Lf/mg protein N) and had an equivalent immunising potency (109 4
IU/dose). AAPT was purified by antibody-affinity chromatography and the
use of equine tetanus antitoxin conjugated to Sepharose by the cyanogen
bromide method. Both vaccines contained 0 69 mg Al3+/dose.
Clinical reactions
Vaccinees were asked to complete a daily record for 7 days after vaccination
so as to record any reactions at the site of injection (pain, redness, tenderness
and the presence of a nodule) as well as systemic reactions (headache,
feverishness and malaise). Pain, redness, and tenderness were graded 1-3
according to whether they were considered mild, moderate or severe. Volun¬
teers recorded their morning oral temperature daily for 7 days after
immunisation.
Measurement of tetanus antitoxin
Blood was collected from 204 volunteers before and approximately 2 weeks
after immunisation. One recipient of AAPT failed to provide paired serum
samples. The concentration of circulating tetanus antitoxin was determined on
paired pre- and post-immunisation serum samples by ELISA for specific IgG
antibodies (G. R. Barclay, unpublished). The concentration of tetanus
antitoxin in a subset of vaccinees was also measured by means of the toxin
neutralising test of Glenny and Stevens.3
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Table II Local reactions reported by participants in a clinical comparison of
conventionally purified (CPT) and antibody-affinity-purified (AAPT) tet¬
anus toxoid
Vaccine CPT AAPT
No. of participants 102 102
Any local reactions
No. (%) reporting 76 (75) 83 (81)
Mean no. of days* (range) 4-14 (1-7) 4'i7 (i-7)
Redness
No. (%) reporting 54 (53) 53 (52)
No. (%) severe reactions 5(5) 5(5)
Mean no. of days* (range) 3-30 (1-7) 3'57 (i-7)
Pain
No. (%) reporting 30 (29) 29 (28)
No. (%) severe reactions 0 (0) 1 (1)
Mean no. of days* (range) 2'47 (i-5) 2-28 (1-7)
Tenderness
No. (%) reporting 62 (61) 61 (60)
No. (%) severe reactions 5(5) 1 (1)
Mean no. of days* (range) 2'95 (i-7) 2-85 (1-6)
Lump at site of injection
No. (%) reporting 49 (48) 53 (52)
Mean no. of days* (range) 4-41 (1-7) 4-30 (1-7)
Other reports!
No. (%) reporting 23 (23) 18 (18)
* Total number of person days on which reactions were reported,
f Itch; bruise; swelling.
Statistics
Statistical evaluation of significance of differences in frequencies of events
between groups was determined by Fisher's exact test.
Results
Clinical reactions
Calendar records were returned by 204 participants in the study. One recipient
of AAPT failed to return a reaction card.
Inspection of the calendar records did not reveal any significant reaction to
either vaccine. Only transient mild systemic symptoms and signs with mild
discomfort at the site of injection were reported. No significant difference in
the overall frequency of reactions was detected between the groups with
83/102 (81%) of CPT recipients as compared with 88/102 (86%) of AAPT
recipients recording any reactions during the study (P > 0 2).
The frequency of local reactions, defined as redness, pain, tenderness, and
the presence of a lump at the injection site, are shown in Table II. The
frequency of local reactions reported in the recipients of CPT was 76/102
(75%) as compared with 83/102 (81 %) in the group receiving AAPT. The
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Table III Systemic reactions reported by participants in a clinical comparison




No. (%) reporting 29 (28) 29 (28)
Mean no. of days* (range) 2-28 (1-7) 1 93 (i-7)
Pyrexia (> 37-5 °C)
No. (%) reporting 5(5) 5(5)
Mean no. of days* (range) i-80 (1-4) 1-50 (1-2)
Headache
No. (%) reporting 14 (14) 14 (14)
Mean no. of days* (range) 2-36 (1-6) 1-64 (1-7)
Feverishness
No. (%) reporting 4 (4) 6(6)
Mean no. of days* (range) 2-00 (1-3) 1 83 (1-3)
Miscellaneous reports!
No. (%) reporting 13 (13) 12 (12)
Mean no. of days* (range) 2-1 (1-6) i'4 (i-3)
Other reactions!
No. (%) reporting 5(5) 7 (7)
Mean no. of days* (range) 2 0 (1-3) 2-i (1-7)
* Total number of person-days on which reactions were reported.
t Possible vaccine-associated reactions: nausea, dizziness, malaise, peripheral parasthesia.
! Diarrhoea, abdominal pain, urinary frequency, upper respiratory tract infections.
difference is not statistically significant. Further details of the incidence of local
reactions are shown in Table II.
In the 7 days following vaccination, 29 (28 %) CPT recipients and 29 (28 %)
AAPT recipients experienced systemic symptoms or signs that might have
been associated with the vaccines (Table III). These included fever
(temperature ^ 37 5 °C), headache, influenza-like symptoms, nausea, dizzi¬
ness, malaise, myalgia, or peripheral paraesthesia. Other symptoms such as
diarrhoea, abdominal pain, urinary frequency and sore throat may have been
related to concurrent infections. They were therefore categorised separately.
One recipient of CPT reported peripheral paraesthesia on the 2nd and 3rd days
after vaccination. It is unclear whether this arose in the injected or contralateral
arm. Analysis of the frequency of symptoms and signs did not demonstrate any
statistically significant difference between the two vaccine groups.
Antitoxin response
The increases in tetanus antitoxin as assessed by ELISA, in the recipients of
each vaccine are shown in Tables IV and V. Of 59 recipients of CPT 44 (75 %)
and of 59 recipients of AAPT 45 (76%) with previously undetectable antitoxin
developed concentrations indicative of immunity to tetanus, i.e., at least
0 01 IU/ml. Altogether, 83 CPT recipients (81%) and 86 AAPT recipients
(84%) had an increase in tetanus antitoxin following immunisation. There was
no difference in either the frequency or magnitude of antibody response in the
two groups.
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Table IV Serological responses to antibody-affinity-purified (AAPT) and
conventionally purified (CPT) tetanus toxoid as assessed by ELISA
CPT AAPT
Total no. assessed 102 102
Pre-immunisation tetanus 59 59
antitoxin value = 0
Post-immunisation tetanus 15 14
antitoxin value = 0
No. with an increase in 83 86
tetanus antitoxin
GMT* pre-vaccination 1-48 152
post-vaccination 621 665
GMT = Geometric mean tetanus antitoxin titre calculated on the assumption that antitoxin
titres were below the limits of detection, i.e., o taken to equal the lowest possible titre.
Table V Increase in tetanus antitoxin
CPT AAPT
> 2-5 IU/ml 12 15
2-5-5-0 IU/ml 7 15
5-0-10-0 IU/ml 29 23
10 0-20 0 IU/ml 23 20
20-0-40-0 IU/ml 12 11
40-0-80-0 IU/ml 0 2
Total 83 86
Analysis of magnitude of increase in tetanus antitoxin titre measured by ELISA
CPT, conventionally purified tetanus toxoid vaccine; AAPT, antibody-affinity-purified tetanus
toxoid vaccine.
Discussion
There was no difference in side effects and immunogenicity between the two
vaccines. In this study the overall incidence of local reactions (83-8%) was
higher than that found in a smaller study by Deacon and colleagues (68%) in
which a similar method of recording reactions was used.1 Of the 29 non-im¬
mune vaccinees who failed to develop antibodies to the toxoid, 18 had no
memory of any tetanus vaccination, seven said that they might have been
vaccinated during schooldays but not in the last 25 years, and four clearly
remembered initial vaccination or 'booster' doses but not within the last 10
years; 24 of the 29 were at least 30 years of age. It may be that many of these
non-responders may not have been able to mount a secondary immune
response since they would not necessarily have received routine primary
tetanus immunisation in infancy.
The lack of any significant difference between the effects of the two vaccines
in this study together with the lower incidence of reactions with plain formol
tetanus toxoid4-5 suggest that local reactions may be due to the toxoid itself
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and/or to inflammatory responses to aluminium hydroxide rather than to the
major impurities that are co-purified with the toxoid in the conventional
purification technique and which are removed by antibody-affinity purifica¬
tion. This is consistent with the results of previous studies.2'6
Development and evaluation of a pure toxoid devoid of contaminating
proteins cross-linked by the toxoiding process will continue. It is possible,
however, that the current local and mild systemic reactions are an inescapable
consequence of repeated administration of tetanus toxoid. Nevertheless,
different analyses of the data yielded by this study suggest that there is no greater
frequency or severity of reactivity associated with high values of preimmuni-
sation tetanus antitoxin. Conversely, higher reactivity may arise in association
with low concentrations of preimmunisation antibody.7 The status of the
vaccinees' immunity to tetanus which may determine whether a reaction arises
after administration of tetanus toxoid is evidently complex and requires further
investigation. Even so, evidence suggests that the risk of a reaction does not
appear to increase with increasing amounts of antibody.7 This does not support
the widely held view that repeated 'booster' doses lead to an increased risk of
reactions.
(We thank all the participating donors from the South-East Scotland Regional
Transfusion Centre without whom this study could not have been performed. We are
also grateful to the nursing, laboratory, scientific, and office staff who have helped with
the study. The vaccines were kindly supplied by Wellcome Research Laboratories.)
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